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Abstract 
 
 
 
The shikimate pathway is responsible for the biosynthesis of essential aromatic metabolites 
and, as such, its enzymes are targets for the design of potential antimicrobial and herbicidal 
agents.  The enzyme 3-dehydroquinate dehydratase (dehydroquinase, DHQase) catalyses the 
conversion of 3-dehydroquinate 1 to 3-dehydroshikimate 2, the third step of the shikimate 
pathway.  There are two types of DHQase, unrelated structurally and mechanistically.  Type I 
DHQase catalyses the rection by via a covalently attached imine intermediate.  Type II 
DHQase catalyses the reaction by way of an enolate intermediate. 
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This thesis describes the synthesis of a series of potential inhibitors of type II DHQase.  
Inhibitors with C and N at C-3 and with both sp2 and sp3 character at this position were 
prepared, with general structures 3-5.  The potential type I DHQase inhibitor 6 was also 
prepared. 
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The biological evaluation of these inhibitors against type II DHQases from Mycobacterium 
tuberculosis and Streptomyces coelicolor and (in the case of 6) type I DHQase from 
Salmonella typhi is described.  Inhibitors were evaluated by spectrophotometric assay.  
However, this proved inappropriate for some inhibitors with the S. coelicolor enzyme.  The 
development of an alternative 1H NMR assay and its application to the evaluation of S. 
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coelicolor DHQase inhibitors is therefore also described.  Some insights into the structure 
activity relationships of type II DHQases, obtained from the results of these studies, are 
discussed. 
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1 Introduction 
 
 
 
1.1  ANTIBIOTICS AND ANTIBIOTIC RESISTANCE 
 
The discovery of penicillin by Alexander Fleming in 1928 heralded a new era in the treatment 
of infectious disease. The drug was initially reserved for military use during WWII and this 
led eventually to the mass production of penicillin for public use by 1944.1  Penicillin was 
hailed as a “miracle drug”.  There followed over the next couple of decades the development 
of a plethora of antimicrobial weapons, so called “magic bullets”, including a variety of new 
and improved β-lactam antibiotics along with new classes such as the tetracyclines, 
aminoglycasides, macrolides and polypeptides (e.g. vancomycin).  Previously fatal infections 
could now be easily cured.  Infectious disease appeared to be on its way out.  For good. 
 
1.1.1 Antibiotic resistance 
 
Unfortunately, claims that the war against infectious disease had been won were premature.  
The excessive use and abuse of antibiotics has led, inevitably, to the development of antibiotic 
resistance.  Antibiotics are taken for ailments against which they have no power, they are fed 
to livestock to enhance growth, sprayed on crops, and added to soaps and household cleaners.2  
The saturation of the environment with antibiotics has created a selection pressure for the 
evolution and spread of antibiotic resistance.  Antibiotic resistant microbes that now plague 
hospital wards and communities include methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and multi drug resistant 
Mycobacterium tuberculosis (MDR-TB).   
 
Alexander Fleming himself warned about the consequences of the misuse of penicillin:3   
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“The greatest possibility of evil in self-medication is the use of too small doses, so 
that, instead of clearing up the infection, the microbes are educated to resist penicillin 
and a host of penicillin-fast organisms is bred out which can be passed on to other 
individuals and perhaps from there to others until they reach someone who gets a 
septicemia or a pneumonia which penicillin cannot save.  In such a case the 
thoughtless person playing with penicillin treatment is morally responsible for the 
death of the man who finally succumbs to infection with the penicillin-resistant 
organism.  I hope this evil can be averted.” 
 
His words were prophetic.  The misuse of antibiotics has lead to microbial resistance on a 
scale that is surely far beyond what Fleming imagined.  He could not have forseen the 
tendency of microorganisms to share their resistance traits amongst themselves.  Although 
organisms may have a natural resistance to a drug or may develop a spontaneous mutation 
which confers a certain degree of resistance, the most significant threat to the viability of 
existing antibiotics is the ability of organisms to acquire whole sets of resistance genes, in the 
form of plasmids, from other microorganisms.  The passing on of resistance genes from one 
organism to another (“horizontal evolution”) can occur by viral delivery (transduction), cell-
to-cell contact (conjugation), or by the scavenging of DNA from the environment 
(transformation).1 
 
Proteins coded for by resistance genes protect microbes from the actions of antibiotics in three 
main ways:  by preventing accumulation of the antibiotic within the cell (e.g. by active efflux 
in Pseudomonas aeruginosa), by altering the target of the antibiotic so it is no longer 
susceptible (e.g. modified peptidoglycan in VRE), or by inactivating the antibiotic itself (e.g. 
hydrolysis of β-lactam antibiotics by β-lactamase enzymes). 
 
1.1.2 Combating Antibiotic Resistance 
 
There are three main chemical strategies for combating antibiotic resistance.4  The primary 
strategy employed by the pharmaceuticals industry for the past 30 years is the modification 
and improvement of existing classes of antibiotics in order to circumvent the microbial 
resistance mechanisms.  Another approach is the administration of drugs designed to inhibit 
the resistance mechanism, such as the synergistic administration of the β-lactam antibiotic 
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amoxicillin with the β-lactamase inhibitor clavulanate.  The third strategy is the production of 
new classes of drugs, with novel targets, such that there is no established resistance amongst 
the microbial population. 
 
Although antibiotic resistance was observed almost from the beginning of the antibiotic era, it 
was not at first thought to be a serious problem.  It could be overcome by coming up with 
slight variations in the antibiotic and the bacterial resistance could be evaded.  In this way it 
was possible to stay one step ahead of the development of resistance.  However, as resistant 
bacteria proliferate and acquire resistance not only to whole classes of antibiotics, but to 
several classes at once, the need for new antibiotics, with new targets becomes increasingly 
apparent.   
 
The genomics revolution is a driving force behind the search for novel antimicrobial targets.5,6 
With genome sequence information for many pathogens now available and more coming, a 
plethora of potential antibiotic targets has become available.  New technologies enable the 
determination of whether a gene is essential to growth or survival under the conditions of the 
infection and whether transcription is induced during infection.  Homology provides clues to a 
protein’s function and in silico analysis can identify highly conserved (broad spectrum) or 
unique (narrow spectrum) targets.  Human genome sequence information provides a basis for 
assessing the selectivity of a potential target relative to mammalian proteins. 
 
 
 
1.2  THE SHIKIMATE PATHWAY AS A TARGET FOR ANTIBIOTIC 
DEVELOPMENT 
 
In plants and microorganisms key aromatic compounds are synthesized via the shikimate 
pathway (Scheme 1.1).  The shikimate pathway consists of seven enzymes catalysing the 
conversion of erythrose 4-phosphate 1.1 and phosphoenol pyruvate (PEP) 1.2 to chorismate, 
the precursor of the aromatic amino acids and other aromatic metabolites including p-
aminobenzoic acid (precursor to folate, essential for neucleotide biosynthesis) ubiquinone (co-
enzyme Q), the vitamins K, flavonoids, lignans and some alkaloids.7  The seven enzymes, 3-
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deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) synthase, dehydroquinate synthase, 3-
dehydroquinate dehydratase (dehydroquinase, DHQase), shikimate dehydrogenase, shikimate 
kinase, 5-enolpyruvylshikimate 3-phosphate (EPSP) synthase and chorismate synthase 
catalyse the formation of DAHP 1.3, dehydroquinate 1.4, dehydroshikimate 1.5, shikimate 
1.6, shikimate 3-phosphate 1.7, EPSP 1.8 and chorismate 1.9 respectively.  The pathway 
occurs in plants, fungi and microorganisms but not in mammals, making the enzymes of the 
pathway appealing targets for the design of potentially highly selective antimicrobial and 
herbicidal compounds. 
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Scheme 1.1  The Shikimate Pathway. 
 
Recent genomic research has confirmed that the shikimate pathway is indeed present in many 
important mammalian pathogens, such as the malaria parasite Plasmodium falciparum8 and 
M. tuberculosis.9  Inactivation of shikimate pathway genes has been shown to lead to 
 1   Introduction 8 
attenuation of virulence and loss of viability in a range of bacterial species including M. 
tuberculosis
9 and Salmonella typhimurium,10 validating the shikimate pathway as a target for 
antimicrobial design.  
 
Inhibition of aromatic biosynthesis as a route to novel antimicrobials has been validated by 
the work of Abell et al. on 6-fluoro- analogues of shikimate pathway substrates.11  The 6-
fluoro analogues of shikimic acid 1.10 and 1.11 were found to act as substrates for shikimate 
kinase, being converted first into (6R)- and (6S)-6-fluoroshikimate-3-phosphate (1.12 and 
1.13) and then into (6R)- and (6S)-6-fluoro-EPSP (1.14 and 1.15) by EPSP synthase (Scheme 
1.2).  (6S)-6-Fluoro-EPSP was found to inhibit Neurospora crassa chorismate synthase,11 the 
succeeding enzyme on the pathway, but not the corresponding E. coli enzyme, for which it is 
a substrate.12  (6S)-6-Fluoroshikimic acid was, however, found to inhibit the growth of an E. 
coli strain on minimal medium (MIC = 0.25µg mL-1) and protected mice infected with the 
same organism (50% protective dose, 0.06mg per kg body weight).13  It was subsequently 
shown that (6S)-6-fluoroshikimate is converted by the shikimate pathway enzymes to 6-
fluorochorismate, which irreversibly inhibits 4-amino-4-deoxychorismate synthase (ADCS), 
the succeeding enzyme en route to folate biosynthesis.14  Spontaneous resistance to the 
inhibitor was found to occur at high frequency.  The resistance mechanism is thought to be 
specific to 6-fluoroshikimic acid however, and should not be a general problem for inhibitors 
of shikimate pathway enzymes.15 
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Scheme 1.2  Enzymatic conversion of (6R)- and (6S)-6-fluoroshikimate (1.10 and 1.11) into 6-fluorochorismate 
1.16. 
 
An excellent example of the selective toxicity of a commercial shikimate pathway inhibitor is 
the herbicide N-phosphonomethyl glycine (glyphosate) 1.17, marketed as Roundup® (Scheme 
1.3).  It has also been shown to inhibit the growth of several clinically important parasitic 
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pathogens.8  Glyphosate inhibits the shikimate pathway enzyme EPSP synthase.16  Glyphosate 
is extremely specific for EPSP synthase and is not known to appreciatively inhibit any other 
enzyme, making it a safe and effective means of weed control.17  Binding of glyphosate is 
competitive with respect to PEP 1.2 and occurs only after the binding of shikimate 3-
phosphate 1.7.  The step-wise binding leads to a dead-end ternary complex 1.18 which 
mimics the tetrahedral intermediate 1.19 of the enzymatic reaction, but does not lead to the 
formation of the product EPSP 1.8.18 
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Scheme 1.3  Inhibition of EPSP synthase by glyphosate 1.17. 
 
 
 
1.3  DEHYDROQUINASE 
 
Dehydroquinase is the third enzyme of the shikimate pathway, catalyzing the conversion of 3-
dehydroquinate (DHQ) 1.4 to 3-dehydroshikimate (DHS) 1.5.  There are two structurally 
distinct classes of DHQase, known as type I and type II, that catalyse the elimination of H2O 
by completely different mechanisms.7  The two types of DHQase are unrelated in an 
evolutionary sense, having completely different three dimensional structures19 and exhibiting 
little or no sequence homology.20 
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Type I DHQase has been reported only as a part of the biosynthetic shikimate pathway.  In 
plants and fungi it is a part of larger multifunctional proteins such as the pentafunctional arom 
complex of Aspergillus nidulans and Neurospora crassa which catalyses steps two to six of 
the shikimate pathway.20-22  In prokaryotes such as Escherichia coli and Salmonella typhi 
however, type I DHQases are distinct, monofunctional enzymes which are dimeric, with a 26-
28 kDa subunit.22-25 
 
Type II DHQases occur as a biosynthetic enzyme of the shikimate pathway, as is the case for 
the M. tuberculosis and Streptomyces coelicolor enzymes.26,27  However, they also occur as a 
part of the catabolic quinate pathway in fungi, in which quinic acid is utilised as a carbon 
source via the β-ketoadipate pathway.7  Fungi such as A. nidulans and N. crassa have both 
types of DHQase, with type I DHQase playing a biosynthetic role as a part of the arom 
protein and type II DHQase involved in quinate catabolism.22  Type II DHQases are 
dodecamers with 12-18 kDa subunits.22,28,29 
 
1.3.1 Mechanism of Type I dehydroquinase 
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Scheme 1.4  Catalytic mechanism of type I DHQase. 
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The elimination catalysed by type I DHQase proceeds via imine formation with a highly 
conserved active site lysine residue (Lys-170 in E. coli DHQase) (Scheme 1.4).30  Evidence 
for an imine intermediate comes from enzyme inactivation by borohydride trapping of the 
imine in the presence of an equilibrium mixture of substrate and product.31  The reduced 
enzyme-product adduct 1.20 has been observed by electrospray mass spectrometry25 and the 
crystal structure of the complex solved for the S. typhi enzyme.19 
 
The elimination of water has been shown by deuterium labelling experiments to occur with 
syn-stereochemistry, involving the loss of the less acidic pro-R proton.32  Substrate binding by 
type I DHQase induces a conformational change from the preferred chair form, resulting in a 
co-planar orientation of the pro-R hydrogen with the pi-acceptor orbital of the imine, 
promoting the syn-stereo chemistry of the elimination.32,33  Experimental evidence supports a 
skew-boat for the reactive conformation, in which the C-4 and C-5 hydroxyls remain in the 
equatorial positions throughout the reaction, while the orientation of the C-1 carboxyl 
becomes more axial.33  When the C-1 carboxyl of the substrate 1.4 was masked by a methyl 
ester, it lost all activity, acting as neither a substrate nor an inhibitor.  This supports the 
hypothesis that the carboxylate is necessary for substrate reactivity and that it is the 
carboxylate, together with the ketone that engages the enzyme and initiates the 
conformational change which results in the syn-elimination. 
 
His-143 was initially proposed to be the active site general base responsible for abstraction of 
the pro-R proton by E. coli DHQase,34 due to resulting enzyme inactivation from modification 
of His-143 by diethyl pyrocarbonate as well as the highly conserved nature of this residue in 
type I DHQases.  Further studies suggested that His-143 is involved in imine formation and 
hydrolysis, as replacement of His-143 with alanine results in a reduced rate of catalysis and 
accumulation of Schiff base-bound product.35  Crystallographic data shows His-143 at the 
centre of a hydrogen-bonded triad involving Lys-170 and Glu-86, which is consistent with a 
role in Schiff base formation, but not as the general base responsible for proton abstraction at 
C-2.36  A logical role for His-143 might then be deprotonation of the ε-NH2 of Lys 170.  
Chemical modification experiments with phenylglyoxal have also identified an essential 
hyper-reactive active site arginine (Arg-213 in E. coli) that may be involved in carboxylate 
recognition.37  
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1.3.2 Mechanism of Type II Dehydroquinase 
 
In contrast to the type I enzyme, the conversion of DHQ 1.4 to DHS 1.5 by type II DHQase 
does not involve a Schiff-base intermediate.  This is indicated by the lack of a conserved 
lysine residue26 and the lack of enzyme inactivation observed upon treatment with sodium 
borohydride in the presence of an equilibrium mixture of substrate and product.22  Another 
notable mechanistic difference between the two types of dehydroquinase is that, in contrast to 
the elimination catalysed by the type I enzyme, the type II dehydroquinase catalysed reaction 
proceeds with anti-stereochemistry and loss of the more acidic axial pro-S proton, as 
confirmed by deuterium labelling experiments.38,39  It was proposed that type II DHQase, by 
analogy with type II aldolases, might require bivalent metal ions for catalysis, however, 
experiments employing metal analysis, chelation, and denaturation/renaturation experiments 
failed to show any evidence of metal ion dependence in the mechanism of A. nidulans type II 
DHQase.40 
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Scheme 1.5  Catalytic mechanism of type II DHQase. 
 
The highly conserved Tyr-28 has been implicated in a catalytic role in S. coelicolor DHQase 
by inactivation of the enzyme following tetranitromethane modification of Tyr-28.37  A 
conserved hyper-reactive active site arginine residue (Arg-23 in S. coelicolor DHQase) has 
been identified by phenylglyoxal modification and electrospray mass spectrometry.29  Both 
chemical modification and site-directed mutagenesis of Arg-23 led to loss of activity.37  The 
crystal structure of S. coelicolor with phosphate bound in a position analogous to that of the 
C-1 carboxyl and hydroxyl of the substrate indicates that recognition of the C-1 carboxylate 
and hydroxyl is important for S. coelicolor DHQase activity.41 
 
A stepwise E1CB mechanism involving an enolate intermediate 1.21 was proposed, supported 
by kinetic isotope experiments, to explain the stereochemistry of the elimination (Scheme 
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1.5).42  The subsequent crystallographic identification of a conserved active site water 
molecule in S. coelicolor DHQase, along with the absence of any suitable residue to stabilise 
an enolate intermediate, suggested that an enol rather than an enolate may be a more likely 
intermediate for this enzyme.43  The conserved Tyr-28 was proposed to be the general base 
responsible for proton abstraction, with His-106 acting as the general acid in the hydroxyl 
elimination step.   
 
 
 
1.4 DEHYDROQUINASE AS A TARGET FOR INHIBITOR DESIGN 
 
Various dehydroquinate analogues have been synthesised and tested for inhibitory activity 
against types I and II DHQase.  The synthesis of such compounds has progressed from 
preparation of analogues for the purpose of mechanistic studies, to the rational design of type-
specific DHQase inhibitors.  Some inhibitors have also been identified by library screening. 
 
Compounds possessing an active methylene group at C-3 (1.22 and 1.23) were proposed by 
Gorrichon et al. to act as inhibitors of type I DHQase.  No time-dependent inhibition of E. 
coli DHQase was observed for compounds 1.22 and 1.23 however.  The lack of activity was 
proposed to be due to the lack of the C-3 carbonyl, or steric constraints of the C-3 functional 
group and active site residues.44 
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A series of affinity labels was designed by Abell and co-workers to investigate the structure of 
the active site of type I DHQase from E. coli.45  Epoxide 1.24 showed rapid active site 
directed irreversible inhibition, with an inhibition constant of 400 µM and a maximal rate of 
inactivation ki of 2.5 x 10
-3 s-1.  Chloromethyl ketone 1.25 also demonstrated irreversible 
inhibition with a Ki of 680 µM and a ki of 5.6 x 10
-4 s-1.  Azide 1.26 acted as a photoaffinity 
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label, presumably via the generation of a reactive nitrene diradical.  The inhibition constant 
for this inhibitor was 1.1 mM, with a maximal rate of inactivation, ki, of 3.9 x 10
-4 s-1.  All 
three compounds were shown to be competitive inhibitors by prevention or reduction of 
inhibition on addition of substrate. 
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The 5-deoxy- and 4,5-dideoxy- analogues of DHQ (1.27 and 1.28 respectively) were 
synthesized by Abell and coworkers to study the substrate specificity of types I and II 
DHQase.46  5-Deoxydehydroquinic acid 1.27 was found to be a modest substrate for type I 
DHQase from E. coli with a reduction in specificity constant kcat/KM of 10
3 L mol-1 s-1 relative 
to the natural substrate.  Although the enzyme tolerates the absence of the C-5 hydroxyl, the 
loss of specificity suggests that the group forms an important binding interaction with the 
enzyme and may be hydrogen bonded to a charged acceptor such as a lysine or arginine 
sidechain.  4,5-Dideoxydehydroquinic acid 1.28 however, was not a substrate, but a reversible 
competitive inhibitor with Ki = 10 ± 1 mM.  This is an indication that the C-4 hydroxyl, unlike 
the C-5 hydroxyl, is necessary for substrate turnover and may be involved in imine formation.  
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In contrast both compounds were found to be poor substrates for type II DHQase from M. 
tuberculosis (with specificities approximately 10-5 that of the natural substrate).  The dideoxy 
analogue 1.28 was also a weak competitive inhibitor with a Ki of 1.0 ± 0.2 mM.  That the 
absence of the C-5 hydroxyl results in such a loss of specificity suggests that it is involved in 
some important enzyme-substrate interaction(s).  The removal of the C-4 hydroxyl did not 
seem to have any further effect on the binding affinity suggesting either that the group does 
not form any significant binding interactions with the enzyme, or that the removal of either C-
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4 or C-5 hydroxyl group results in a breakdown of important enzyme-substrate binding 
interactions.  Subsequent attempts to prepare 4-deoxydehydroquinic acid 1.29 in order to 
further investigate the contribution of the C-4 hydroxyl to substrate binding were unsuccessful 
due to the propensity of the β-hydroxy ketone to eliminate and aromatise.47  No formation of 
4-deoxydehydroquinic acid was observed on incubation of 4-deoxydehydroshikimic acid 1.30 
with either type I DHQase from E. coli or type II DHQase from M. tuberculosis, however this 
may be due to an unfavourable equilibrium between the species. 
 
OH
HO
OH
CO2H
O
F
OH
HO
OH
CO2H
O
Br
OH
OHO
Br
CO2H
OH
OHN
H
O
Enz
OH
OHN
H
CO2
Enz
NuEnz
1.321.31
1.34
1.33
1.35  
 
Halogenated DHQ analogues, substrates for type II DHQase,48 were shown to be mechanism 
based inhibitors of type I DHQase from E. coli.49  (2R)-2-Bromo-3-dehydroquinic acid 1.31 
proved to be a weak competitive inhibitor of type I DHQase (Ki = 3.7 mM) that slowly 
inactivated the enzyme irreversibly (70% inactivation after 24h at 10 mM).  The mass 
spectrum of a partially inactivated sample of enzyme showed a peak for modified enzyme 
corresponding to an additional mass of 126 ± 5 Da.  The corresponding fluoro-analogue 1.32 
was shown to be a moderate competitive inhibitor with a Ki of 80 µM and also slowly 
inactivated the enzyme irreversibly (45% inactivation after 22h at 2.4 mM).  The mass 
spectrum in this case also showed a new peak for modified enzyme corresponding to an 
additional mass of 126 ± 5 Da.  This suggests the formation of a common adduct in which the 
halogen substituent has been lost to form 1.33.  A possible mechanistic rationale is depicted in 
Scheme 1.6.  Binding of the C-2 halo-analogues 1.31 and 1.32 and formation of the imine 
intermediate is proposed to initiate a conformational change which brings the C-2 halogen 
bond closer to an antiperiplanar orientation with respect to the C-1–carboxyl bond.  This may 
trigger a decarboxylative elimination reaction.  Subsequent tautomerisation of the enol 
 1   Introduction 16 
iminium adduct would form the vinylogous amide 1.33, which is irreversibly bound to the 
enzyme, preventing further catalysis. 
 
Incubation of type I DHQase with 2-bromo-3-dehydroshikimate 1.34 also resulted in slow 
irreversible inactivation (60% after 24h at10 mM), with the enzyme-inhibitor adduct observed 
by electrospray mass spectrometry now corresponding to and additional mass of 154 ± 5 Da.  
This may be due to the formation of the adduct 1.35 via imine formation, followed by 
conjugate attack at C-2 and subsequent elimination of bromide. 
 
OH
O2C
OH
OH
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H
X
HO
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O
OH
HO
H
N
O
Enz
H
1.31 R = Br
1.32R = F
1.33
 
Scheme 1.6  Proposed mechanism of inhibition of type I DHQase by 2-bromo- and 2-fluorodehydroquinic acids 
(1.32 and 1.32). 
 
Investigation into the mechanism of type II dehydroquinase by Abell et al. prompted the 
synthesis of 1.36 and 1.37 as analogues of the enolate intermediate 1.21 (Scheme 1.5).50  
Compounds 1.38 and 1.39 were also prepared as controls lacking the hydrogen bonding 
potential of the oxime functionality and the partial ring flattening due to the C-2–C-3 double 
bond respectively.  The results of the biological studies are shown in Table 1.1.  Oxime 1.36 
was found to be much more potent an inhibitor than 1.38, indicating the importance of 
hydrogen bonding interactions in both the stabilization of the enolate intermediate and 
inhibitor binding.  2,3-Anhydroquinic acid 1.37 was found to be more potent than the 
saturated analogue 1.39.  This is consistent with stabilisation by the enzyme of a transition 
state with some degree of ring flattening as would be expected to occur in enolate 
intermediate 1.21.  The inhibitors showed high selectivity for type II DHQase over the type I 
enzyme.  The inhibitors also demonstrated unexpected selectivity between different species of 
type II enzyme, with the oxime 1.36 being more potent against M. tuberculosis DHQase and 
2,3-anhydroquinic acid 1.37 being more potent against the S. coelicolor enzyme. 
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1.37 1.391.38  
 
The selectivity of inhibitors 1.36-1.39 for different species of type II DHQase may be 
explained in part by subsequent studies of the binding of phosphate and sulphate anions by S. 
coelicolor, M. tuberculosis and Helicobacter pylori DHQases.41  Phosphate and sulphate 
anions were both found to be weak competitive inhibitors of S. coelicolor DHQase, with 
inhibition constants of 7 mM and 11 mM respectively.  They were also found to inhibit H. 
pylori DHQase with Ki values of 9 mM for both anions.  Phosphate has also previously been 
shown to be a competitive inhibitor of A. nidulans type II DHQase.22  The anions also 
appeared to inhibit M. tuberculosis DHQase but the kinetics were more complex than the 
simple competitive inhibition observed for the other enzymes, suggesting that the anions may 
bind to more than one site.  The crystal structure of S. coelicolor with phosphate shows a 
single anion bound in the active site, occupying a position analogous to the carboxylate and 
C-1 hydroxyl of the substrate.  This was also observed to be the case for the crystal structure 
of S. coelicolor DHQase with sulphate bound.43  This suggests that C-1 hydroxyl and 
carboxylate recognition is important for binding by S. coelicolor DHQase. 
 
Table 1.1  Inhibition constants, Ki (µM) for inhibitors 1.36 – 1.41 against Types I and II dehydroquinase 
    
Inhibitor  Ki (µM)  
 Type I Type II Type II 
 S. typhi M. tuberculosis S. coelicolor 
    
    
1.36 > 25000 20 ± 2 500 ± 200 
1.37 3000 ± 1000 200 ± 20 30 ± 10 
1.38 > 25000 700 ± 200 2500 ± 200 
1.39 4500 ± 500 1200 ± 20 600 ± 20 
1.40 1500 ± 500 10 ± 2 15 ± 2 
1.41 8000 ± 1000 700 ± 100 700 ± 100 
    
 
In the case of M. tuberculosis DHQase however, the presence of two sulphate ions was 
observed in the active site.41  One of the sulphate ions was bound in a position near but not 
identical to the C-1 hydroxyl/carboxylate binding site, but lacking some of the interactions 
OH
HO
OH
CO2H
F
OH
HO
OH
CO2H
F
F
1.40
1.41
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observed for the phosphate ion in the S. coelicolor structure.  It was, however, seen to interact 
with Arg-19, a residue shown to be important for catalysis.37  The second sulphate ion also 
interacts with Arg-19 and with residues of the flexible lid domain.  These results, along with 
the lack of potency observed for inhibitors 1.37-1.39 against M. tuberculosis DHQase relative 
to S. coelicolor DHQase and the increased activity of 1.36 relative to 1.37-1.39 against M. 
tuberculosis DHQase, suggest that although C-1 carboxylate/hydroxyl recognition is 
necessary for specific binding by S. coelicolor DHQase, the C-3 carbonyl is more important 
for binding by M. tuberculosis DHQase, possibly by interacting with Arg-19. 
 
Inhibitor 1.40 was prepared by Frederickson et al., incorporating the vinyl fluoride moiety as 
an isoelectronic and isosteric replacement for the enolate anion of 1.21.51,52  It was shown to 
be highly selective for type II DHQase over type I, and was equally active against type II 
DHQases from both M.  tuberculosis and S. coelicolor.52  Although fluoro- analogue 1.40 
showed only a small improvement in activity over 1.36 and 1.37 with the enzymes against 
which they were most potent, it shows a 20-30 fold increase in activity with the enzymes 
against which they were less potent (Table 1.1).  This makes it the most effective “broad-
spectrum” inhibitor of type II DHQases reported to date.  3,3-Difluoro analogue 1.41 was also 
a competitive reversible inhibitor, selective for type II DHQase, but was much less potent 
than enolate analogue 1.40. 
 
N
Ar
N
S
S
R3
O O
O O
R4
R1
R2
Ar = aryl or heteroaryl
R1 = H, alkyl or R1 and R2 together form a C1 - C3 alkylene group, CO or CS
R2 = H, alkyl or R1 and R2 together form a C1 - C3 alkylene group, CO or CS
R3 = aryl, heteroaryl, alkyl-aryl, alkyl-heteroaryl, alkenyl-aryl, alkenyl-heteroaryl, 
alkynyl-aryl, or alkynyl-heteroaryl
R4 = aryl, heteroaryl, alkyl-aryl, alkyl-heteroaryl, alkenyl-aryl, alkenyl-heteroaryl, 
alkynyl-aryl, or alkynyl-heteroaryl
1.42  
 
Library screening has unearthed a completely different class of DHQase inhibitors.  
Bissulfonamide derivatives of general structure 1.42 were assayed against shikimate pathway 
enzymes and some were found to be moderate inhibitors of type II dehydroquinase from M. 
tuberculosis with IC50 values in the micromolar range.
53,54  Several of the compounds were 
demonstrated to have inhibitory activity against bacterial cell growth with minimum 
inhibitory concentrations (MIC) in the low micromolar range.  The mode of action of the 
compounds was not described. 
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Table 1.2  Inhibition constants, Ki (µM) for inhibitors 1.43-1.50 against types I and II DHQase 
      
Inhibitor Ki (µM) 
 Type I DHQase Type II DHQase 
 S. typhi S. coelicolor 
      
   
KM
a 16 250 
1.37
b
 3000 ± 1000 30 ± 10 
1.39
b
 4500 ± 500 600 ± 200 
1.43
a
 > 20000 420 ± 50 
1.44
a
 > 20000 > 20000 
1.45
a
 > 20000 180 ± 20 
1.46
a
 > 20000 3000 ± 500 
1.47
a
 > 20000 1200 ± 150 
1.48
a
 > 20000 530 ± 50 
1.49
a
 > 20000 > 20000 
1.50
a
 > 20000 3500 ± 400 
      
a Ref. 55.  b Ref. 50. 
 
The crystal structure of S. coelicolor dehydroquinase has been reported with inhibitor 1.37 
bound in the active site.43  The structure also shows a molecule of glycerol bound 3.7Å from 
the inhibitor.  A new series of inhibitors was designed by Abell et al. intended to fill both 
binding sites by incorporating both inhibitor and glycerol components in the structure.55  
Compounds 1.43-1.50 were prepared and assayed against type I DHQase from S. typhi and 
type II DHQase from S. coelicolor (Table 1.2).  None of the compounds showed any 
measurable inhibition against the type I enzyme.  Compounds 1.43, 1.45 and 1.48 were found 
to be more potent than compound 1.37 against type II dehydroquinase but none of the 
inhibitors were as potent as 2,3-anhydroquinic acid 1.37. 
 
Another series of analogues of inhibitor 1.37 has been prepared on solid-phase and assayed 
against type II DHQase from S. coelicolor.56  The inhibition results for compounds 1.51a-i 
and 1.52a-i are given in Table 1.3.  All of the compounds were found to be reversible 
competitive inhibitors of S. coelicolor DHQase, the 4-substituted series 1.52a-i being 
generally more potent than the 1-substituted series 1.51a-i.  2-Nitrobenzyl derivative 1.52i 
was particularly potent showing almost a four-fold improvement over the parent inhibitor 
1.37, making it the most potent inhibitor of S. coelicolor type II DHQase reported to date.  
Docking studies indicated that most of the inhibitors bind in a similar mode to inhibitor 1.37, 
with the benzyl substituent in the pocket previously occupied by the glycerol molecule.  
OH
HO
OH
CO2H
1.43 R = CH2CH=CH2
1.44 R = CH2CH(OH)CH3
1.45 R = CH2CH2CH2OH
1.46 R = CH2CH(OH)CH2OH
1.47 R = OCH2CH=CH2
1.48 R = OCH2CH(OH)CH2OH
OH
HO
OH
CO2H
1.49 R = OCH2CH=CH2
1.50 R = OCH2CH(OH)CH2OH
R
R
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However, in the case of inhibitor 1.52i, the nitrobenzyl group is bound in the pocket normally 
occupied by the anhydro ring, with the nitro group in the carboxylate binding site, while the 
cyclohexene ring is bound in the glycerol binding pocket.  However, this may be an artefact 
of the way the active site was prepared for docking, as when more water molecules were 
retained, docking similar to that for the other inhibitors was observed. 
 
OH
O
OH
CO2H
O
HO
OH
CO2H
R
R
1.51
a R = H
b R = 4-F
c R = 3-F
d R = 2-F
e R = 4-CO2H
f  R = 4-CO2OH
g R = 4-CN
h R = 4-NO2
i  R = 2-NO2
1.52
a R = H
b R = 4-F
c R = 3-F
d R = 2-F
e R = 4-CO2H
f  R = 4-CO2OH
g R = 4-CN
h R = 4-NO2
i  R = 2-NO2  
 
 
Table 1.3  Reported inhibition constants for inhibitors 1.51 and 1.52 a-i against S. coelicolor DHQase. 
      
 Ki (µM) 
 S. coelicolor type II DHQase 
 1.51 1.52 
      
   
a 380 ± 30 200 ± 20 
b 375 ± 30 70 ± 5 
c 425 ± 40 140 ± 10 
d 260 ± 20 130 ± 10 
e 170 ± 15 100 ± 10 
f 1330 ± 100 >2000 
g 430 ± 40 330 ± 30 
h 980 ± 90 200 ± 20 
i 45 ± 5 8 ± 2 
      
 
A recent paper from the Abell group describes the rational design of new DHQase inhibitors 
combining the strategies of having a glycerol mimic as a C-3 side-chain as seen in compounds 
1.43-1.50 and using a phenyl ring to fill the glycerol binding pocket as seen in compounds 
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1.51a-i and 1.52a-i.57  Inhibitors 1.53-1.55 were prepared and assayed against type I DHQase 
from S. typhi and type II DHQase from S. coelicolor.  None of the inhibitors were active 
against type I DHQase.  The results of the assays against type II DHQase are shown in Table 
1.4.  Compound 1.53 was found to be almost as good an inhibitor of S. coelicolor DHQase as 
anhydroquinic acid 1.37, though 1.54 and 1.55 were less potent, showing a decrease in 
potency with increasing hydrophilicity of the ortho-substituent.  
 
Molecular docking studies suggested ring stacking between the aromatic rings of 1.53-1.55 
and Tyr-28 as well as a possible interaction of any ortho-substituent with Arg-23.  The crystal 
structure of S. coelicolor DHQase with 1.53 bound in the active site shows the quinate ring in 
the main binding pocket and the phenyl ring in the glycerol binding-pocket, with ring stacking 
between the benzyl ring and the side chain of Tyr-28 as predicted.  However, the decreasing 
trend in activity with increasing hydrophilicity of the ortho-substituent suggests that there is 
no favourable interaction with Arg-23. 
 
Table 1.4  Inhibition constants for inhibitors 1.53-1.55 against type II DHQase. 
  
Inhibitor Ki (µM) 
 S. coelicolor Type II DHQase 
  
  
1.53 33 ± 5.4 
1.54 84 ± 13 
1.55 220 ± 50 
  
 
 
Inhibition studies with DHQase have progressed from employing inhibitors as tools for 
elucidating structural and mechanistic details to the rational design of type-specific inhibitors.  
The most potent inhibitors of both types of DHQase to date have inhibition constants (Ki) in 
the low micromolar range.  These inhibition studies have yielded information to be exploited 
in the rational design of future generations of inhibitors.  For example, the C-4 and C-5 
hydroxyl groups are important for binding by both enzyme types, the presence of hydrogen 
bonding substituents at C-3, and a C-2–C-3 double bond yield inhibitors specific for type II 
DHQases, and 2-halo analogues of DHQ are specific for type I DHQases.  S. coelicolor 
DHQase also has an additional “glycerol” binding pocket which can be exploited. 
 
OH
HO
OH
CO2H
O
R
1.53 R = H
1.54 R = NO2
1.55 R = CO2H
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1.5 OUTLINE OF THIS THESIS 
 
The object of this work was to prepare new potential DHQase inhibitors and evaluate their 
biological activities.  This would provide information about structure-activity relationships for 
DHQases, which could then be incorporated into the design of future generations of 
inhibitors.  Work carried out by others in this area (described above), and the insights gained 
from this into the structure and mechanism of DHQase, were used as the basis for the design 
of a series of new inhibitors intended to further explore the structure activity relationships of 
type II DHQases. 
 
Chapter 2 describes the preparation of a number of new potential type II DHQase inhibitors.  
The preparation of an inhibitor expected to be both a competitive inhibitor of type II DHQase 
and an irreversible inhibitor of type I DHQase is also described.  The evaluation of the 
activities of theses inhibitors against the type II DHQases from M. tuberculosis and S. 
coelicolor using the standard spectrophotometric assay for DHQase is described in Chapter 3.  
The investigation of the irreversible inhibition of type I DHQase from S. typhi by one 
inhibitor is also described.  Some of the inhibitors however, were UV active and were unable 
to be assayed against S. coelicolor DHQase by this method.  An alternative 1H NMR based 
assay was developed to evaluate these inhibitors against S. coelicolor DHQase.  The 
development of this method and the results obtained are described in Chapter 4.  Some 
insights into the structure-activity relationships for the two species of type II DHQase, 
obtained from the evaluation of the new inhibitors and by comparison with published results, 
are also discussed in Chapters 3 and 4. 
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2 Synthesis of Potential Dehydroquinase Inhibitors 
 
 
 
2.1 INTRODUCTION 
 
The design of new potential inhibitors of type II DHQase was based on the structure of the 
known oxime inhibtor 1.36.1  The oxime functionality, which is thought to participate in 
stablising hydrogen bonding interactions with active site residues, is a major factor 
contributing to the strength of binding of 1.36 by type II DHQase.  Potential inhibitors were 
therefore designed with other hydrophilic functionalities at C-3, while retaining the 
functionality and stereochemistry of the natural substrate at all other positions of the 
carbocyclic ring.  This chapter describes the preparation of potential inhibitors with general 
structures 2.1-2.3, where X is a hydrophilic functional group. 
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The activity of (2R)-2-fluorodehydroquinic acid 1.32 against type I dehydroquinase from E. 
coli suggested that other 2-fluorodehydroquinate derivatives could potentially display 
interesting biological activities against both types of DHQase.  This chapter also describes an 
investigation into the synthesis of some (2S)-2-fluorodehydroquinate derivatives. 
 
The synthesis of epoxide 2.4 is also reported in this chapter.  It was thought that the epoxide 
of 2.4 would be susceptible to nucleophilic attack and ring-opening by the active site lysine of 
type I DHQase, resulting irreversible inhibition. 
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2.2  SELECTIVE OXIDATION OF THE C-3 HYDROXYL 
 
The starting point for the synthesis of the proposed inhibitors was commercially available 
quinic acid 2.5.  This is a convenient starting material since it has the necessary substituents 
and stereochemistry at positions 1, 4 and 5.  Selective oxidation of the C-3 hydroxyl was 
necessary, to furnish the corresponding ketone for subsequent derivatisation. 
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Scheme 2.1  Literature method for the direct oxidation of quinic acid 2.5.  Reagents and conditions:  i. 
c.HNO3(aq), 0ºC (45-50%).
2
 
 
Methods for this selective oxidation reported in the literature included the direct oxidation of 
quinic acid 2.5 to dehydroquinic acid 1.4 by concentrated nitric acid (Scheme 2.1).2  This 
method however, requires lengthy purification and is only low to moderate yielding.  
Dehydroquinic acid 1.4 is also synthetically inconvenient, requiring protection of the various 
functional groups prior to derivatisation. 
 
An alternative route to oxidation of the C-3 hydroxyl via a more synthetically convenient 
protected dehydroquinate analogue was reported by Abell and co-workers (Scheme 2.2).3  
The quadruple protection of quinic acid 2.5 by p-toluenesulfonic acid catalysed reaction with 
benzaldehyde with azeotropic removal of water furnished the benzylidene acetal 2.6.  
Catalytic hydrogenation to remove the benzylidene protecting group, followed by selective 
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protection of the C-4 hydroxyl group with tert-butyldimethylsilyl chloride (TBDMSCl) gave 
the selectively protected diol 2.7.  The secondary alcohol of this was then oxidised using 
pyridinium dichromate (PDC), to furnish the desired DHQ analogue 2.8.  This intermediate 
was then further derivatised to give reported inhibitors 1.31, 1.32 and 1.36.1,3 
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i ii, iii iv
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Scheme 2.2  Literature method for the preparation of protected dehydroquinate derivative 2.8.  Reagents and 
conditions:  i. PhCHO, 4-TsOH, toluene, reflux (74%);  ii. H2, 10%Pd/C, AcOH, rt (94%);  iii. TBDMSCl, 
DMAP, ET3N, Bu4NI, 90ºC (54%);  iv. PDC, 4Å molecular sieves, CH2Cl2, rt (87%)
3
 
 
A two step procedure for the selective protection of quinic acid using 2,2,3,3-
tetramethoxybutane (TMB) 2.9 was reported by Montchamp et al. (Scheme 2.3).4  This 
involved the preparation of TMB 2.9 by heating butane-2,3-dione and trimethyl orthoformate 
at reflux in the presence of sulphuric acid.  Quinic acid methyl ester 2.10 was then reacted 
with 2.9 by heating at reflux with trimethyl orthoformate and camphorsulfonic acid (CSA) 
catalyst, in methanol, to furnish butane-2,3-bisacetal (BBA) protected quinic acid 2.11.  The 
RuCl3 catalysed KIO4 oxidation of the secondary hydroxyl of 2.11 gave protected 
dehydroquinate 2.12, an important intermediate in the synthesis of tricarboxylate 
dehydroquinate synthase inhibitors.5,6  
 
A more convenient one-pot procedure for the BBA protection of quinic acid 2.5 was 
subsequently employed by Armesto et al. in the synthesis of quinic and shikimic acid 
derivatives (Scheme 2.3).7  This procedure involves heating quinic acid 2.5 at reflux with 
butane-2,3-dione, trimethyl orthoformate, and a catalytic amount of CSA in methanol for 1 h 
to furnish protected quinic acid 2.11.  The secondary hydroxyl at C-3 was then selectively 
oxidised using pyridinium chlorochromate (PCC) to yield ketone 2.12.   
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Scheme 2.3  Reported methods for the preparation of protected dehydroquinate 2.12.  Reagents and conditions:  
i. H2SO4, MeOH, reflux (53%);  ii. Dowex 50 (H
+), MeOH, reflux;  iii. CH(OMe)3, (±)-CSA (87% over 2 
steps);4  iv. KIO4, K2CO3, RuCl3, H2O, CHCl3 (77%);
5  v. Butane-2,3-dione, CH(OMe)3, (±)-CSA, MeOH, 
reflux (90%);7  vi. PCC, CH2Cl2 (82%).
7
 
 
A modified version of the procedure of Armesto et al. was adopted by this group for the 
preparation of protected quinic acid 2.11 (Scheme 2.4).8  However longer reaction times (16-
20 h) were required and lower yields (70-80%) obtained than reported by Armesto et al.7  
Protected dehydroquinate 2.12 was prepared by PCC oxidation of 2.11 in CH2Cl2 over 4 Å 
molecular sieves for 18-48 h to produce the desired ketone in 70-80% yield.  This key 
intermediate was utilised in the preparation of the majority of putative inhibitors described in 
this work.   
 
The deprotected ketone 2.13 was also employed as an intermediate in cases where introduced 
functional groups where unstable under the acidic deprotection conditions (Scheme 2.4).  
Deprotection of 2.12 on treatment with 50% aqueous trifluoroacetic acid (TFA) at 60 ºC gave 
the desired product 2.13 in 42% yield, along with dehydroshikimate methyl ester 2.14 (13%), 
and other unidentified minor elimination products.  However, when the reaction was carried 
out in 95% TFA(aq) over ice, the undesired side-products were virtually eliminated, and the 
desired product 2.13 obtained in 90% yield following flash chromatography.  This second 
procedure often produced 2.13 in pure enough form, following evaporation of the solvent, that 
chromatographic purification was unnecessary.  In such cases the yield was deemed to be 
quantitative although the sample generally contained some residual moisture which could not 
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be completely removed by drying under vacuum.  Heating was avoided due to the sensitive 
nature of the compound. 
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Scheme 2.4  Preparation of key intermediates 2.12 and 2.13 and enzymatic substrate DHQ 1.4.  Reagents and 
conditions:  i. (CH3CO)2, CH(OMe)3, (D)-CSA, MeOH, reflux (70-80%);  ii. PCC, CH2Cl2, rt (70-80%);  iii. 
95% TFA/H2O, 0 ºC (90-100%);  iv. KOH, H2O (100%);  v. 50% TFA/H2O, 60 ºC (2.13 42%, 2.14 13%). 
 
The enzymatic substrate DHQ 1.4, required for the biological assays, was prepared from 2.13.  
The ester of 2.13 was removed by basic hydrolysis in 1 equivalent of KOH(aq) over ice as 
described in the literature,8 to furnish the substrate DHQ 1.4 quantitatively as the potassium 
salt.  The potassium salt was employed directly in the biological assays without conversion to 
the carboxylic acid. 
 
 
 
2.3  INHIBITORS WITH C ATTACHED AT C-3 
 
2.3.1 Synthesis of the Inhibitors 
 
It was anticipated that a Wittig reaction could be employed to functionalise ketone 2.12 at C-3 
en route to inhibitors of general structures 2.1 and 2.2.  However, the strongly basic 
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conditions commonly employed in some Wittig reactions would be expected to be 
incompatible with the highly functionalised and sensitive nature of the substrate 2.12.  
Consequently, the stabilised ylides (cyanomethylene)triphenylphosphorane (Scheme 2.5) and 
(carbethoxymethylene)triphenylphosphorane (Scheme 2.6) were used, eliminating the need 
for harsh basic conditions. 
 
The proposed inhibitors 2.15–2.18 were prepared as described in Scheme 2.5.  This initially 
involved the Wittig reaction of protected dehydroquinate 2.12 with 
(cyanomethylene)triphenylphosphorane (Scheme 2.5).  This ylide was prepared from the 
commercially available (cyanomethyl)triphenylphosphonium chloride by addition of 50% 
NaOH(aq) to an aqueous solution of the salt.  Protected deydroquinate 2.12 was then heated at 
reflux with the ylide to give protected allylic nitrile 2.19 as a single isomer, in 60% yield 
following recrystallisation.  The configuration was assigned as (E)-, the expected 
thermodynamic product, however attempts to confirm this by NOESY NMR were 
unsuccessful with the only through-space interactions of the vinyl proton observed to be with 
the CH3 groups of the protecting groups.  Treatment of 2.19 with 95% TFA(aq) then gave the 
methyl ester 2.20 in 72% yield following recrystallisation.  Hydrolysis of 2.20 in KOH(aq) 
furnished vinyl nitrile inhibitor 2.16 quantitatively as the potassium salt. 
 
Protected nitrile 2.19 was also subjected to catalytic hydrogenation over palladium on 
charcoal, to give the diastereomeric nitriles 2.21 and 2.22 and the amine 2.23 in varying 
amounts depending on the conditions (Scheme 2.5).  Reaction in CH2Cl2 with 40 mol% of 5% 
palladium on carbon gave a 1.2:3:1 ratio of 2.21:2.22:2.23.  Flash chromatography, followed 
by recrystallisation from pet. ether/EtOAc gave 2.21 and 2.22 in 5% and 19% yield 
respectively.  Reaction in methanol however, with 10 mol% of 10% palladium on charcoal 
gave 2.22 and 2.23 in a ratio of 1:3 with only trace amounts of 2.21.  Flash chromatography 
gave 2.22 and 2.23 in 20% and 39% yields respectively.  The configuration of the new 
asymmetric centre at C-3 was assigned for each of the products by 1H NMR, as described in 
section 2.3.2. 
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Scheme 2.5  Synthesis of nitrile inhibitors 2.15-2.17 and amine inhibitor 2.18.  Reagents and conditions:  i. 
PPh3CHCN, MeCN, reflux, (82%);  ii. 95% TFA(aq), 0ºC, (2.20 72%, 2.24 100%, 2.25 100%);  iii. KOH, H2O, 0 
ºC (2.15 100%, 2.16 100%, 2.17 100%);  iv. H2, 5% Pd/C, CH2Cl2 rt ( 2.21 5%, 2.22 19%);  v. H2, 10% Pd/C, 
MeOH, rt (2.22 20%, 2.23 38%);  vi. H2, 5% Pd/C, MeOH, rt;  vii. KOH, H2O, 0 ºC (71% over 2 steps). 
 
Diastereomers 2.21 and 2.22 were separately subjected to TFA deprotection to furnish diols 
2.24 and 2.25 respectively, the esters of which were hydrolysed with KOH(aq) to give 2.16 and 
2.17 quantitatively as the potassium salts.  A similar treatment of amine 2.23 with 95% 
TFA(aq) however, gave a mixture of compounds which proved unstable on attempted 
chromatographic purification.  An alternative preparation of 2.26 was attempted by catalytic 
hydrogenation of olefin 2.20.  This gave what appeared to be the desired product amino ester 
2.26, with some loss of the ester.  The poor resolution of the 1H NMR spectrum of the mixture 
however, made it impossible to accurately assign and the mixture was not further 
characterised.  The hydrolysis of the ester of 2.26 was completed in KOH(aq) to give the salt 
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2.18.  The 1H and 13C NMR showed a single isomer but the 1H NMR spectrum was again too 
poorly resolved to unambiguously assign the configuration at C-3.  It seems likely however, 
that the configuration of the product would be the same as that obtained when the reaction 
was carried out in MeOH on the protected substrate 2.19 to furnish the 3R-epimers of the 
nitrile 2.22 and amine 2.23 as the major products. 
 
The potential inhibitors 2.27–2.29 were prepared by Wittig reaction of protected 
dehydroquinate 2.12 with (carbethoxymethylene)triphenylphosphorane (Scheme 2.6).  As 
with nitrile 2.19, a single isomer was obtained in 89% yield and its NMR data were in 
agreement with the reported literature.5  Diester 2.30 was deprotected in 95% TFA(aq) to give 
the trans-diol 2.31, followed by basic hydrolysis of the ester to give the salt 2.27 
quantitatively over 2 steps.   
 
Diester 2.30 was also hydrogenated over palladium on charcoal to give diastereomers 2.32 
and 2.33 in a ratio of 9:7.  Chromatographic separation yielded the (3R)- and (3S)-epimers 
2.32 and 2.33 respectively, both in 37% yield.  The configuration at C-3 was assigned by 1H 
NMR as discussed in Section 2.3.2.  
 
Deprotection of 2.32 in 95% TFA(aq) gave the diester 2.34 which was treated with KOH(aq) to 
give the potential inhibitor 2.28 quantitatively as the potassium salt.  Deprotection of 2.33 in 
95% TFA(aq) furnished a product (obtained in 58% yield following chromatographic 
purification), the NMR of which indicated loss of the ethyl ester.  This, coupled with an 
observed mass of 231 Da (MH+), corresponding to a loss of 46 mass units (C2H5OH ) relative 
to the expected product, suggested that lactonisation had occurred.  Although there are three 
free hydroxyl groups which could potentially participate in the formation of a lactone, 2.35 is 
considered the most likely regioisomer on the basis of the 1H NMR spectrum, as discussed in 
Section 2.3.2.  Hydrolysis of the lactone 2.35 in aqueous KOH yielded dicarboxylate 2.29 
quantitatively as the potassium salt. 
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Scheme 2.6  Preparation of potential inhibitors 2.27-2.29.  Reagents and conditions:  i. MeCN, reflux, (89%);  ii. 
95% TFA, 0ºC, (2.31 100%, 2.34 100%, 2.35 58%);  iii. KOH, H2O, 0 ºC (2.27 100%, 2.28 100%, 2.29 100%);  
iv. H2, 10% Pd/C, EtOAc, rt ( 2.32 37%, 2.33 37%). 
 
2.3.2 Assignment of Configuration of Wittig Derivatives by 
1
H NMR 
 
The relative configuration at C-3 of the reduced Wittig derivatives 2.21, 2.22, 2.23, 2.32 and 
2.33 can be determined by 1H NMR.  The absolute configuration at C-3 can then be assigned 
on the basis of the known absolute configuration at C-4.  The proton at C-3 (2.0-2.5 ppm) is 
coupled to five adjacent protons and its resonance is therefore very complex and generally too 
poorly resolved to be analysed.  However, H-4 which is known to occupy the axial position, 
above the plane of the 6-membered ring, when in the preferred chair form (that in which the 
C-1 carboxyl and the C-4 and C-5 hydroxyls are all equatorial) has an appropriate resonance 
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for analysis.  H-4 is coupled to only two protons, H-5 which also has an axial orientation, and 
H-3 whose orientation is to be determined.  The H-4 signal therefore, is used to determine the 
relative configuration at C-3.   
 
The vicinal coupling constants between H-4 and neighbouring H-3 and H-5 protons are 
indicative of the dihedral angle between the two protons as described by the Karplus 
relationship.9  Both coupling constants for H-4 are large (9-11 Hz) and of similar magnitude 
when H-3 is in the axial position, resulting from the two trans-diaxial interactions with H-3 
and H-5.  However, the H-4 signal shows one large and one smaller (5-6 Hz) coupling 
constant when H-3 is in the equatorial position, resulting from the trans-diaxial interaction 
with H-5, and the gauche-interaction with the equatorial H-3 respectively. 
 
2.3.2.1 Assignment of Configuration at C-3 for Nitriles 2.21 and 2.22 
 
Figure 2.1 shows 1H NMR spectra of the diastereomeric nitriles 2.21 and 2.22.  Figure 2.1A 
shows the spectrum of the (3S)-diastereomer 2.21, in which the H-4 signal can be seen to be a 
double doublet at 3.50 ppm with two very similar coupling constants.  One constant, of 
magnitude 9.8 Hz arises from the interaction with axial H-5.  The second arises from the 
interaction with H-3 and has a magnitude of 10.7 Hz.  This is large for a vicinal coupling 
constant and indicates that the dihedral angle between H-3 and H-4 is approximately 180º.  
This means that H-3 must be in the axial position, in a trans- relationship to H-4 as illustrated 
in Figure 2.1A.   
 
Figure 2.1B shows the 1H NMR spectrum of the (3R)-diastereomer 2.22.  In this case the H-4 
signal can be seen to be a double doublet described by one large and one significantly smaller 
coupling constant.  The diaxial interaction between H-4 and H-5 has a coupling constant of 
10.5 Hz, similar to that for the (3S)-diastereomer.  The coupling constant defining the 
interaction between H-4 and H-3 however, is a substantially smaller 5.6 Hz, consistent with a 
gauche relationship between H-3 and H-4.  As H-4 is known to occupy the axial position, H-3 
must therefore occupy the equatorial position at C-3 as illustrated in Figure 2.1B. 
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Figure 2.1  
1H NMR spectra of diastereomeric nitriles 2.21 and 2.22.  A. 1H NMR spectrum of 2.21.10  B. 1H 
NMR spectrum of 2.22. 
 
2.3.2.2 Assignment of Configuration at C-3 for Amine 2.23 
 
The H-3 resonance of amine 2.23 can not be used to assign the relative configuration as it 
overlaps with other signals in the spectrum.  Therefore the configuration at C-3 must be 
determined by observing the influence of H-3 on the H-4 signal as described for 2.21 and 
2.22.  The H-4 signal again exhibits two vicinal coupling interactions, one large (10.1 Hz) 
indicative of a trans-diaxial coupling to H-5 and one smaller (5.3 Hz) indicative of a gauche 
coupling to H-3.  As H-4 is in an axial position, H-3 must therefore be in an equatorial 
position, in a syn- relationship to H-4 as illustrated in Figure 2.2. 
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Figure 2.2  
1H NMR spectrum of amine 2.23. 
 
2.3.2.3 Assignment of Configuration at C-3 for Diesters 2.32 and 2.33 
 
The respective configurations of the diastereomeric esters 2.32 and 2.33 were assigned as for 
the nitriles 2.21 and 2.22.  Figure 2.3A shows the 1H NMR spectrum of 2.32, in which the H-
4 resonance is a double doublet described by two relatively large coupling constants of 9.8 Hz 
and 10.7 Hz.  This is consistent with a diaxial relationship between H-3 and H-4.  H-3 must 
therefore be in the axial position as shown.  The 1H NMR of 2.33 (Figure 2.3B) shows a 
smaller coupling constant of 5.2 Hz between H-3 and H-4, relative to the larger constant of 
10.5 Hz between H-4 and H-5 consistent with a gauche relationship between H-3 and H-4.  
As H-4 is axial, H-3 must therefore occupy an equatorial position as shown in Figure 2.3B. 
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Figure 2.3  
1H NMR spectra of diastereomeric esters 2.32 and 2.33.  A. 1H NMR spectrum of 2.32.  B. 1H NMR 
spectrum of 2.33. 
 
2.3.2.4 Structural Assignment of Lactone 2.35 by 1H NMR 
 
The 1H and 13C NMR spectra of the sample in question indicate the loss of the ethyl ester and 
a mass of 231 (MH+), suggesting the formation of a lactone, rather than the free acid.  The 
formation of a lactone could potentially take place with any of the three free hydroxyl groups 
at C-1, C-4 or C-5, giving rise to three possible regioisomeric products 2.36, 2.35 and 2.37 
respectively.  An analysis of the proton NMR spectrum however, strongly supports the 
formation of the 3,4-lactone 2.35 (Figure 2.4). 
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Again the diagnostic signal was that of H-4.  The H-4 signal at 4.36 ppm displays a 0.8 ppm 
downfield shift relative to the to the corresponding signal (3.65 ppm) of the precursor 2.33 
(Figure 2.3B), suggestive of acylation of the C-4 hydroxyl.  The coupling constants for H-4 
were also altered relative to 2.33.  The proton NMR spectrum of the precursor 2.33 shows one 
large constant (10.5 Hz) describing the diaxial interaction with H-5 and one smaller (5.2 Hz) 
constant describing the gauche coupling with H-3.  The 1H NMR spectrum of the lactone 2.35 
however, shows the vicinal coupling of H-4 to H-3 and H-5 to be described by two 
intermediate, identical coupling constants of 7.8 Hz.  This suggests a change in conformation 
from the usual chair form, with the dihedral angle between H-4 and H-5 becoming slightly 
less than 180º, and the dihedral angle between H-3 and H-4 becoming less than 60º, resulting 
in a decrease and an increase respectively, in the corresponding coupling constants.  This is 
consistent with the formation of a bicyclic structure, resulting in a slight distortion of the 
original geometry.   
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Figure 2.4  
1H NMR spectrum of bicyclic lactone 2.35. 
 
Geometry optimisation of structure 2.35 using Spartan ‘04 quantum mechanics program 
suggests that the formation of lactone 2.35 would deform the usual geometry of the chair form 
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of the six-membered ring sufficiently to bring the H-3 and H-4 protons into an almost syn 
relationship and also skew the H-4 and H-5 protons slightly out of the normal diaxial 
relationship.  The predicted structure of lactone 2.35 has a dihedral angle of 164º between H-4 
and H-5, and a dihedral angle of 36º between H-3 and H-4 (Figure 2.5).  This is consistent 
with the differences between the coupling constants exhibited by the H-4 signals of 2.33 and 
2.35 as discussed above and supports the assigned structure as that of 2.35. 
 
 
Figure 2.5  Calculated geometry of bicyclic lactone 2.35 with Newman projections illustrating the calculated 
dihedral angles between H-3, H-4 and H-5. 
 
 
 
2.4 SYNTHESIS OF INHIBITORS WITH N ATTACHED AT C-3 
 
The preparation of semicarbazone inhibitor 2.38 was initially attempted by reaction of 
protected ketone 2.12 with semicarbazide hydrochloride in the presence of NaOAc (Scheme 
2.7).  This produced two isomers of protected semicarbazone 2.39 in a 2:1 ratio.  The 
stereochemistries of the isomers were not assigned, but it is likely that the major isomer was 
the thermodynamically more favourable (E)-isomer.  The semicarbazone functionality 
however was not stable under the acidic conditions of the BBA protecting group removal, 
yielding dehydroquinate methyl ester 2.13 instead of the desired semicarbazone methyl ester 
2.40. 
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Methyl dehydroquinate 2.13 (prepared by deprotection of 2.12) was subsequently employed 
as the intermediate ketone in the synthesis of semicarbazone inhibitor 2.38 (Scheme 2.7).  
Methyl dehydroquinate 2.13 was reacted with semicarbazide hydrochloride and sodium 
acetate (1:1.3) in water at 50-60 ºC to give a mixture of semicarbazone 2.40, elimination 
products and highly coloured (yellow-brown) impurities.  It was found that carrying out the 
reaction in a solution adjusted to pH 7 by addition of excess sodium acetate prevented the 
elimination of the hydroxyl groups and reduced the occurrence of the coloured impurities.  
This gave a mixture of isomers of 2.40 in a 10:1 ratio.  The residual acetic acid and sodium 
acetate were removed from the product mixture by silica gel chromatography to furnish 
semicarbazone 2.40 as a 20:1 ratio of isomers in 82% yield.  The ester of 2.40 was then 
hydrolysed in KOH(aq) to furnish salt 2.38 quantitatively. 
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Scheme 2.7  Synthesis of semicarbazone inhibitor 2.38.  Reagents and conditions:  i. NH2NHCONH2·HCl, 
NaOAc, MeOH, H2O, 50 ºC  (53%);  ii. 95% TFA/H2O, 0 ºC (90%);  iii. NH2NHCONH2·HCl, NaOAc, MeOH, 
H2O, 40 ºC (20:1 E:Z, 82%),  iv. KOH, H2O, 0 ºC (quant). 
 
It is not known for certain whether the stereochemistry of the major isomer is E or Z.  
However, the known inhibitor 1.36 (see Scheme 2.8) was prepared as a single isomer by 
Abell and co-workers following a similar route.1  The stereochemistry of 1.36 was assigned as 
E (the likely thermodynamic product) and confirmed by the crystal structure of M. 
tuberculosis DHQase with oxime 1.36 bound in the active site.11  It seems likely that the 
hydrazone derivatives would follow a similar pattern, though apparently with less 
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stereoselectivity.  On this basis the major isomer in each case was assumed to be the (E)-
isomer. 
 
Hydrazone methyl ester 2.41 was prepared from methyl dehydroquinate 2.13 and hydrazine 
hydrochloride (Scheme 2.8).  The solution was adjusted to pH 7 by addition of excess 
NaOAc.  The product 2.41 was obtained as 2:1 ratio of isomers containing a very intensely 
coloured brown impurity which was not detectable by NMR.  It was observed that increasing 
the scale of the reaction from 50 mg to 1 g dramatically increased the apparent proportion of 
the coloured impurity.  Repetitive flash chromatography on deactivated silica (1% Et3N in the 
solvent used to pack the column to protect the acid-sensitive compound from the silica) only 
intensified the colour and left large amounts of Et3N in the product which could not be 
removed in vacuo.  Chromatography on non-deactivated silica was found to be preferable, 
however the recovery of the product from the column was low (10% overall yield), with the 
minor isomer not recovered. 
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Scheme 2.8  Synthesis of hydrazone inhibitors 2.39, 2.41, 2.43 and 2.45.  Reagents and conditions:  i. 
NH2NH2·2HCl, NaOAc, H2O, pH 7, rt (E only, 10%);  ii. NH2NH2·H2O, H2O, rt (3:1 E:Z, 44%);  iii. 
NH2NHCSNH2, NaOAc/AcOH, H2O, MeOH, 40 ºC. (9:1 E:Z, 51%);  iv. NH2NHCOH, H2O, rt (3:2 E:Z, 24%);  
v. NH2OH·HCl, NaOAc. H2O, pH 7, rt (55%);  vi. KOH, H2O, 0 ºC, (quant). 
 
An alternative approach to the preparation of hydrazone 2.41 involved the reaction of methyl 
dehydroquinate 2.13 with one equivalent of hydrazine hydrate in water at ambient 
temperature.  Though this method significantly reduced the amount of the coloured impurity, 
the reaction did not go to completion, and produced a mixture of the two isomers of 2.41 
 2   Synthesis of Potential Dehydroquinase Inhibitors 44 
(5:4), starting material and an unidentified side-product.  The mixture was purified by column 
chromatography, without deactivating the silica, to furnish a 3:1 ratio of the isomers 2.41 in 
44% yield.  Increasing the amount of hydrazine hydrate in the reaction from 1 equivalent to 
1.5 in an attempt to force the reaction to completion resulted in partial loss of the ester as 
indicated by 1H NMR.  The ester of 2.41 was hydrolysed in KOH(aq) to furnish 2.42 
quantitatively. 
 
Thiosemicarbazone methyl ester 2.43 was prepared by reaction of methyl dehydroquinate 
2.13 with thiosemicarbazide (Scheme 2.8) in a mixture of 1.8 M acetate buffer (pH 7) and 
MeOH.  A 9:1 ratio of isomers (with the major isomer assumed to be E) was obtained in 51% 
yield following chromatography on deactivated silica.  The esters 2.43 were converted 
quantitatively to the potassium salts 2.44 by hydrolysis in aqueous KOH. 
 
Formylhydrazone methyl ester 2.45 was prepared from methyl dehydroquinate 2.13 by 
reaction with formic hydrazide in H2O at rt.  Formic hydrazide was used as the free amine and 
as such it was not necessary to buffer the reaction mixture to prevent acid catalysed 
elimination of the hydroxyl groups.  The crude sample contained the isomers 2.45 in a 4:3 
ratio (E:Z) and 10% unidentified side-product (as determined by 1H NMR).  The undesired 
side-product was difficult to remove chromatographically.  Therefore only the fraction shown 
by 1H NMR to contain the least impurity (4%) was taken for deprotection and assay.  This 
represented a 24% yield of 2.45, in a 3:2 (E:Z) ratio of isomers.  A further 39% was recovered 
from the column, containing 14% impurity and a 4:3 (E:Z) ratio of isomers.  The esters 2.45 
(3:2 E:Z) was converted quantitatively into the potassium salt by basic hydrolysis to yield 
inhibitor 2.46 as a 3:2 mixture of isomers.  
 
Known dehydroquinase inhibitor, oxime 1.36 was also prepared as a standard with which to 
compare the assay results obtained for new inhibitors (Scheme 2.8).  The oxime methyl ester 
2.47 was prepared by reacting hydroxylamine hydrochloride with methyl dehydroquinate 
2.13, in the presence of NaOAc at pH 7.  A single isomer (assigned as the (E)-isomer based 
on the literature)1 was obtained, which was purified by silica gel chromatography to obtain 
oxime methyl ester 2.47 in 55% yield.  The carboxyl group was deprotected by basic 
hydrolysis of the methyl ester to furnish oxime 1.36 quantitatively as the potassium salt, the 
1H NMR data of which agreed with the literature.1,12 
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2.5 INVESTIGATIONS INTO THE SYNTHESIS OF FLUORINATED 
DEHYDROQUINATE DERIVATIVES 
 
2.5.1 Background 
 
Dehydroquinate derivatives with fluorine incorporated at C-2, C-3 and C-6 have been 
prepared by various methods and these display a variety of biological activities.3,13-18  (2R)-2-
Fluorodehydroquinate 1.32 (Scheme 2.9) is a suicide inhibitor of type I DHQase and a 
substrate for type II DHQase.17,18  The 3-fluoro-analogues 1.40 and 1.41 (Scheme 2.10) are 
competitive reversible inhibitors of type II DHQase and also poor competitive inhibitors of 
type I DHQase.13,14  The 6-fluorodehydroquinate epimers 2.51a and 2.51b (Scheme 2.11) are 
substrates for both type I and II DHQase.15 
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Scheme 2.9  Reported synthesis of (2R)-2-fluorodehydroquinate 1.32.3  Reagents and conditions:  i. TMSOTf, 
Et3N, toluene, reflux; ii. Selectfluor®, DMF, rt (89%);  iii. AcOH, H2O, 50 ºC (90%). 
 
The synthetic method used by Abell and coworkers to prepare type I DHQase inhibitor (2R)-
2-fluorodehydroquinic acid 1.32 involved the initial selective protection and oxidation of 
quinic acid 2.5 to give protected dehydroquinic acid 2.8 (Scheme 2.2).3,18  This was then 
converted into protected fluoroketone 2.48 by electrophilic fluorination of its corresponding 
silylenolether using Selectfluor® fluorinating reagent (Scheme 2.9).  This was deprotected in 
aqueous acetic acid to give (2R)-2-fluorodehydroquinic acid 1.32. 
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Scheme 2.10  Reported synthesis of fluorinated DHQase inhibitors 1.40 and 1.41.13,14  Reagents and conditions:  
i. CH2(OMe)2, P2O5, CHCl3 (80%);  ii. DAST, DME, 80 ºC (2.49 13%, 2.50 45%);  iii. TFA, H2O, 60 ºC;  iv. 
NaOH, H2O;   v. Amberlite IR-120(H) (1.40 63%, 1.41 96% over 3 steps). 
 
The 3-fluoro derivatives of dehydroquinic acid 1.40 and 1.41 were prepared by Abell and co-
workers using BBA protected dehydroquinic acid 2.12 as an intermediate (Scheme 2.10).13,14  
The C-1 hydroxyl was protected as the methoxymethy (MOM) ether, and fluorine was 
introduced into the cyclohexanone ring upon treatment with diethylaminosulfur trifluoride 
(DAST) in 1,2-dimethoxyethane (DME), giving fluorinated products 2.49 and 2.50 in 13% 
and 45% yield respectively.  Compounds 2.49 and 2.50 were separately deprotected over 
three steps to give the free acids 1.40 and 1.41 respectively. 
 
An enzymatic approach was used by Abell et al. to prepare (6R)- and (6S)-
fluorodehydroquinic acids (2.51a and 2.51b),  en route to the corresponding fluoroshikimic 
acids (2.52a and 2.52b).16  6-Fluoroshikimate was prepared from 3-
fluorophosphoenolpyruvate (2.53a and 2.53b) and erythrose-4-phosphate 1.1 using the 
shikimate pathway enzymes DAHP synthase, dehydroquinate synthase, dehydroquinase and 
shikimate dehydrogenase.  The fluorodehydroquinates 2.51a and 2.51b were employed in 
mechanistic studies on types I and II DHQase.15 
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Scheme 2.11  Reported enzymatic synthesis of (6R)- and (6S)-fluorodehydroquinate 2.51a and 2.51b.15,16  
Reagents and conditions:  i. DAHP synthase, Mn2+;  ii. DHQ synthase, Co2+, NAD+;  iii. DHQase;  iv.  shikimate 
dehydrogenase, NADPH (2.52a 17%, 2.52b 17%). 
 
2.5.2 Synthesis of 2-Fluorodehydroquinate Derivatives 
 
The participation of the C-2 protons of DHQ 1.4 in the mechanisms of both types of DHQase 
(Section 1.3), coupled with the known inhibitory activity of (2R)-2-fluorodehydroquinate 1.32 
against type I DHQase (Section 1.4) suggested that other 2-fluorodehydroquinate derivatives 
might have interesting biological properties. The synthesis of 2-fluorodehydroquinate 
derivatives was therefore investigated.  The method chosen was similar to that employed by 
Abell and coworkers in the synthesis of (2R)-2-fluorodehydroquinic acid 1.32, however 
ketone 2.12 was employed in preference to 2.8 as the selectively protected intermediate 
(Scheme 2.12). 
 
Protected dehydroquinate 2.12 was heated at reflux in toluene with trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) and triethylamine, as described by Abell and 
coworkers.3  This gave a mixture of the desired C-1 protected silylenolether 2.54 and the 
intermediate TMS protected ketone 2.55 in a ratio of 1.4:1 as determined by 1H NMR.  The 
TMS protection of the C-1 hydroxyl was not reported by Abell et al.3 in their fluorination of 
the dehydroquinate 1,5-lactone 2.8 and was expected to have implications for the 
stereochemistry of the subsequent fluorination.  The lack of completion of the reaction was 
attributed to the consumption of the silylating reagent by the tertiary hydroxyl. 
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Scheme 2.12  Synthesis of 2-fluorodehydroquinate analogues 2.57 and 2.59.  Reagents and conditions:  i. 
TMSOTf, Et3N, toluene, reflux;  ii. Selectfluor
®, MeCN, 4 Å molecular sieves, rt (32% from 2.12);  iii.  SiO2, 
EtOAc/pet. ether/Et3N (51% from 2.12). 
 
Attempts to increase the yield of silylenolether 2.54 by doubling the amount of TMSOTf in 
the reaction resulted in the formation of protected dehydroshikimate 2.56 as the major 
product.  This was presumed to be due to the Lewis acidity of the TMSOTf, as 
dehydroquinate derivatives are known to undergo elimination of the C-1 hydroxyl under 
acidic conditions.  The amount of Et3N in the reaction mixture relative to the amount of 
TMSOTf was therefore increased.  A combination of ketone starting material 2.12, TMSOTf 
and Et3N in a 1:6:10 ratio drove the reaction to completion and prevented the formation of the 
side-product 2.56, giving silylenolether 2.54 as the sole product, which was used directly in 
the fluorination step without purification. 
 
Silylenolether 2.54 was stirred with Selectfluor® in dry dimethylformamide (DMF) at rt to 
give a mixture of products containing TMS-protected ketone 2.55, protected 
dehydroshikimate 2.56, and α-fluoroketones 2.57 and 2.58 (4:2:2:1).  An alternative solvent 
was chosen and the reaction carried out again over 4 Å molecular sieves in an attempt to 
maximise the formation of fluoroketone 2.57. 
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The desired α-fluoroketone 2.57 was obtained as the major product on carrying out the 
reaction in acetonitrile, with ketone 2.55 also obtained as a minor product (6:1).  The 2-
fluoroketone 2.57 was obtained as a single diastereomer, and the configuration at C-2 
assigned by 1H NMR as discussed in section 2.5.3 (Figure 2.6).  Unsurprisingly, given the 
expected steric hindrance due to the axial TMS-protected C-1 hydroxyl, the configuration at 
C-2 was found to be S, with the fluorine in the axial position.  The Selectfluor® electrophilic 
fluorinating reagent (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis-
(tetrafluoroborate)) is bulky, and it makes sense that it would be forced to approach from 
above the six-membered ring with the TMS group blocking approach from below. 
 
Purification of (2S)-2-fluoroketone 2.57 proved problematic however, as its behaviour on 
attempted chromatographic separation was somewhat capricious.  Flash chromatography on 
deactivated silica gave the (2R)-2-fluoroketone 2.59 as the main product, obtained in 51% 
yield (from 2.12).  Chromatography on alumina gave a mixture of both C-2 epimers as the 
free alcohols 2.58 and 2.59 in a ratio of 1:2 in 24% yield.  Chromatography on silica (without 
deactivation) of a 1:1 mixture of 2.57 and 2.55 gave (2S)-2-fluoroketone 2.57 and ketone 2.55 
in 32% and 31% yield respectively from 2.12.   
 
(2S)-2-Fluoroketone 2.57 was deprotected in 95% TFA(aq) to liberate the hydroxyl groups but 
attempts to deprotect the carboxyl group to give 2.60 were unsuccessful (Scheme 2.12).  Basic 
hydrolysis in KOH(aq) destroyed the starting material.  Acid hydrolysis in AcOH/H2O resulted 
in partial epimerisation at the fluorinated centre with no ester hydrolysis observed by 1H 
NMR.  The mixture of epimers (1:2.5 R:S) recovered from the attempted acid hydrolysis was 
subjected to nucleophilic dealkylation conditions using sodium cyanide, which destroyed the 
starting material.   
 
(2S)-2-Fluorodehydroquinic acid 2.60, whose synthesis has not been reported, was expected 
to exhibit interesting biological activity against types I and II DHQase.  It was therefore 
desirable to solve the problem of the final deprotection of the carboxylate.  As appropriate 
deprotection conditions could not be investigated further without preparing more (2S)-2-
fluoroketone 2.57, it was decided to incorporate an alternative carboxyl protecting group into 
the synthesis, which could be removed either under the conditions of the diol deprotection or 
under mild neutral conditions. 
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Two alternative esters were investigated, an allyl ester which can be cleaved by palladium(0) 
catalysed allyl transfer,19,20  and an acid-labile p-methoxybenzyl ester (reported by Abell and 
co-workers to solve a related problem).17  It was thought that this second ester could be 
removed simultaneously with the BBA protecting group in a single step, eliminating the need 
for a separate carboxyl deprotection step. 
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Scheme 2.13  Preparation of allyl ester protected intermediate 2.63.  Reagents and conditions:  i. a) KOH, H2O 0 
ºC b) Amberlite IR-120(H) (95%);  ii.  AllBr, KHCO3, DMF, rt (65%);  iii. PCC, CH2Cl2, rt (71%);  iv. 95% 
TFA, H2O, 0 ºC (96%);  v. Pd(0)(PPh3)4, dimedone, THF, rt (75%). 
 
Allyl ester intermediate 2.63 was prepared as illustrated in Scheme 2.13.  The key 
intermediate ketone 2.12 was not directly converted to the allyl ester 2.63 as it was known to 
decompose under the conditions of the basic ester hydrolysis.21  Protected quinic acid 2.11 
was therefore converted into the corresponding allyl ester by basic hydrolysis of the methyl 
ester followed by acidification over Amberlite IR-120(H) ion exchange resin to give the free 
acid intermediate 2.61.  This was followed by reaction with allyl bromide in the presence of 
KHCO3 to furnish the allyl ester 2.62 in 65% yield following flash chromatography.  This 
secondary alcohol was oxidised using PCC, to give protected dehydroquinic acid 2.63 in 71% 
yield following chromatography.   
 
Deprotection conditions were investigated, using DHQ as a model system, prior to carrying 
out the fluorination reaction.  The diol was successfully liberated employing 95% TFA(aq) to 
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furnish ester 2.64 in 96% yield.  The allyl ester deprotection method of Kunz and Waldmann 
(employed in glycoprotein synthesis), using tetrakis-triphenylphosphine palladium (0) in THF 
with morpholine (10 equivalents) acting as the nucleophilic allyl acceptor, was initially 
attempted.19  While this method was observed by 1H NMR to remove the ester of 2.64, the 
work up was problematic, due to the high water and low organic solubility of the product, and 
the residual morpholine could not be completely separated from the product.  An alternative 
allyl acceptor was sought.  It was desirable that the chosen nucleophile be taken up into the 
organic fraction during the work-up, without necessitating the use of any acids, bases or salts, 
as the solubility of the product was such that it would be extracted into the aqueous fraction.  
 
Palladium catalysed deprotection methods for allyl protecting groups have been reviewed by 
Guibé.20  Dimedone was used as an allyl scavenger in the deprotection of allyl carbamates by 
Kunz and coworkers.22  It was thought that the excess dimedone might be more easily 
separated from the water soluble product by extraction than was the case for morpholine.  The 
Pd(PPh3)4 catalysed removal of the ester from 2.64 did not go to completion with 10 
equivalents of dimedone in acetonitrile.  However, the use of THF as solvent and a 40 min 
reaction time resulted in complete conversion.  Both catalyst and dimedone were removed by 
multiple extractions with chloroform and ethyl acetate to yield the free product dehydroquinic 
acid 1.4 in 75% crude yield. 
 
The successful allyl ester methodology was subsequently applied to the preparation of (2S)-2-
fluorodehydroquinate 2.60 (Scheme 2.14).  Protected DHQ allyl ester 2.63 was converted into 
the silylenolether 2.65 and this was fluorinated using the conditions described for 2.57 
(Scheme 2.12) to give a 3:1 mixture of the desired (2S)-2-fluoroketone 2.66 and the 
unfluorinated ketone 2.67.  Fluoroketone 2.66 was obtained in 37% yield following flash 
chromatography on silica.  The fluorketone 2.66 was obtained as a single diastereomer, the 
stereochemistry of which was assigned by 1H NMR (Section 2.5.3).  The configuration at C-2 
was found to be the same as that of 2.57, with the fluorine in the axial position. 
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Scheme 2.14  Fluorination of protected dehydroquinate allyl ester 2.63.  Reagents and conditions:  i. TMSOTf, 
Et3N, toluene, reflux;  ii. Selectfluor
®, MeCN (37% over 2 steps);  iii.  95% TFA, H2O, 0 ºC; iv. Pd(0)(PPh3)4, 
dimedone, THF, rt. 
 
Ketone 2.66 proved to be unstable under the TFA deprotection conditions, although some 
peaks which were consistent with the expected product were discernable in the 1H NMR 
spectrum of the resulting mixture.  The crude mixture was subjected to palladium catalysed 
removal of the allyl ester as described previously but peaks indicative of the desired product 
were not visible in the 1H NMR spectrum. 
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Scheme 2.15  Preparation of p-methoxybenzyl quinate derivative 2.68.  Reagents and conditions:  i. a) KOH, 
H2O, 0 ºC b) Amberlite IR-120(H); ii. p-methoxybenzyl chloride, KHCO3, DMF, rt (41% over 2 steps); iii. PCC, 
CH2Cl2, rt 
 
The p-methoxybenzyl (PMB) ester was also investigated as a carboxy protecting group.  The 
PMB protected quinic acid 2.68 was prepared in the same way as the corresponding allyl ester 
2.62 (Scheme 2.15).  The methyl ester of 2.11 was hydrolysed in aqueous KOH and acidified 
over Amberlite IR-120(H) ion exchange resin.  The free acid 2.61 was subsequently converted 
into the PMB protected derivative by reaction with p-methoxylbenzyl chloride in the presence 
of KHCO3, to furnish 2.68 in 41% yield following column chromatography on silica.  The 
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secondary alcohol 2.68 was then subjected to the conditions of the PCC oxidation, however 
the starting material proved to be unstable under the reaction conditions and neither starting 
material nor desired product 2.69 were recovered following filtration through silica. 
  
It was subsequently elected not to continue further with the attempted synthesis of (2S)-2-
fluorodehydroquinic acid 2.60 due to time constraints.  The investigation of more appropriate 
protecting groups might be continued by others in the future.  However, the (2S)-2-
fluorodehydroquinate derivatives investigated thus far appear to be substantially less stable 
than the corresponding (2R)-2-fluorodehydroquinate derivatives and it may be that the desired 
product (2S)-2-fluorodehydroquinate 2.60 simply isn’t stable enough for isolation and 
biological assay. 
 
2.5.3 Assignment of the Configuration at C-2 of Fluorinated 
Dehydroquinate Derivatives by 
1
H NMR 
 
The relative configuration at C-2 of the α-fluoroketones 2.57, 2.59 and 2.66 was determined 
by 1H NMR.  The absolute configurations of C-1, C-4 and C-5 are known (depicted in Figure 
2.6 to Figure 2.8) and from this information the absolute configuration at C-2 can be inferred.  
The evidence of interactions of protons with the C-2 fluorine was considered, as well as the 
absence of interactions with the C-2 proton which was replaced by the fluorine.  The specific 
details of the analysis of each spectrum, and comparisons to the spectra of each of the 
corresponding parent ketones 2.55, 2.12 and 2.63 are discussed below. 
 
2.5.3.1 Assignment of Configuration at C-2 for (2S)-2-Fluoroketone 2.57 
 
The H-2eq proton of ketone 2.55 displays a long-range W-coupling of 2.5 Hz with H-6eq 
(Figure 2.6B).  This interaction is also observed between H-6 and the remaining H-2 signal of 
the fluorinated analogue 2.57 (J = 1.5 Hz) suggesting that the remaining proton at C-2 retains 
its equatorial position in 2.57 (Figure 2.6A).  The 1.2 Hz long-range coupling apparent 
between H-4 and H-2ax in the spectrum of ketone 2.55 is not observed in the H-4 signal of 
fluoroketone 2.57, suggesting that there is no H-2ax proton present. 
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Figure 2.6  A. Partial 1H NMR spectrum of 2.57.  B. Partial 1H NMR spectrum of 2.55. 
 
The H-4 signal of 2.57 does display an additional 7.5 Hz coupling which is not observed in 
the corresponding resonance of the parent compound 2.55, and is attributed to a long-range 
coupling to the C-2 fluorine atom.  As H-4 is known to occupy an axial position, the 
occurrence of a long-range coupling to the fluorine atom suggests that the orientation of the 
fluorine is also axial.  H-6ax also displays a coupling (4.7 Hz) which to the C-2 fluorine.  
Again, the long-range coupling to this axial proton suggests that the fluorine atom also 
occupies an axial position.  However, H-6eq also displays a coupling to the fluorine atom, 
although it is weaker with a coupling constant of approximately 3 Hz.  The 19F NMR shows a 
multiplet, with a large geminal coupling to H-2 (48.9 Hz) and several other interactions with 
smaller coupling constants.  However, the resolution is such that only the geminal coupling 
constant could be determined. 
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2.5.3.2 Assignment of Configuration at C-2 for (2R)-2-Fluoroketone 2.59 
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Figure 2.7   A.  Partial 1H NMR spectrum of 2.59.  B. Partial 1H NMR spectrum of 2.12. 
 
The 1.5 Hz long-range di-axial coupling between H-4 and H-2ax, seen in the spectrum of 2.12 
(Figure 2.7B), is also evident between H-4 and the remaining H-2 proton signal of 2.59 
(Figure 2.7A), suggesting that the H-2 proton is axial in 2.59.  In contrast to the spectrum of 
2.57 (Figure 2.6A), the H-4 signal of 2.59 (Figure 2.7A) does not display an additional di-
axial coupling to the fluorine atom, but is identical to the H-4 signal of the parent ketone 2.12 
(Figure 2.7B), suggesting that the fluorine does not occupy the axial position in 2.59.  The H-
6eq resonance on the other hand, displays a 4.8 Hz coupling to the fluorine atom.  This 
replaces the 2.9 Hz long-range W-coupling with H-2eq observed in the spectrum of 2.12, 
indicating that the fluorine occupies the equatorial position in 2.59.  The equatorial fluorine of 
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ketone 2.48 (Scheme 2.9), whose configuration at C-2 was assigned in a similar manner, was 
also reported by Manthey et al. to be coupled to H-6eq, with J = 8 Hz.3 
 
2.5.3.3 Assignment of Configuration at C-2 for (2S)-2-Fluoroketone 2.66 
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Figure 2.8  A. Partial 1H NMR spectrum of 2.66.  B. Partial 1H NMR spectrum of 2.63. 
 
The 1H NMR spectrum of fluorinated allyl ester 2.66 (Figure 2.8A) is very similar to that of 
the methyl ester 2.57 (Figure 2.6A).  The long-range W-coupling interaction between H-6eq 
and H-2eq, observed in the spectra of the parent ketone 2.63 (Figure 2.8B) and 2.57, is also 
apparent for α-fluoroketone 2.66 (Figure 2.8A).  However, the 1.1 Hz long-range coupling to 
H-2ax visible in the H-4 resonance of the parent ketone 2.63 is not evident in the 
corresponding resonance of fluoroketone 2.66.  The H-4 signal of 2.66 does, however, display 
a 7.4 Hz coupling to the fluorine atom.   Like H-4, H-6ax also appears to be coupled (4.7 Hz) 
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to the C-2 fluorine.  These factors indicate that, as in the case of fluoroketone 2.57, the 
fluorine occupies the axial position in 2.66. 
 
 
 
2.6 SYNTHESIS OF AN EPOXIDE-BASED INHIBITOR 
 
Proposed epoxide inhibitor 2.4 was thought to be a possible candidate for an inhibitor of both 
types I and II DHQase.  The epoxide provides both an electronegative atom at C-3 for 
inhibition of type II DHQase, and a site for irreversible alkylation by the active site lysine of 
type I DHQases.  The synthesis of 2.4 is described in Scheme 2.16 and Scheme 2.18. 
 
Olefin 2.70 was prepared as an intermediate in the synthesis of both the desired epoxide 2.4 
and allylic bromide 2.71, a potentially useful intermediate in the synthesis of a range of C-2 – 
C-3 unsaturated analogues (Scheme 2.16).  In order to avoid the harsh basic conditions 
required for carbonyl methylenation via the Wittig reaction, Takai’s method was employed, as 
described by Frost for the methylenation of protected dehydroquinic acid 2.12.6,23  The C-1 
tertiary hydroxyl was reacted with trimethylsilyl (TMS) chloride to give the TMS protected 
ketone 2.55 in 96% yield.  This was then treated with diiodomethane, titanium (IV) chloride, 
and activated zinc to give protected olefin 2.70.  This reaction was found to be somewhat 
fickle.  It did not go to completion unless the THF used as solvent was not only anhydrous, 
but oxygen free (judged by formation of a deep purple, rather than blue, complex with 
sodium/benzophenone).   
 
The successful reaction also produced mixtures of the three products 2.70, 2.72 and 2.73.  
Typically the fully protected olefin 2.70 was obtained in 64% yield, along with the partially 
protected product 2.72 in 10% yield, following flash chromatography.  On one occasion, the 
partially protected product 2.72 and the free triol 2.73 were obtained in 50% and 25% yields 
respectively, following column chromatography.  This partial deprotection was most likely 
due to the acidic nature of the workup and seemed to be exacerbated by increasing the scale of 
the reaction, perhaps due to the greater amount of heat liberated when the zinc metal 
dissolved in the cold 1 N HCl(aq).  Although this was carried out over an ice bath, the 
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precaution may not have been sufficient, or the reaction mixture may have been added too 
quickly. 
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Scheme 2.16  Synthesis and derivatisation of olefin intermediates 2.70-2.72 and allylic bromide intermediates 
2.73-2.75.  Reagents and conditions: i. TMSCl, HMDS, pyridine, rt (96%);  ii. Zn, CH2I2, TiCl4, THF, 0 ºC – rt 
(2.70 64%, 2.72 50%, 2.73 25%);  iii. a) PhSeBr, Na2CO3, CH2Cl2, -78 ºC, b) m-CPBA, pyridine, CH2Cl2, -78 ºC 
– rt (2.74 42%);  iv. SiO2 (40%, 2 steps);  v. 95% TFA, H2O,  0 ºC (100%);  vi. KOH(aq), 0 ºC. 
 
The allylic bromide intermediate 2.71 was prepared from olefin 2.70 according to the method 
of Kolt24 as employed by Frost.6  The regiospecific anti- Markovnikov addition of 
phenylselenyl bromide to olefin 2.70 was carried out at -78 ºC for 23 h.  The adduct thus 
obtained was converted into the allylic bromide 2.71 in situ by oxidative elimination with m-
chloroperbenzoic acid (m-CPBA) in the presence of pyridine.  Purification of the crude 
product by flash chromatography on silica resulted in the loss of the TMS group to give 2.74 
in 40% yield.  This reaction was also successfully carried out on the free alcohol 2.72 to yield 
the corresponding allylic bromide 2.74 in 42% yield following flash chromatography. 
 
Time constraints meant that it was not practical to pursue the derivatisation of allylic bromide 
2.74 in the preparation other C-2–C-3 unsaturated DHQ analogues.  The deprotection of 2.74 
was attempted however, as it was thought that the free allylic bromide 2.76 was worth 
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investigating.  The similarity to anhydroquinic acid 1.37, a potent inhibitor of type II DHQase 
from S. coelicolor, and the expected susceptibility of the allylic bromide to nucleophilic attack 
by the active site lysine of type I DHQase suggested that 2.75 could potentially be an inhibitor 
of both types of DHQase.  Deprotection of 2.74 in 95% TFA(aq) furnished 2.75 quantitatively, 
however, this proved to be unstable under the conditions of the basic ester hydrolysis. 
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Scheme 2.17  Attempted deprotection of allylic bromide derivative 2.78.  Reagents and conditions:  i. 95% 
TFA(aq), 0 ºC (91%);  ii. KOH(aq), 0 ºC;  iii. HCl(aq), reflux;  iv. TMSCl, NaI, MeCN, reflux. 
 
It was thought that 2.77 might also be susceptible to nucleophilic attack by type I DHQase.  
Deprotection of allylic bromide 2.7825 in 95% TFA(aq) was therefore carried out to furnish the 
free diol 2.79 in 91% yield following chromatography (Scheme 2.17).  Like allylic bromide 
2.75 however, 2.79 was unstable to basic hydrolysis.  Acidic conditions and TMSCl/NaI were 
equally unsuccessful for 2.79 and 2.78 respectively.  The investigation of deprotection 
conditions for allylic bromides 2.75 and 2.79 was not pursued. 
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Scheme 2.18  Synthesis of epoxide inhibitor 2.4.  Reagents and conditions:  i. a) KOH, H2O, 0 ºC  b) Amberlite 
IR-120(H);  ii.  AllBr, KHCO3, DMF, rt (45% over 2 steps);  iii.  m-CPBA, CH2Cl2, rt (major isomer 60%, minor 
isomer 13%);  iv.  Pd(0)(PPh3)4, dimedone, THF, rt (72%). 
a This reaction was carried out on the major isomer only. 
 
The epoxide of proposed inhibitor 2.4 was expected to be unstable under the acidic and basic 
conditions of the usual diol and ester deprotection steps.  The epoxide was therefore prepared 
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from the free triol 2.73, and an allyl ester employed in preference to a methyl ester as the 
carboxy protecting group (Scheme 2.18). 
 
The triol 2.73, obtained as a side product in the methylenation step (Scheme 2.16), was 
converted to the allyl ester 2.80 in two steps (Scheme 2.18).  The methyl ester was hydrolysed 
in aqueous KOH, followed by acidification over amberlite IR-120(H) ion exchange resin.  
The resulting acid was then reacted with allyl bromide in the presence of KHCO3 to furnish 
the olefin allyl ester 2.80 in 45% yield following column chromatography.  The olefin 2.80 
was then reacted with just over one equivalent of m-CPBA to give the epoxide 2.81 as two 
isomers in a ratio of 1:4 as determined by 1H NMR.  Flash chromatography separated the 
major and minor isomers, giving 60% and 13% yields respectively.  The yields were 
determined by 1H NMR as both isomers contained some residual reagent (15% in the case of 
the minor isomer and 11% in the case of the major isomer).  The major isomer was used in the 
subsequent step, and the impurity removed during the work-up.  The carboxyl deprotection 
conditions developed for the deprotection of the DHQ allyl ester 2.64 (Scheme 2.13) were 
applied to the major isomer of 2.81 and the allyl ester removed by Pd(0)(PPh3)4 catalysed 
allyl transfer to dimedone to yield the free acid 2.4 in 72% yield. 
 
 
 
2.7 CONCLUSION 
 
A series of potential inhibitors with general structures 2.1, 2.2 and 2.3 were prepared, where 
X is a hydrophilic functionality. 
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Potential inhibitors of general structure 2.1 were prepared by Wittig reaction of the protected 
ketone 2.12 with the corresponding stabilised ylide.  Single isomers, presumed to be the E-
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isomers, were obtained in each case.  The hydroxyl and carboxyl groups were then 
deprotected to give compounds 2.15 and 2.27. 
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Compounds of general structure 2.2 were also prepared Wittig reaction of ketone 2.12.  This 
was followed by catalytic hydrogenation of the double bond to give mixtures of the 3R- and 
3S- epimers.  Separation of the products by chromatography, followed by deprotection gave 
potential inhibitors 2.16, 2.17, 2.18, 2.28 and 2.29. 
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Compounds of general structure 2.3, were prepared from ketone intermediate 2.13, as the 
hydrazone functionality was unstable under the acidic conditions of the diol deprotection.  
Ketone 2.13 was reacted with the corresponding hydrazide to give mixtures of E- and Z-
isomers, with the major isomer presumed to be E.  Subsequent deprotection of the C-1 
carboxyl gave potential inhibitors 2.38, 2.42, 2.44 and 2.46 as mixtures of isomers. 
 
The epoxide-based derivative 2.4 was prepared by carbonyl methylenation of ketone 2.12, and 
deprotection of the trans-diol.   The methyl ester was then exchanged for an allyl ester as the 
carboxy protecting group.  Epoxidation of the double bond, followed by palladium(0) 
catalysed allyl transfer gave potential inhibitor 2.4 as the free acid. 
 2   Synthesis of Potential Dehydroquinase Inhibitors 62 
OH
HO
OH
CO2
N
2.42
OH
HO
OH
CO2
N
H
NH2N
S
2.44
OH
HO
OHN
H
NH
O
2.46
OH
HO
OH
CO2
N
H
NH2N
O
2.38
CO2
OH
HO
OHO
2.13
CO2Me
HN
 
 
The synthesis of potential inhibitors 2.59, 2.76 and 2.77 was investigated but was 
unsuccessful due to the instability of the compounds to the deprotection conditions.  The 
possibility of employing alternative deprotection conditions and/or carboxy protecting groups 
warrants further investigation. 
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The potential inhibitors whose preparation is described in this chapter were tested for 
biological activity against type II DHQases from M. tuberculosis and S. coelicolor and in the 
case of epoxide 2.4, against type I DHQase from S. typhi.  The results of these studies are 
discussed in the following chapters. 
 2   Synthesis of Potential Dehydroquinase Inhibitors 63 
2.8 REFERENCES FOR CHAPTER 2 
 
 (1) Frederickson, M.; Parker, E. J.; Hawkins, A. R.; Coggins, J. R.; Abell, C. J. 
Org. Chem. 1999, 64, 2612. 
 (2) Grewe, R.; Haendler, H. Biochemical Preparations 1966, 21-26. 
 (3) Manthey, M. K.; Gonzales-Bello, C.; Abell, C. J. Chem. Soc., Perkin Trans. 1 
1997, 625. 
 (4) Montchamp, J.-L.; Tian, F.; Hart, M. E.; Frost, J. W. J. Org. Chem. 1996, 61, 
3897. 
 (5) Tian, F.; Montchamp, J.-L.; Frost, J. W. J. Org. Chem. 1996, 61, 7373. 
 (6) Montchamp, J.-L.; Frost, J. W. J. Am. Chem. Soc. 1997, 119, 7645-7653. 
 (7) Armesto, N.; Ferrero, M.; Fernandez, S.; Gotor, V. Tetrahedron Lett. 2000, 41, 
8759. 
 (8) Le Sann, C.; Abell, C.; Abell, A. D. Synthetic Communications 2003, 33, 527-
533. 
 (9) Karplus, M. J. Am. Chem. Soc. 1963, 85, 2870-2871. 
 (10) This sample contains 8% 2.22.  This spectrum was chosen for the purposes of 
this discussion as it is better resolved than that of pure 2.21. 
 (11) Roszak, A. W.; Frederickson, M.; Abell, C.; Coggins, J. R.; Lapthorn, A. J. In 
RCSB Protein Databank 2003. 
 (12) Le Sann, C.; Abell, C.; Abell, A. D. J. Chem. Soc., Perkin Trans. 1 2002, 
2065-2068. 
 (13) Frederickson, M.; Coggins, J. R.; Abell, C. Chem. Commun. 2002, 1886-1887. 
 (14) Frederickson, M.; Roszak, A. W.; Coggins, J. R.; Lapthorn, A. J.; Abell, C. 
Org. Biomol. Chem. 2004, 2, 1592-1596. 
 (15) Parker, E. J.; Gonzales-Bello, C.; Coggins, J. R.; Abell, C. Bioorganic and 
Medicinal Chemistry Letters 2000, 10, 231. 
 (16) Duggan, P. J.; Parker, E. J.; Coggins, J. R.; Abell, C. Bioorg. Med. Chem. Lett. 
1995, 5, 2347-2352. 
 (17) González-Bello, C.; Manthey, M. K.; Harris, J.; Hawkins, A. R.; Coggins, J. 
R.; Abell, C. J. Org. Chem 1998, 63, 1591-1597. 
 2   Synthesis of Potential Dehydroquinase Inhibitors 64 
 (18) González-Bello, C.; Harris, J. M.; Manthey, M. K.; Coggins, J. R.; Abell, C. 
Bioorg. Med. Chem. Lett. 2000, 10, 407. 
 (19) Kunz, H.; Waldmann, H. Angew. Chem. Int. Ed. Engl. 1984, 23, 71-72. 
 (20) Guibé, F. Tetrahedron 1998, 54, 2967-3042. 
 (21) Le Sann, C.; Abell, A. D. Aust. J. Chem. 2004, 57, 355-358. 
 (22) Kunz, H.; Unverzagt, C. Angew. Chem. Int. Ed. Engl. 1984, 23, 436-437. 
 (23) Hibino, J.-i.; Okazoe, T.; Takai, K.; Nozaki, H. Tetrahedron Lett. 1985, 26, 
5579-5580. 
 (24) Ho, P.-K.; Kolt, R. J. Can. J. Chem. 1982, 60, 663-666. 
 (25) Compound 2.78 was prepared by R. Payne 
 3   Biological Studies: Spectrophotometric Assay 65 
 
3 Biological Studies: Spectrophotometric Assay 
 
 
 
3.1 INTRODUCTION 
 
3.1.1 Steady-State Enzyme Kinetics 
 
A simple mechanism for the enzymatic conversion of substrate to product is depicted in 
Scheme 3.1, where S is the substrate, E the enzyme, ES the enzyme-substrate complex and P 
the enzymatic product.  The rate constants for the binding and dissociation of the substrate 
from the enzyme are represented by k1 and k-1 respectively, while k2 represents the rate 
constant for the conversion of the ES complex to product. 
 
E + S ES E + P
k1
k-1
k2
 
Scheme 3.1  Generalised mechanism for an enzymatic reaction. 
 
The steady-state approach to enzyme kinetics relies on the assumption that the concentration 
of the ES complex remains constant within a finite period and thus the rate of the enzymatic 
reaction (d[P]/dt = k2[ES]) also remains constant (i.e. the reaction progress curve remains 
linear within a defined period of time).  It is also assumed that the product formation step is 
irreversible, or that the concentration of product is sufficiently small that the contribution of 
the competing back-reaction is negligible.  These assumptions are valid during the initial 
stage of the reaction. 
 
 v  =  
Vmax[S]
KM + [S]
  (3.1) 
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From these assumptions is derived the fundamental equation of enzyme kinetics: the 
Michaelis-Menten equation (Equation 3.1).1-4  In the equation as written, v is the initial rate of 
reaction, Vmax is the limiting rate, and KM is the Michealis constant.  For the simplified 
mechanism depicted in Scheme 3.1 KM is defined as (k-1 + k2)/k1 and Vmax as k2[E]t (where [E]t 
is the total enzyme concentration).  However, the equation is also applicable to more general 
circumstances than Scheme 3.1 in which Vmax is defined as kcat[E]t where kcat is the rate 
constant for the conversion of the enzyme-substrate complex ES to product and does not 
necessarily represent a single step.  In the general case, KM is not necessarily equal to (k-1 + 
k2)k1.  It can be shown that KM is equal to the substrate concentration at which the rate is half 
the limiting rate Vmax, and this is taken as a working definition of KM.
1  The curve defined by 
the Michaelis-Menten equation is depicted in Figure 3.1.   
 
v
Vmax
0.5Vmax
KM [S]  
Figure 3.1  Generalised Michaelis–Menten curve. 
 
3.1.2 Competitive Reversible Inhibition 
 
Competitive inhibition occurs when an inhibitor competes with the substrate for binding at the 
active site of the enzyme.  The inhibitor cannot be converted to product and thus remains 
bound in the active site, preventing the binding and catalysis of substrate by the enzyme.  A 
mechanism for competitive inhibition (specific inhibition) may be represented in general 
terms by Scheme 3.2, where I is the competitive inhibitor and EI the enzyme-inhibitor 
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complex.  In the case of reversible competitive inhibition, the inhibitor binds reversibly and 
equilibrium is established, as indicated in Scheme 3.2.   
 
S  +  E ES E  +  P
I
+
EI
Ki
 
Scheme 3.2  Generalised mechanism for competitive reversible inhibition. 
 
The equilibrium constant for dissociation of the enzyme-inhibitor complex is known as the 
inhibition constant, Ki.  However, irreversible competitive inhibition can also occur, in which 
the inhibitor becomes covalently attached to the enzyme active site.  The effect of competitive 
inhibition on the rate of product formation v, is defined by equation 3.2.  This equation is of 
the same form as the Michaelis-Menten equation and can be written as shown in equation 
3.3.1 
 
 v  =  
Vmax[S]
KM (1 + [I]/Ki) + [S]
 (3.2) 
 
 v  =  
V
app[S]
K
 app
M  + [S]
  (3.3) 
 
The inhibition constant Ki is a convenient means of quantifying inhibitor potency. The smaller 
Ki, the more potent the inhibitor and the more strongly it is bound by the enzyme.  Ki can be 
determined experimentally by Dixon plot.1,2  The inverse rate (1/v) is plotted against inhibitor 
concentration for a series of substrate concentrations.  From equation 3.2 it can be shown that 
the intersection of the different series occurs at the point (-Ki, 1/Vmax) (Figure 3.2).
1 
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Figure 3.2  Generalised Dixon plot. 
 
 
 
3.2 GENERAL METHOD 
 
In order to determine inhibition constants (Ki) for the potential inhibitors 2.4, 2.15-2.18, 2.27-
2.29, 2.38, 2.42, 2.44 and 2.46, whose synthesis was discussed in the previous chapter, a 
means of monitoring the progress of the DHQase catalysed conversion of dehydroquinate 
(DHQ) 1.4 to dehydroshikimate (DHS) 1.5 (Scheme 3.3) was required.  The method of choice 
was UV/visible spectroscopy as the enone-carboxylate chromophore of the enzymatic product 
DHS 1.5 gives rise to a strong absorbance at 234 nm.  The initial rate of the enzymatic 
reaction can be determined by monitoring the increase in absorbance at 234 nm due to the 
formation of DHS 1.5 for the initial stage of the reaction, during which the reaction progress 
curve is approximately linear.  A straight line is fitted to the absorbance vs. time data and the 
slope of the line, dA/dt is determined.  From this the initial rate of product formation 
d[DHS]/dt is calculated using Beer’s Law (Eq. 3.4), where A is the measured absorbance, ε is 
the molar absorptivity in Lmol-1cm-1 of DHS, c is the concentration of DHS in molL-1 and l is 
the path length in cm. 
 
 A = εcl (3.4) 
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Initial rate data is obtained for a series of samples, consisting of 3 or 4 substrate 
concentrations and 4-8 inhibitor concentrations.  A Dixon plot is prepared by plotting the 
inverse of a series of initial rates, determined as described above, against the corresponding 
inhibitor concentrations.  A straight line is fitted to the 1/v vs. [I] data for each substrate 
concentration to give a Dixon plot as illustrated in Figure 3.2.  The inhibition constant Ki is 
determined from the intersection point. 
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Scheme 3.3  Enzymatic conversion of DHQ 1.4 to DHS 1.5. 
 
 
 
3.3 ENZYMATIC STUDIES ON S. COELICOLOR TYPE II DHQASE 
 
3.3.1 Michaelis-Menten Curve 
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Figure 3.3  Michaelis-Menten curve for S. coelicolor DHQase at 25ºC and pH 7. 
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Kinetic parameters for the S. coelicolor DHQase catalysed conversion of DHQ 1.4 to DHS 
1.5 at an enzyme concentration of 25.5 ngmL-1 at 25ºC and pH 7 were determined by 
obtaining initial rate data for a series of substrate concentrations.  Non-linear least squares 
fitting of the data to the Michaelis-Menten equation (Equation 3.1) gave the curve shown in 
Figure 3.3.  A Michaelis constant KM of 200 ± 20 µM and a limiting rate Vmax of 0.32 µMs
-1 
were obtained.  This value of KM is slightly lower than the value of 250 µM reported by Abell 
et al. for the same conditions.5 
 
3.3.2 Assay Results for S. coelicolor DHQase  
 
Preliminary investigations with potential inhibitors 2.15-2.17, 2.38 and 2.44 at low inhibitor 
concentrations ([I] < 100 µM) yielded no useful result.  The range of data on which the 
extrapolation was based was insufficient, and when the linear substrate series were 
extrapolated, the error introduced was too great for the series to intersect at a common point.  
This suggested that the inhibitors were likely to have a Ki well in excess of 100 µM, and that 
substantially higher inhibitor concentrations would be required for the assay.   
 
The oxime inhibitor 1.36, upon which the design of the new potential inhibitors was based, 
was known to be less active against S. coelicolor DHQase than M. tuberculosis DHQase by 
more than one order of magnitude.  If the new inhibitors were expected to exhibit activity on 
the order of that of oxime 1.36, inhibitor concentrations in excess of 500 µM would be 
required for the assay, in order to obtain sufficient data for the extrapolation back to –Ki.   
 
The assay against S. coelicolor DHQase was initially attempted at higher inhibitor 
concentrations with the new inhibitors 2.15 and 2.44.  However, the absorbance at 234 nm 
due to the inhibitors was extremely high at the concentrations employed and caused too much 
interference to obtain meaningful rate data.  Acquisition of UV/vis spectra for the inhibitors 
revealed that all of the sp2 hybridised inhibitors 2.15, 2.27, 2.38, 2.42, 2.44 and 2.46 absorbed 
at 234 nm.  Inhibitors with sp3 character at C-3 (2.16-2.18, 2.28 and 2.29) did not absorb at 
234 nm.   
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It was apparent that the strongly absorbing inhibitors could not be assayed against S. 
coelicolor DHQase by this method.  By analogy with oxime 1.36, it was anticipated that the 
new potential inhibitors would be substantially more active against M. tuberculosis DHQase 
than S. coelicolor DHQase.  Future assays with M. tuberculosis DHQase could therefore be 
expected to require lower inhibitor concentrations than was the case for S. coelicolor 
DHQase, and so could be conducted by this method. 
 
Known oxime inhibitor 1.36, which absorbed only weakly at 234 nm, was assayed against S. 
coelicolor DHQase in order to test the method.  A Dixon plot was prepared and a Ki of 530 ± 
80 µM determined (Figure 3.4).  This was in agreement with the result of 500 ± 200 µM 
reported by Abell and coworkers for this inhibitor with S. coelicolor DHQase.6   
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Figure 3.4  Dixon plot for known inhibitor oxime 1.36 against S. coelicolor DHQase. 
 
Saturated inhibitors 2.16-2.18, 2.28 and 2.29, which did not absorb at 234 nm, were assayed 
against S. coelicolor DHQase.  Inhibitor 2.17 was assayed against S. coelicolor DHQase in 
the form of a 2:1 mixture with the C-3 epimer 2.16.  It was thought that the commercially 
available quinic acid 2.5 might inhibit DHQase and so it was also assayed against S. 
coelicolor DHQase.  Absorbance vs. time data obtained at 234 nm was analysed as described 
previously to obtain Dixon plots for each of the inhibitors (Figure 3.5 to Figure 3.10).  The 
inhibition constants thus obtained are reported in Table 3.1.   
 
 
Figure 3.5  Dixon plot for Quinic acid 2.5 against S. coelicolor DHQase. 
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Figure 3.6  Dixon plot for inhibitor 2.16 against S. coelicolor DHQase. 
 
Figure 3.7  Dixon plot for a 1:2 mixture of diastereomers 2.16 and 2.17 against S. coelicolor DHQase with the 
x-axis showing the combined concentration of both diastereomers. 
 
Figure 3.8  Dixon plot for inhibitor 2.18 against S. coelicolor DHQase. 
0
2
4
6
8
10
12
14
16
18
20
-8000 -6000 -4000 -2000 0 2000
[I] (µM)
1
/r
a
te
 (
s
µ
M
-1
)
25 µM
50 µM
100 µM
200 µM
OH
HO
OH
CO2
H2N
2.18
0
5
10
15
20
25
30
-1250 -750 -250 250 750
[I] (µM)
1
/r
a
te
 (
s
µ
M
-1
)
25 µM
50 µM
100 µM
200 µM
OH
HO
OH
CO2
NC
2.16
0
5
10
15
20
25
30
-2000 -1500 -1000 -500 0 500 1000 1500
[I] (µM)
1
/r
a
te
 (
s
µ
M
-1
)
25 µM
50 µM
100 µM
200 µM
OH
HO
OH
CO2
NC
OH
HO
OH
NC
CO2
2.17
1:2
+
2.16
 3   Biological Studies: Spectrophotometric Assay 74 
 
 
Figure 3.9  Dixon plot for inhibitor 2.28 against S. coelicolor DHQase. 
 
Figure 3.10  Dixon plot for inhibitor 2.29 against S. coelicolor DHQase. 
 
Table 3.1  Inhibition constants (Ki) for inhibitors 2.16-2.18, 2.28 and 2.29 against S. coelicolor DHQase. 
  
Inhibitor Ki (µM) 
 S. coelicolor DHQase 
  
  
KM 200 ± 20 
2.16 800 ± 100 
2.17
a
 1600 ± 200 
2.18 6000 ± 500 
2.28 3000 ± 1000 
2.29 1500 ± 500 
  
a
 Ki for a 2:1 mixture of 2.17 and 2.16. 
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3.3.3 Discussion of S. coelicolor DHQase Assay Results 
 
The inhibition constants obtained from the assays of inhibitors 2.16-2.18, 2.28 and 2.29 
against S. coelicolor DHQase are shown in Table 3.1.  The inhibition constants reported for 
some known inhibitors are given in Table 3.2. 
 
Table 3.2  Inhibition constants for reported inhibitors of S. coelicolor DHQase. 
    
Inhibitor Ki (µM) 
 S. coelicolor DHQase 
    
  
1.36
a
 500 ± 200 
1.37
a
 30 ± 10 
1.38
a
 2500 ± 500 
1.39
a
 600 ± 200 
1.43
b
 420 ± 50 
1.44
b
 >20000 
1.45
b
 180 ± 20 
1.46
b
 3000 ± 500 
1.47
b
 1200 ± 450 
1.48
b
 530 ± 50 
1.49
b
 >20000 
1.50
b
 3500 ± 400 
1.53
c
 33 ± 5.4 
1.54
c
 84 ± 13 
1.55
c
 220 ± 50 
  
a
 Ref. 6.  b Ref. 5.  c Ref. 8. 
 
Inhibitor 2.17 was assayed against S. coelicolor as a 2:1 mixture of 2.17 and 2.16.  The Ki was 
determined by plotting the inverse rate against the total combined concentration of the two 
isomers (Figure 3.7).  This method of determining Ki gives an averaged approximation of the 
activity of the mixture.  It is clear that 2.17 is a substantially less potent inhibitor of S. 
coelicolor DHQase than its C-3 epimer 2.16, as the activity of the 2:1 mixture of 2.17 and 
2.16, with a Ki of 1600 ± 200 µM is a factor of 2 less potent than 2.16 alone, which has a Ki of 
800 ± 100 µM.  Amine 2.18, whose absolute configuration at C-3 is not known, but is 
suspected to be the same as that of 2.17 (i.e. with the C-3 substituent in the axial position), 
was substantially less active than the nitriles 2.16 and 2.17, with an inhibition constant of 
6000 ± 500 µM.  The fact that 2.16, for which the C-3 side-chain is equatorial, is more active 
than 2.17 (and 2.18), for which the side chain is axial, suggests that the equatorial 
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configuration is preferred by the enzyme.  This is consistent with results reported by Abell et 
al. for epimeric inhibitors 1.47 (Ki = 1200 ± 450) and 1.49 (Ki > 20000) and 1.48 (Ki = 530 ± 
50) and 1.50 (Ki = 3500 ± 400).
5 
 
OH
HO
OH
CO2H
1.47 R = OCH2CH=CH2
1.48 R = OCH2CH(OH)CH2OH
OH
HO
OH
CO2H
1.49 R = OCH2CH=CH2
1.50 R = OCH2CH(OH)CH2OH
R R
 
 
In the case of carboxylate inhibitors 2.28 and 2.29 however, the enzyme appeared to show a 
preference for the axial side-chain.  Inhibitor 2.29, for which the C-3 substituent is in the axial 
position, has a Ki of 1500 ± 500.  This is twice as potent as its C-3 epimer 2.28, which has a 
Ki of 3000 ± 1000.  This is inconclusive however, as the inhibition constants could be said to 
be in agreement within the stated errors. 
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All of the new inhibitors assayed thus far against S. coelicolor DHQase are less potent than 
the known inhibitors 1.36 (Ki = 500 ± 200) and 1.37 (Ki = 30 ± 10).
6  The inhibition constant 
for nitrile 2.16 however, is close to that of 1.36 and the values could be said to be in 
agreement within the stated errors.  A comparison of the inhibition constants of known 
inhibitors 1.36 and 1.38 (Ki = 2500 ± 500) indicates that exchanging the oxime for carbon at 
the 3-position leads to a loss of potency against S. coelicolor DHQase.  As such it is perhaps 
not so surprising that these new inhibitors, all of which have carbon at C-3, were in general 
less potent than 1.36.   
 
With the exception of 2.18 and 2.28, the new inhibitors were more potent than exo-methylene 
1.38.  This suggests that extending the C-3 side-chain could be a favourable modification, 
possibly enabling the inhibitor to occupy additional binding sites such as the glycerol binding 
pocket reported by Abell et al.7  However, when compared to the new inhibitors, the complete 
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lack of a C-3 side-chain seems to be preferred, as shown by the lower Ki of the unsubstituted 
analogue 1.39 (Ki of 600 ± 200).  A number of S. coelicolor DHQase inhibitors 1.43-1.46 
have been reported by Abell et al. which bear a side-chain at C-3.  In some cases the carbon 
chain was found to increase the potency relative to the unsubstituted analogue 1.39 and in 
some cases to decrease the potency, depending on the specific nature of the side-chain.  The 
lack of potency of the new inhibitors described in this thesis relative to the unsubstituted 
analogue 1.39 suggests that these particular side chains do not form favourable interactions 
with the active site. 
 
OH
HO
OH
CO2H
O
R
1.53 R = H
1.54 R = NO2
1.55 R = CO2H
OH
HO
OH
CO2H
1.43 R = CH=CH2
1.44 R = CH(OH)CH3
1.45 R = CH2CH2OH
1.46 R = CH(OH)CH2OH
R
 
 
Compounds 1.43 (Ki = 420 ± 50) and 1.45 (Ki = 180 ± 20) were reported by Abell et al. to be 
more potent than the corresponding unsubstituted derivative 1.39.5  Compounds 1.44 (Ki > 
20000) and 1.46 (Ki = 3000 ± 500) which have a secondary hydroxyl group on the side-chain, 
two carbons removed from the six-membered ring, are substantially less potent than their 
corresponding non-hydroxylated equivalents 1.43 (Ki = 420 ± 50) and 1.45 (180 ± 120).  They 
are also less potent than the unsubstituted analogue 1.39.  The side-chain carboxylate oxygen 
atoms of the inhibitors 2.28 and 2.29 are in a corresponding position to the secondary 
hydroxyl groups of 1.44 and 1.46.  The carboxylate inhibitor 2.28 (Ki = 3000 ± 1000), in 
which the C-3 side-chain is in the equatorial position (as in 1.43-1.46) shows a substantial 
loss of potency relative to the corresponding nitrile analogue 2.16 (Ki = 800 ± 100).  This is 
consistent with the lack of potency of 1.44 and 1.46 relative to 1.43 and 1.45 respectively and 
suggests that having an oxygen containing group at this particular position on the equatorial 
side chain may result in an unfavourable interaction with the enzyme active site.  The 
inhibitors 2.17 and 2.29, in which the C-3 side-chain is in the axial position, have very similar 
activities, suggesting that there is no additional unfavourable interaction of the carboxyl group 
when the side chain has this orientation.  An unfavourable interaction of the carboxylate of 
the equatorial side-chain might account for the apparent preference of S. coelicolor DHQase 
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for the carboxylate inhibitor 2.29, bearing the axial side-chain, over 2.28, in contrast to the 
preference for the equatorial side-chain observed for nitrile inhibitors 2.26 and 2.17 and 
reported inhibitors 1.47-1.50.5  A similar trend was observed by Abell et al. in the substitution 
of the phenyl ring of inhibitors 1.53-1.55 in which increasing hydrophilicity of the ortho-
substituent was found to decrease the strength of binding to S. coelicolor DHQase.8 
 
Although quinic acid 2.5 was seen to inhibit S. coelicolor DHQase (as shown by the increase 
in inverse rate with inhibitor concentration in Figure 3.5), the data series were more or less 
parallel i.e. the inhibition appeared to be independent of substrate concentration.  This 
suggests that the inhibition is not of a competitive nature. 
 
 
 
3.4 ENZYMATIC STUDIES ON M. TUBERCULOSIS TYPE II DHQASE 
 
Oxime inhibitor 1.36 has been shown to be more potent against type II DHQase from M. 
tuberculosis than that from S. coelicolor by a factor of 25.6  The design of the putative 
inhibitors prepared in this work was based on the hypothesis that inhibitors with hydrophilic 
groups at C-3 would mimic the structure and activity of oxime 1.36.  It was perhaps 
unsurprising therefore, that the new inhibitors showed relatively poor activity against type II 
DHQase from S. coelicolor.  It was anticipated however, by analogy with oxime 1.36, that the 
same inhibitors would demonstrate significantly increased potency against type II DHQase 
from M. tuberculosis, relative to the S. coelicolor enzyme.  More potent inhibitors would 
require lower inhibitor concentrations in the spectrophotometric assay, as the data would not 
need to be extrapolated back so far to reach -Ki.  All of the putative inhibitors whose 
preparation was described in Chapter 2, as well as compounds 3.1 and 3.2 (prepared by K. 
Smith)9 where thus assayed against type II DHQase from M. tuberculosis.  In the cases where 
the inhibitors absorbed at 234 nm, the maximum inhibitor concentration that could be used 
was limited by the absorbance due to the inhibitor. 
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3.4.1 Michaelis-Menten Curve 
 
Rate vs. substrate concentration data was obtained for M. tuberculosis DHQase at an enzyme 
concentration of 0.5 µgmL-1 at 25ºC and pH 7 and the Michaelis-Menten curve plotted 
(Figure 3.11).  Non-linear least squares fitting of the data to equation 3.1 gave a Michaelis 
constant KM of 15 ± 1 µM and a limiting rate Vmax of 0.028 ± 0.002 µMs
-1.  This value of KM is 
slightly higher, though very close to the value of 13 µM reported by Abell et al. for the same 
conditions.10  
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Figure 3.11  Michaelis-Menten curve for M. tuberculosis DHQase. 
 
3.4.2 Assay Results for M. tuberculosis DHQase 
 
3.4.2.1 Inhibitors with C Attached at C-3 
 
Inhibitors 2.4, 2.15, 2.16, 2.17, 2.18, 2.27, 2.28, 2.29, 3.1 and 3.2 were assayed against type II 
DHQase from M. tuberculosis by the method described in Section 3.2.  The Dixon plots are 
shown in Figure 3.12 to Figure 3.21 and the Ki values thus obtained are listed in Table 3.3. 
 
In order to conserve the sample of epoxide inhibitor 2.4 for further experiments, only the 
minimum data required to estimate a value of Ki was obtained.  Thus the accuracy of the Ki 
value obtained was not verified by multiple data sets and so is only an approximate value. 
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Figure 3.12  Dixon plot for inhibitor 2.15 against M. tuberculosis DHQase. 
 
 
Figure 3.13  Dixon plot for inhibitor 2.16 against M. tuberculosis DHQase. 
 
 
Figure 3.14  Dixon plot for inhibitor 2.17 against M. tuberculosis DHQase. 
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Figure 3.15  Dixon plot for inhibitor 2.18 against M. tuberculosis DHQase. 
 
Figure 3.16  Dixon plot for inhibitor 2.27 against M. tuberculosis DHQase. 
 
Figure 3.17  Dixon plot for inhibitor 2.28 against M. tuberculosis DHQase. 
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Figure 3.18  Dixon plot for inhibitor 2.29 against M. tuberculosis DHQase. 
 
 
Figure 3.19  Dixon plot (minimal data) for inhibitor 2.4 against M. tuberculosis DHQase. 
 
 
Figure 3.20  Dixon plot for inhibitor 3.1 against M. tuberculosis DHQase. 
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Figure 3.21  Dixon plot for inhibitor 3.2 against M. tuberculosis DHQase. 
 
Inhibitors 2.15, 2.16, 2.17, 2.27, 2.28, 2.29, 2.4, 3.1 and 3.2 were found to be less potent 
against M. tuberculosis DHQase than was anticipated (Table 3.3).  The range of inhibitor 
concentrations used was therefore not really sufficient in some cases to reliably extrapolate 
the data back to such low values of –Ki, especially in the cases of inhibitors 2.15, 2.16, 2.27 
and 3.2.  No Ki was obtained for inhibitor 2.15 as it seemed pointless to continue the 
extrapolation beyond -3000 µM given the range of inhibitor concentrations was less than 300 
µM. 
 
The saturated nitrile and carboxylate inhibitors 2.16, 2.17, 2.28 and 2.29 appear to be 
preferred to the corresponding olefinic analogues 2.15 and 2.27 which are less potent by a 
factor of two. 
 
There is no apparent preference for axial or equatorial configuration at C-3 as the inhibition 
constants for both pairs of epimers 2.16 and 2.17 and 2.28 and 2.29 are in agreement within 
the experimental error. 
 
There may be a slight preference for the saturated carboxylate inhibitors 2.28 and 2.29 over 
the nitrile equivalents 2.16 and 2.17 but this is uncertain as the respective inhibition constants 
can also be said to be in agreement within the stated errors.  It was expected that ester 3.2 
would be a poorer inhibitor than the corresponding free carboxylate 2.27, due to reduced 
hydrophilicity.  This is not evident in the results for Ki however, as 3.2 is as active, or slightly 
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more so, than 3.1.  This would suggest that the carboxylate does not participate in any 
significant binding interactions with the active site of M. tuberculosis DHQase. 
 
Table 3.3  Inhibition constants Ki for inhibitors with C attached at C-3. 
  
Inhibitor Ki (µM) 
 M. tuberculosis DHQase 
  
  
KM 15 ± 1 
1.36
a
 20 ± 2 
2.4 ~ 900 
2.15 >3000 
2.16 1150 ± 150 
2.17 1000 ± 200 
2.18 2000 ± 400 
2.27 2000 ± 600 
2.28 850 ± 150 
2.29 900 ± 150 
3.1 1100 ± 100 
3.2 1600 ± 400 
  
 a Ref. 6.   
 
 
 
3.4.2.2 Inhibitors with N Attached at C-3 (and Quinic Acid) 
 
Hydrazone inhibitors 2.38, 2.42, 2.44 and 2.46 were assayed against M. tuberculosis DHQase 
by the method described previously and the Dixon plots are shown in Figure 3.22 to Figure 
3.25.  The inhibition constants obtained are listed in Table 3.4.  Quinic, thought to be a 
potential inhibitor, was also assayed against M. tuberculosis DHQase and the corresponding 
Dixon plot is shown in Figure 3.26. 
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Figure 3.22  Dixon plot for inhibitor 2.38 (20:1 E:Z) against M. tuberculosis DHQase. 
 
The sample of inhibitor 2.46 contained both E and Z isomers in a ratio of 3:2.  The inhibition 
constant was therefore determined by plotting the inverse rate against the total concentration 
and so is an average result for the mixture rather than for either of the individual isomers.  It is 
to be expected therefore that the Ki obtained is higher than the actual Ki of the more active 
component of the mixture.  Inhibitor samples 2.38 and 2.44 were also assayed as mixtures of 
E and Z isomers (20:1 and 9:1 respectively). In these cases the minor isomer amounted to no 
more than 10% of the total inhibitor concentration and the reported inhibition constants are 
therefore based on the concentration of the major isomer alone.  The sample of inhibitor 2.42 
contained only the major isomer. 
 
  
Figure 3.23  Dixon plot for inhibitor 2.42 against M. tuberculosis DHQase. 
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Figure 3.24  Dixon plot for inhibitor 2.44 (9:1 E:Z) against M. tuberculosis DHQase. 
 
Figure 3.25  Dixon plot for inhibitor 2.46 (3:2 E:Z) against M. tuberculosis DHQase, with the x-axis showing 
the combined concentration of both isomers. 
 
Figure 3.26  Dixon plot for Quinic acid 2.5 against M. tuberculosis DHQase. 
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The inhibitors with nitrogen at C-3, particularly 2.38 and 2.42, are almost as active against M. 
tuberculosis DHQase as known inhibitor oxime 1.36.  A comparison of the inhibition 
constants obtained for inhibitors 2.38, 2.42 and 2.46, as shown in Table 3.4, suggests no 
apparent trend in activity with increasing size of the substituent at C-3 and the inhibitors with 
the shortest and longest side-chains (2.42 and 2.38 respectively) have approximately equal 
inhibition constants.  
 
Semicarbazone inhibitor 2.38 is more potent than the corresponding sulphur analogue 2.44 by 
a factor of 10, indicating that hydrogen bonding to the carbonyl oxygen must be a 
contributing factor in the potency of these inhibitors. 
 
Table 3.4  Inhibition constants Ki for inhibitors with N attached at C-3 and quinic acid. 
  
Inhibitor Ki (µM) 
 M. tuberculosis DHQase 
  
  
KM 15 ± 1 
1.36
a
 20 ± 2 
2.38
b
 45 ± 5 
2.42 50 ± 5 
2.44
b
 425 ± 75 
2.46
c
 90 ± 10 
2.5 2000 ± 800 
  
a Ref. 6.  b Based on the concentration of the major isomer only.  c Based on the 
combined concentration of a 3:2 mixture of isomers. 
 
 
 
3.4.3 Discussion of M. tuberculosis DHQase Assay Results 
 
The most striking observation that can be made about the results of the M. tuberculosis 
DHQase assays is that although all of the inhibitors assayed have a hydrophilic group attached 
at the 3-position, those which have a non-hydrogen bonding carbon atom directly adjacent to 
the ring are substantially less active than those with a nitrogen atom at the same position.  The 
Ki values in Table 3.3 indicate that all of the inhibitors with C attached at C-3 (2.15-2.18, 
2.27-2.29, 3.1 and 3.2) are relatively poor inhibitors of type II DHQase from M. tuberculosis 
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compared to oxime 1.36.6  In contrast, the nitrogen containing inhibitors (2.38, 2.42, 2.44 and 
2.46) were roughly one order of magnitude more potent, with activities similar to that of 
oxime 1.36. 
 
The general lack of potency of the carbon based inhibitors relative to the nitrogen based 
inhibitors would appear to be consistent with the findings of Frederickson et al.6 and Evans et 
al.11 which suggest that the C-3 carbonyl is particularly important in substrate recognition for 
M. tuberculosis DHQase, relative to S. coelicolor DHQase, possibly interacting with the 
active site residue Arg-19.11 
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The importance of the C-3 carbonyl in substrate recognition by M. tuberculosis DHQase may 
be such that the enzyme cannot easily accommodate substitutions at this position.  It may be 
necessary to have an electronegative element such as nitrogen, oxygen or fluorine directly 
attached to the ring at the 3-position in order to maximise the strength of binding by the 
enzyme.  Known potent inhibitors of M. tuberculosis DHQase 1.36 (Ki = 20 ± 2 µM) and 1.40 
(Ki = 10 ±2 µM) as well as the substrate DHQ 1.4 all meet this criterion, having nitrogen, 
fluorine and oxygen atoms respectively at this position (Table 3.5).6,12  Inhibitor 1.37, a good 
inhibitor of S. coelicolor DHQase but with no electronegative atom at C-3 is a much less 
potent inhibitor of M. tuberculosis DHQase, with a Ki of 200 ± 2 µM.
6   
 
An apparent contradiction to this hypothesis can be seen in the inhibition constants for 
epoxide inhibitor 2.4 and quinic acid 2.5, which have Ki values of approximately 900 and 
2000 ± 800 respectively.  Although the epoxide inhibitor 2.4 has an oxygen atom directly 
attached to the ring at the 3-position, it is no more potent than the majority of the other 
inhibitors with C at C-3.  This might be a consequence of the stereochemistry of the epoxide 
being such that the oxygen atom is not well positioned for binding to the relevant active site 
residue(s) and that the carbon of the epoxide ring is instead positioned in the preferential 
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binding position.  It could therefore provide potentially useful information to assay the C-3 
epimer of epoxide 2.4. 
 
Quinic acid 2.5 however, which has no carbon atom at C-3, only the axial hydroxyl group, 
also proved to be a poor inhibitor of M. tuberculosis DHQase.  The results of the assays of 
compounds 2.4 and 2.5 with M. tuberculosis DHQase suggest that the presence of an 
electronegative element adjacent to the ring at C-3 is alone insufficient to insure a strong 
interaction with this enzyme.  This is also observed with the 3-fluoro analogue 1.41 (Ki = 700 
± 100 µM), which has fluorine at C-3, but is not a very good inhibitor of M. tuberculosis 
DHQase. 
 
Table 3.5  Inhibition constants for reported inhibitors of M. tuberculosis DHQase. 
  
Inhibitor Ki (µM) 
 M. tuberculosis DHQase 
  
  
1.36
a
 20 ± 2 
1.37
a
 200 ± 20 
1.38
a
 700 ± 200 
1.40
b
 10 ± 2 
1.41
b
 700 ± 100 
  
a Ref. 6.  b Ref. 12,13. 
 
 
There are two possible factors which could be influencing the activity of the inhibitors against 
M. tuberculosis DHQase, in addition to having an electronegative atom at C-3.  The first is 
stereochemistry.  The C-3 hydroxyl of quinic acid 2.5 is known to be in the axial position 
(though the configuration of 2.4 at C-3 is unknown).  It was suggested in the discussion of the 
S. coelicolor DHQase assay results (Section 3.3.3) that the equatorial position was the 
preferred position for substituents at C-3.  This may also be the case here, even though 
configuration at C-3 was not observed to significantly affect the activities of the nitrile 
epimers 2.16 and 2.17 or the carboxylate epimers 2.28 and 2.29.  With an electronegative 
atom in place of C at the 3-position, the potential for interaction with the active site residues 
responsible for carbonyl recognition may make the influence of configuration at C-3 more 
substantial.  It might therefore be informative to assay the C-3 epimer of 2.5.  However, the 
difluoro inhibitor 1.41 has fluorine atoms occupying both the equatorial and axial positions at 
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C-3 and yet is a fairly poor inhibitor of M. tuberculosis DHQase.  This would suggest that 
configuration at C-3 is not a major factor in determining affinity for M. tuberculosis DHQase 
and that the poor activity of 2.4 and 2.5, relative to the N containing inhibitors, may be a 
result of some other factor. 
 
The second factor potentially affecting the activity of the inhibitors against M. tuberculosis 
DHQase, in addition to the presence of the electronegative atom at C-3, is the presence of a 
double bond to C-3.  Known potent inhibitors of M. tuberculosis DHQase 1.36 and 1.40 along 
with the enolate intermediate 1.19 and the substrate 1.4, have an sp2 carbon at the 3-position.  
Although sp2 character at C-3 alone does not make a good inhibitor of M. tuberculosis 
DHQase (as shown by the modest activity of inhibitors 1.37 and 1.38), in combination with an 
element such as N, O or F attached to C-3, it could potentially make the difference between a 
good and a poor inhibitor.  This makes sense when one considers that the natural substrate 
DHQ 1.4 has a carbonyl group at C-3, i.e. it has both an electronegative atom and a double 
bond to C-3.  Perhaps a double bond is necessary, either to the attached atom, as in the 
substrate, or between C-2 and C-3, as in the enolate intermediate, in order to correctly 
position the electronegative atom for optimal binding.  Such a contribution can be observed in 
the differing potencies of 3-fluoro analogues 1.40 and 1.41.  Inhibitor 1.40 has an sp2 centre at 
C-3 and is the most potent M. tuberculosis DHQase inhibitor reported to date.  Inhibitor 1.41 
however, has an sp3 centre at C-3 and is a comparatively weak inhibitor.12,13   
 
In summary, the results of the assays against M. tuberculosis DHQase, along with 
comparisons to reported results, suggest that the most crucial factor in determining whether a 
dehydroquinate analogue, retaining the functionality and stereochemistry of the natural 
substrate at all positions except C-3, will be a good inhibitor of M. tuberculosis DHQase, is 
the combination of an electronegative element directly attached to the carbocyclic ring at C-3 
and sp2 character at C-3.  That the presence of the electronegative element alone is 
insufficient, is indicated by the poor activity of 2.4, 2.5 and 1.41, relative to 2.38, 2.42 and 
1.40.  That sp2 character at C-3 is insufficient on its own is indicated by the poor activity of 
2.15, 2.27, 3.1 and 3.2 relative to 2.38, 2.42, and 2.46. 
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3.4.4 Anomalous Interaction of Inhibitors 2.38 and 2.46 with Type II 
DHQases. 
 
On carrying out the assay of hydrazone derivatives 2.38 and 2.46 (Scheme 3.4) an increase in 
absorbance in the absence of substrate was observed which increased with increasing inhibitor 
concentration. 
 
The observed increase in absorbance of solutions of inhibitors 2.38 and 2.46 in the presence 
of both M. tuberculosis and S. coelicolor DHQases led to the investigation of the reaction of 
inhibitor 2.46 with DHQase by 1H NMR.  Inhibitor 2.46 was chosen as a representative 
example as the reaction progress could be followed by monitoring the intensity of the 
aldehyde proton signals of the isomers.  It seemed likely that the product of the reaction of 
inhibitor 2.46 with type II DHQases might be either the C-1–C-2 unsaturated inhibitor-
product analogue 3.3, or the natural enzymatic product DHS 1.5, with the hydrazone 
functionality being lost (Scheme 3.4). 
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Scheme 3.4  Hydrolysis of formylhydrazone isomers 2.46 in the presence of DHQase. 
 
The mixture of inhibitor isomers 2.46 (3:2 E:Z) was incubated with S. coelicolor DHQase at 
room temperature in a 5 mm NMR tube with a D2O filled insert and the progress of the 
reaction recorded periodically by 1H NMR (Figure 3.27).  If the product was in fact 3.3, then 
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two sets of product signals for the two isomers would be expected in the 1H NMR spectrum.  
If the product was the natural product DHS 1.5 however, then only one set of new signals 
would be observed. (Scheme 3.4). 
 
Observation of the proton signals at 8.0 and 8.6 ppm of the isomers 2.46, showed the signals 
of both isomers decreasing, but only one corresponding signal appearing at 7.8 ppm (Figure 
3.27).  It is unlikely that two isomers of 2.46 would be converted into only one product 
isomer.  The most likely explanation therefore, was that the isomers were being converted 
into the natural product DHS 1.5 and liberating the formyl hydrazone functionality as formic 
hydrazide 3.4 (Scheme 3.4).  To confirm this, 1H NMR spectra of formic hydrazide and DHS 
were obtained under the same conditions.  These showed identical signals to those observed 
in the spectrum of the product of the enzymatic reaction of the isomers 2.46. 
 
 
Figure 3.27  
1H NMR spectra showing the enzymatic conversion of formylhydrazone isomers 2.46 into DHS 
and formic hydrazide at  A. 0 h; B. 42 h; C. 138 h and D. 306 h. 
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The progress of the enzymatic reaction as monitored by 1H NMR can be seen in Figure 3.27, 
showing A) the initial spectrum of the enzymatic reaction of 2.46, with only the two isomers 
of inhibitor 2.46, B) the NMR spectrum of the reaction at 42 h, C) the spectrum at 138 h and 
D) the final spectrum at 306 h, showing only the products DHS 1.5 and formic hydrazide 3.4.  
The spectra were acquired with simultaneous suppression of the buffer and water signals.  The 
residual water signal (4.7 ppm) and buffer satellite peaks (3.45 and 3.75 ppm) can still be 
seen.  The spectra clearly show the decrease in concentration of the signals due to the isomers 
of 2.46 (particularly those at 8.0 and 8.6 ppm).  The corresponding increase in a single proton 
signal at 7.8 ppm belonging to formic hydrazide 3.4, along with signals belonging to DHS 1.5 
(especially the olefinic H-2 signal at 6.3 ppm) can also be seen. 
 
The next question was whether the enzyme itself was catalysing the removal of the hydrazone 
functionality, or if the hydrazone was being non-enzymatically hydrolysed under the assay 
conditions, liberating free DHQ 1.4, which was then converted to DHS 1.5 by the enzyme.  
Inhibitor 2.46 was incubated under the assay conditions, but in the absence of enzyme, in an 
NMR tube and spectra acquired periodically over several days.  The spectra did indeed show 
a decrease in the signals of the isomers 2.46 and an increase in that corresponding to formic 
hydrazide as well as those corresponding to the natural substrate DHQ 1.4. 
 
In order to determine whether the hydrolysis of the hydrazone functionality in the presence of 
type II DHQase was occurring enzymatically or non-enzymatically, the rates of reaction in the 
presence and absence of the enzyme were compared.  The enzymatic reaction showed a 57% 
conversion of the isomers 2.46 to formic hydrazide 3.4 after 5.1 days, whereas the non-
enzymatic reaction showed a 51% conversion after 4.9 days.  These rates were deemed to be 
equivalent within a reasonable experimental error.  The fact that the enzymatic rate was the 
same as the non-enzymatic rate indicates that the rate-determining step in each case is the 
non-enzymatic removal of the hydrazone functionality. 
 
Such a rate of hydrolysis of the hydrazone functionality under the assay conditions was 
considered to be too low to cause a significant decrease in inhibitor concentration over the 
few minutes required to prepare the assay samples and acquire the data.  This instability of the 
inhibitors would be expected to be a deterrent to their development as potential therapeutics 
as it seems likely that such compounds would be unstable under physiological conditions.  
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They do, however, provide useful information about structure-activity relationships and 
insights into the active site structure of type II DHQase. 
 
The rate of hydrolysis of the hydrazone functionality is also too low to account for the 
increase in absorbance observed over a short period (<30 min) by UV/vis spectroscopy in the 
presence of type II DHQases.  No reaction other than the disappearance of the inhibitor 
signals and appearance of the formic hydrazide and DHS signals was observed in the 1H 
NMR of the assay solution.  At higher inhibitor concentrations however, the 1H NMR shows 
the presence of a small amount of contaminating substrate in the inhibitor solution, which is 
barely detectable by NMR, but is sufficient for the formation of the product to be observed by 
the more sensitive UV/vis spectroscopy. 
 
3.4.5 Whole-Cell Testing Against M. tuberculosis 
 
Compounds 1.36, 2.27, 2.31, 2.34, 2.35, 2.38, 2.43, 2.44 and 2.47 were screened for activity 
against M. tuberculosis strain H37Rv by the Tuberculosis Antimicrobial Acquisition & 
Coordinating Facility (TAACF) Southern Research Institute in Birmingham Alabama.  It was 
anticipated that the free carboxylate salts might exhibit little ability to permeate the plasma 
membrane.  The corresponding esters were therefore screened instead of or in addition to the 
salts in the hope that these would traverse the cell membrane more easily.  Although it was 
not expected that the esters themselves would be very active against M. tuberculosis DHQase, 
as the C-1 carboxylate is thought to contribute to substrate recognition,11,14 it was thought that 
the esters might be hydrolysed in vivo, freeing the carboxylate for binding. 
 
Compounds were tested at a concentration of 6.25 µgmL-1.  None of the compounds were 
found to be active at this concentration, demonstrating no inhibition of the growth of the M. 
tuberculosis strain.  This is not very surprising in the case of the inhibitors with carbon at C-3, 
or even thiosemicarbazone inhibitors 2.43 and 2.44 which were shown to be poor inhibitors of 
M. tuberculosis DHQase.  Compounds 1.36 and 2.38 however, are good inhibitors of M. 
tuberculosis DHQase and so it is a little disappointinng that the oximes 1.36 and 2.47 and the 
semicarbazone 2.38 showed no activity against M. tuberculosis.  It is possible that the lack of 
activity of the salts is due to an inability to traverse the cell membrane.  In the case of the ester 
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2.47, the compound may still be too hydrophilic to permeate the membrane, or it might be 
that the ester could not be hydrolysed by the organism. 
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A possible strategy for overcoming both membrane permeability and ester hydrolysis issues 
might be to adopt a prodrug approach which utilises an ester that is known to be susceptible to 
enzymatic hydrolysis and which would also make the inhibitors more lipophilic, enabling 
them to more easily traverse the plasma membrane.  The standard spectrophotometric assay 
for DHQase could easily be adapted, by incorporation of a suitable esterase, to test whether 
the carboxyl group could be unmasked to regenerate the free inhibitor and restore its activity. 
 
 
 
3.5 ENZYMATIC STUDIES ON S. TYPHI TYPE I DHQASE 
 
3.5.1 Michaelis-Menten Curve 
 
Data for a Michaelis-Menten curve was obtained for S. typhi DHQase at 25ºC and pH 7 
(Figure 3.28).  Non-linear least-squares fitting of the data to the Michealis-Menten equation 
(equation 3.1) gave KM = 17 ± 1 and Vmax = 0.045 ± 0.005 µMs
-1 at a total enzyme 
concentration of 46 ngmL-1.  The Michaelis constant obtained is in agreement with that 
reported by Abell and co-workers who obtained KM = 16 under the same conditions.
5 
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Figure 3.28  Michaelis-Menten curve for Type I DHQase from S. typhi. 
 
3.5.2 Assay Results and Discussion 
 
The only inhibitor synthesised with the type I DHQase in mind was the epoxide inhibitor 2.4.  
It was thought that the active site lysine residue of the type I enzyme might ring-open the 
epoxide, causing the inhibitor to become covalently bound to the enzyme, irreversibly 
inhibiting the enzyme.   
 
Precedent has shown that inhibitors of type II DHQase are type selective and thus poor 
inhibitors of type I DHQase.5,6,12  It was therefore deemed unnecessary to waste the prepared 
type II DHQase inhibitors on an assay against type I DHQase.  Epoxide inhibitor 2.4 was 
therefore the only inhibitor assayed against type I DHQase from S. typhi.   
 
3.5.2.1 Reversible Competitive Inhibition Study 
 
Epoxide inhibitor 2.4 was first assayed for competitive inhibition against S. typhi DHQase.  
Minimal data was collected in order to conserve the inhibitor for future experiments.  A 
Dixon plot was prepared and is shown in Figure 3.29. 
 
This Dixon plot gives a value of Ki for this inhibitor of 1.1 mM.  This Ki is an approximation 
and is unconfirmed, as multiple data sets leading to a common intersection point on the Dixon 
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plot were not obtained.  This result for Ki indicates that epoxide 2.4 is a relatively weak 
inhibitor of S. typhi DHQase.   
 
 
Figure 3.29  Dixon plot (minimal data) for inhibitor 2.4 against S. typhi DHQase. 
 
Table 3.6 shows reported inhibition constants for some inhibitors of type I DHQases from S. 
typhi and E. coli.  By comparison, epoxide inhibitor 1.24 was a more potent inhibitor of E. 
coli DHQase with a reported Ki of 400 µM.
15  Known inhibitor fluoroketone 1.32 was much 
more potent an inhibitor of type I DHQase from E. coli, with a reported Ki of 80 µM.
16  The 
activities of these inhibitors have not been reported for S. typhi DHQase however and so no 
direct comparison to the activity of epoxide 2.4 can be made.  Epoxide 2.4 is marginally more 
potent than 1.37 and 1.40, the most potent competitive inhibitors reported for S. typhi 
DHQase, however these inhibitors are type selective and thus more active against type II 
DHQase.6  Epoxide 2.4 however, is no more active type II DHQase from M. tuberculosis than 
type I DHQase from S. typhi. 
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Table 3.6  Reported inhibition constants for known type I DHQase inhibitors. 
   
Inhibitor Ki (µM) 
 S. typhi DHQase E. coli DHQase 
   
   
2.4 1100  
1.24
a
  400 
1.32
b
  80 
1.37
c
 3000 ± 1000  
1.40
d
 1500 ± 500  
   
a Ref. 15.  b Ref. 16.  c Ref. 6.  d Ref. 12,13. 
 
 
3.5.2.2 Time-Dependent Inhibition Study 
 
Epoxide inhibitor 2.4 was incubated with type I DHQase from S. typhi at ambient 
temperatutre.  A control sample was also incubated, identical except for the absence of 
inhibitor.  Aliquots of the enzyme incubation were taken at intervals, added to a solution 
containing substrate and buffer, and absorbance vs. time data collected for the enzymatic 
reaction. 
 
 
Figure 3.30  Plot of fractional activity vs. pre-incubation time for inhibitor 2.4 (400 µM) against showing time-
dependent inhibition of S. typhi DHQase. 
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On addition of the enzyme-inhibitor solution to the buffered substrate solution an initial 
induction period was observed before picking up to the steady-state rate.  The fractional rate 
vi/v0, where vi is the steady state rate of the sample containing inhibitor 2.4 and v0 is the initial 
(steady-state) rate of the control sample, was plotted against time.  The activity of the enzyme 
was seen to drop off quite quickly confirming that epoxide 2.4 is a time dependent inhibitor of 
type I DHQase from S. typhi (Figure 3.30).  The full activity (i.e. that of the control sample) 
was not recovered after dilution into the substrate solution, indicating that epoxide 2.4 is, as 
anticipated, an irreversible inhibitor of type I DHQase from S. typhi. 
 
A second experiment was carried out in which an incubation of S. typhi DHQase and inhibitor 
2.4 was prepared for LCMS, to determine whether the inhibitor was in fact becoming 
covalently bound to the enzyme.  A solution containing inhibitor and enzyme (200 : 1) at pH 
7 was incubated for 93 hours.  An aliquot was taken and diluted into a solution containing 
substrate and the absorbance was recorded over a period of 3 hours.  The data showed an 
extended induction period, followed by a linear period (the steady-state) after which the rate 
tailed off as the substrate was consumed (Figure 3.31).  The steady-state rate was compared to 
the control enzyme incubation (lacking inhibitor) and showed a 90% loss of activity over the 
93 hours (Figure 3.32). 
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Figure 3.31  Reaction progress curve for S. typhi DHQase after incubation for 93 hours in the presence of 
inhibitor 2.4. 
 
The enzyme incubation containing 200:1 inhibitor 2.4 : S. typhi DHQase was subjected to 
LCMS.  The resulting spectrum showed a pair of peaks, one at 27462 Da representing the 
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subunit mass of the free enzyme and the second at 27665 Da representing the enzyme subunit 
with a gain in mass of 203 Da.  This is in agreement (within an acceptable margin of error) 
with the mass gain that would be expected (204 Da) if inhibitor 2.4 had become covalently 
attached to the enzyme, by ring opening of the epoxide.  
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Figure 3.32  Illustration of time dependent inhibition of S. typhi DHQase by inhibitor 2.4 by comparison of 
steady-state rates of control incubation ([I] = 0 µM) and experimental incubation ([I] = 9 mM) after 93 h. 
 
The proposed mechanism of the time-dependent inhibition is one in which the epoxide is 
opened by the active site lysine residue of type I DHQases.  This is the lysine residue 
responsible for nucleophilic attack at the carbonyl carbon (C-3) and Schiff base formation 
during normal substrate turnover and so it seems reasonable to expect that the lysine would 
also attack the epoxide at C-3 to form enzyme bound adduct 3.5 (Scheme 3.5). 
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Scheme 3.5  Proposed mechanism of S. typhi DHQase time-dependent inhibition by epoxide 2.4. 
 
However, it is equally possible that the active site lysine attacks instead at the carbon exo to 
the carbocyclic ring, opening the epoxide to form adduct 3.6 (Scheme 3.6).  This is the 
chemically preferred pathway but the steric requirements of the enzyme may influence the site 
of attack.  As both possible products have identical mass, it is not possible to determine from 
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the LCMS result which is being formed.  This question could be answered however, if crystal 
structures of the enzyme-inhibitor adduct could be obtained.  The preferred mode of attack 
might also be predicted by computer modelling studies. 
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Scheme 3.6  Alternative mechanism of time-dependent inhibition of S. typhi DHQase by epoxide 2.4. 
 
 
 
3.6 CONCLUSION 
 
A spectrophotometric assay was used to evaluate the biological activity of the inhibitors 
whose preparation was described in Chapter 2.   
 
All of the inhibitors were assayed against type II DHQase from M. tuberculosis.  Inhibitors 
with a carbon atom attached at the 3-position were found to be universally weak inhibitors of 
M. tuberculosis DHQase.  Inhibitors with a nitrogen atom double bonded to C-3, on the other 
hand, were found to be more active than the carbon containing inhibitors by a factor ten or 
more.  These inhibitors displayed activity similar that of known inhibitor oxime 1.36.  The 
importance of the combination of an electronegative atom directly attached to the carbocyclic 
ring at the 3-position, and sp2 character at C-3, offers a clear direction for the design and 
synthesis of future generations of M. tuberculosis DHQase inhibitors.  
 
Epoxide inhibitor 2.4 was found to be a weak competitive inhibitor of type I DHQase from S. 
typhi which displayed rapid time-dependent irreversible inhibition of the enzyme.  LCMS 
confirmed that the inhibitor was becoming covalently attached to the enzyme, most likely by 
ring-opening of the epoxide by the active site lysine residue.  An x-ray crystal structure of the 
inactivated enzyme-inhibitor adduct could confirm this. 
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Inhibitors with sp3 character and C at C-3 were assayed against S. coelicolor DHQase.  These 
were found to be poor to moderate inhibitors of this enzyme.  The enzyme appeared to favour 
an equatorial side-chain at C-3 over an axial one, however, increasing the hydrophilicity of 
the equatorial side-chain appeared to result in a decrease in activity. 
 
Inhibitors with sp2 character at C-3 were not assayed against type II DHQase from S. 
coelicolor DHQase by this method due to their high absorbance at 234 nm.  In order to 
evaluate the biological activity of these inhibitors against S. coelicolor DHQase an alternative 
assay methodology was investigated.  This is discussed in the following chapter. 
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4 Biological Studies: 
1
H NMR Assay 
 
 
 
4.1 INTRODUCTION 
 
The highly UV active nature the inhibitors with sp2 character at C-3 prohibited using the 
spectrophotometric assay (described in Chapter 3) to obtain inhibition constants for their 
activity against S. coelicolor DHQase.  The spectrophotometric assay for DHQase consists of 
measuring the initial rate of the enzymatic conversion of dehydroquinate (DHQ) 1.4 to 
dehydroshikimate (DHS) 1.5 by monitoring the increase in absorbance at 234 nm due to the 
enone-carboxylate chromophore of the product DHS 1.5 (Scheme 4.1).  At the inhibitor 
concentrations required for the S. coelicolor DHQase assay, the absorbance due to the 
inhibitors was too great to obtain meaningful rate data spectrophotometrically.  In the initial 
stages of this work, S. coelicolor DHQase was the only type II enzyme available against 
which to assay the putative inhibitors.  An alternative means of measuring the rate of the 
enzymatic reaction was required.  This meant finding an alternative method for detecting 
either the appearance of the product, or the disappearance of the substrate. 
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Scheme 4.1  Conversion of substrate DHQ 1.4 to product DHS 1.5 by DHQase. 
 
Two possibilities were considered for an alternative detection method.  The first was 1H 
NMR.  The change in concentration of substrate or product could be measured by monitoring 
the decrease or increase respectively in an appropriate signal in the 1H NMR spectrum of the 
assay sample.  The second possibility was HPLC.  The concentration changes could be 
determined by stopping the enzymatic reaction after a certain interval and the various 
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components separated by HPLC and the amounts determined.  The discontinuous HPLC 
assay method seemed time consuming and inconvenient.  The continuous NMR method 
seemed preferable as the data could be acquired during the course of the reaction and no 
subsequent separation of the reaction components would be necessary. 
 
1H NMR would be expected to possess certain advantages over UV/vis spectroscopy as a 
detection method for the S. coelicolor assay.  It would allow the independent resolution of 
signals from the different components of the sample, enabling product, substrate and inhibitor 
to be distinguished in the spectrum.  This would avoid the problem of interference by the 
inhibitor encountered when attempting to monitor the formation of the product during the 
spectrophotometric assay. 
 
 
 
4.2 DETERMINATION OF DHS CONCENTRATION BY 
1
H NMR 
 
4.2.1 Choice of the Signal to be Monitored 
 
In order to measure the rate of the enzymatic reaction by 1H NMR, an appropriate signal from 
either the substrate 1.4 or the product 1.5 needed to be chosen, by which to monitor the 
concentration changes.  Such a signal must not overlap or be subject to interference from any 
of the other signals arising from the components of the assay solution.  Ideally it would be an 
intense peak as this would maximise the signal to noise ratio. 
 
The preferable choice would be to monitor the decrease in a substrate signal, however, all 
signals in the substrate spectrum were coupled to at least one other proton and usually more, 
making the signals broader and less intense.  All of the substrate signals also occur in the 
busy region of the spectrum between 2 and 5 ppm, in close proximity to other signals arising 
from the substrate itself, the product or from the intense signals due to the buffer and solvent.  
The doublet (J = 2.9 Hz) at 6.3 ppm in the product spectrum was chosen instead as it is a 
narrow signal relative to all others in the substrate and product spectra (there are no singlets 
in either spectrum), but more importantly, is well removed from any other signals in the assay 
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spectrum.  This signal arises from the olefinic proton at the 2-position of the product DHS 
1.5.  Figure 4.1 shows the 1H NMR spectrum of the product DHS 1.5. 
 
 
Figure 4.1  1H NMR spectrum of DHS 1.5 in D2O (the solvent peak has been partially deleted for convenience). 
 
4.2.2 Choice of a Reference Substance 
 
The relative concentrations of the components of the assay mixture could be determined by 
measuring peaks integrals.  However, for the purposes of the assay, the absolute 
concentration of the product at a given time needed to be measured.  This required the 
introduction of a known amount of a reference substance into the sample.  The absolute 
concentration of the product DHS 1.5 could then be calculated from the relative areas of the 
product and reference signals. 
 
4.2.2.1 Internal vs. External Reference 
 
Two possible means existed for introducing a reference substance into the assay sample.  An 
internal reference could be employed, in which case the reference substance is added directly 
to the assay solution. Alternatively an external reference could be chosen whereby a known 
amount of the reference substance is added to the D2O in the NMR tube insert and so is 
detected by the NMR spectrometer but does not come into contact with the assay solution. 
 
An external reference has the advantage of being isolated from the assay sample, negating 
any potential interaction of the reference with the components of the sample, particularly the 
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enzyme.  The known amount of reference would then be used to determine the amount of 
product present from the integrals of the respective NMR signals.  This would require the 
transferral of the assay sample into the NMR tube to be quantitative, or else introduce a 
significant source of error to the experiment by altering the relative amounts of product and 
reference. 
 
On the other hand, in the case of an internal reference, the reference would be in the solution 
with the other components of the assay and so the concentration of DHS would be 
determined from the concentration of the reference.  If the transferral of the assay sample to 
the NMR tube were not quantitative, the concentrations of the product and reference in the 
solution would not be affected. 
 
In practice, all of the components of the assay sample are combined in a vial, the reaction is 
initiated by the addition of enzyme, and the sample transferred to the NMR tube.  It is quite 
common for droplets of the aqueous solution to adhere to the pipette used to transfer the 
solution, to the walls of the NMR tube and to the sides of the NMR tube insert.  Minor 
spillages also occasionally occur.  It was thought that an internal reference was a more 
practical choice than an external one, as it eliminated these factors as a source of error. 
 
4.2.2.2 Nature of the Reference 
 
Choosing a reference substance imposed certain constraints.  The substance had to have an 
appropriate signal to monitor in its 1H NMR spectrum.  The requirements for the reference 
signal were the same as those for the product signal.  A signal well removed from all others 
in the assay spectrum was required and a narrow, intense signal was preferred.  It was 
desirable that the reference spectrum contained only the signal to be monitored and no others 
to avoid complicating the spectrum further.  It was also preferred that the signal to be 
monitored be an intense, uncoupled signal such as that for a methyl or tert-butyl group as this 
would reduce the concentration of reference required to get a good signal and minimise any 
interactions with the components of the assay.  
 
The decision to use an internal rather than external reference imposed the additional 
requirement that the reference compound must not inhibit the enzyme.  Therefore any 
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potential reference compound must first be assayed to determine whether or not it 
demonstrated any inhibitory activity against DHQase and thus whether it could be adopted as 
the standard reference for the 1H NMR assay. 
 
4.2.2.2.1 tBuOH as a Reference 
Tertiary butanol was the first substance trialled as a reference.  It gave a very intense, singlet 
signal at 1.2 ppm, well removed from substrate and product signals.  It also showed no 
competitive inhibition of S. coelicolor DHQase by the standard spectrophotometric assay 
described in Chapter 3. 
 
Figure 4.2  shows a 1H NMR spectrum of an assay sample with tBuOH used as the reference.  
The details of the spectrum about the very intense suppressed water signal and unsuppressed 
buffer signal are difficult to see clearly due to the distortion of the baseline arising from the 
baseline correction.  The baseline correction is used to bring the DHS 1.5 and tBuOH signals 
into line with each other so that the respective integral regions may be directly compared.  
The apparent distortion increases as the concentration of DHS 1.5 is reduced due to the 
greater vertical expansion of the spectrum required to clearly view the DHS 1.5 peak. 
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Figure 4.2  1H NMR spectrum showing enzymatic product DHS 1.5 H-2 and tBuOH reference signals. 
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Although tBuOH proved to be an adequate reference the large separation of the reference 
signal from the product signal made processing of the spectrum inconvenient and time 
consuming.  Because the regions about the peaks cannot be viewed in great detail, it makes 
optimising the phasing and integral regions of both peaks by eye difficult.   
 
It was thought that using an alternative reference substance with a signal that was closer in 
chemical shift to that of the DHS H-2 proton at 6.3 ppm would circumvent the extreme 
distortion of the central region of the spectrum resulting from the baseline correction.  It 
would also allow significant expansion during processing of the region of the spectrum about 
the two peaks to be monitored, allowing the regions around the signals of interest to be 
viewed in more detail.  This in turn would allow optimisation of the resulting data by 
increasing the precision with which the spectra could be phased and the integral regions 
selected. 
 
4.2.2.2.2 An Aromatic Compound as Reference 
It was thought that an aromatic proton would give a signal in the desired region of the 
spectrum, near the product H-2 signal but not too near the distortion arising from the water 
signal (Figure 4.2).  The signal would ideally be a singlet and would not overlap any other 
signals arising from the same compound.  Polyhydroxylated aromatics hydroquinone 4.1 
(δH(D2O) = 6.7 ppm), and phloroglucinol 4.2 (δH(D2O) = 5.9 ppm) seemed likely candidates 
as they would be expected to be sufficiently soluble in the aqueous assay solution.  Both 
showed a single singlet in their 1H NMR spectra, which was close to that of H-2 of DHS 1.5, 
but not so close as to overlap. 
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Hydroquinone 4.1 however, was found to inhibit S. coelicolor DHQase, i.e. the initial rate of 
the enzymatic reaction was observed (spectrophotometrically) to decrease with increasing 
concentration of 4.1 (Figure 4.3) and it was thought that this was also likely to be the case for 
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phloroglucinol 4.2.  Benzene 4.3 (δH(D2O) = 7.3 ppm) however, might be less likely to 
inhibit the enzyme as it lacked the potential for hydrogen bonding interactions of hydroxyl 
groups with the enzyme active site.  Benzene was therefore tested for inhibition of S. 
coelicolor DHQase, however a decrease in initial rate with increasing benzene concentration 
was still observed (Figure 4.3).  It is apparent that monocyclic aromatic compounds of this 
type would not make appropriate reference substances for a 1H NMR assay for S. coelicolor 
DHQase.  However, their potential as inhibitors of DHQase warrants further investigation. 
 
4.2.2.2.3 A Small Molecule as Reference 
It was thought that a small molecule would be less likely to inhibit S. coelicolor DHQase and 
so small molecules with a signal above 5 ppm in their proton NMR spectrum were 
considered.  Chloroform (δH(D2O) = 7.3 ppm), dichloromethane (DCM) (δH(D2O) = 5.4 ppm) 
and N,N-dimethylformamide (DMF) (δH(D2O) = 7.8 ppm for the COH proton) were 
considered the most likely candidates.  The chlorocarbons were considered preferable to 
DMF as each contained only a single proton signal in their respective NMR spectra, and 
chloroform was preferable to DCM as its proton signal was further removed from possible 
interference by the very intense water signal at 4.7 ppm. 
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Figure 4.3  Comparison of the effect of the possible alternative references on the initial rate of the enzymatic 
reaction. 
 
The small molecules were consequently investigated for inhibition of S. coelicolor DHQase 
(Figure 4.3).  In the cases of chloroform and dichloromethane, a definite decrease in the rate 
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of the enzymatic reaction was observed with increasing concentration of the small molecule.  
DMF however, displayed no such trend.  When tested for time dependent inhibition of S. 
coelicolor DHQase, DMF, at a concentration of 2 mM, caused no apparent decrease in 
enzyme activity over a period of 4 h.  This met the necessary requirements for a reference 
substance, as the enzyme would only be in contact with approximately 500 µM solutions of 
the reference, for reaction times of less than 15 minutes. 
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Figure 4.4  Partial 1H NMR spectrum of an assay sample showing DHS 1.5 H-2 and DMF signals (lb = 2). 
 
DMF was consequently selected as the most appropriate of the potential reference 
compounds investigated.  Although the DMF spectrum contains more than one proton 
resonance, the methyl peaks are well removed from the signals to be monitored during the 
assay.  With DMF as the reference, only the region of the spectrum between 6 and 8 ppm 
need be considered when processing the data (Figure 4.4).  All other signals arising from the 
substrate, product, buffer and solvent, which occur up field of this region, can be ignored.  
Figure 4.4 shows the region of the spectrum from which the data is extracted for a typical 
assay using DMF as the reference.  The improvement in clarity, when compared to the 
spectrum using tBuOH as the reference (Figure 4.2) is obvious.  As anticipated, the use of a 
reference compound with a signal closer in chemical shift to that of the DHS 1.5 proton, 
made processing the spectral data easier, more efficient and, most importantly, more precise. 
 
4.2.2.3 Spin-Lattice Relaxation Times 
 
An accurate concentration of product relative to reference can not be directly obtained from 
the respective peak integrals.  This is because the spin-lattice relaxation times (T1) for the 
protons in question are different.  While the DHS H-2 has a T1 of 6.0 s (averaged over both 
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peaks of the doublet), the DMF signal has a T1 of 8.4 s.  To allow for full relaxation of the 
protons between acquisitions (in order to obtain quantitative data from the integrals), a 
relaxation delay (d1) of approximately 5T1 is required.  This amounts to a necessary 
relaxation delay (d1) of 42 s.  This was completely inappropriate as data acquisition would 
take much too long.  An alternative value of d1 needed to be chosen. 
 
The longer the time interval between pulses, the greater the extent of relaxation of the proton, 
and the greater the intensity of the resulting signal.  The effect of the value of d1 on the 
intensity of the signals to be monitored and the quality of the data obtained was investigated.  
Increasing the value of d1 in 1 s increments from 0 up to 5 seconds showed a corresponding 
significant increase in the intensity of the product signal.  Beyond this point however, the 
improvement in the signal with each 1 s increase in d1 was less dramatic.  Values for d1 of 5 
s and 10 s were considered as a compromise between maximum signal intensity and 
minimum acquisition time.  While d1 = 10 gave slightly better data, with better signal to 
noise in the NMR spectrum and less scatter in the rate data, it also took much longer to 
acquire the data, meaning that fewer data points could be obtained for the [DHS] vs. time 
curve during the initial phase of the reaction. 
 
4.2.2.3.1 Calibration Curves 
A relaxation delay (d1) significantly below the time required for full relaxation of both DHS 
and reference peaks results in a ratio of signal areas which is not equal to the ratio of the 
concentrations.  This necessitates the construction of a calibration curve, in order to obtain a 
constant of proportionality, allowing the ratio of the concentrations of DHS and DMF to be 
calculated from the ratio of signal areas.   
 
 [DHS]calc = 
DHS integral
Reference integral  
x  [Reference] (4.1) 
 
To obtain a calibration curve for the reference, spectra were acquired for samples of known 
product and DMF concentrations and the integrals measured for the reference and product 
signals.  A calculated value for the concentration of the product DHS 1.5 ([DHS]calc) was 
obtained by measuring the integrals and calculated according to Equation 4.1.  Calibration 
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curves were prepared with [DHS]calc on the abscissa and the actual known product 
concentration [DHS]actual on the ordinate axis. 
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Figure 4.5  Calibration curve for DMF as reference (d1 = 5). 
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Figure 4.6  Calibration curve for DMF as reference (d1 =10). 
 
Calibration curves were obtained for DMF as a reference with d1 = 5 s (Figure 4.5) and 10 s 
(Figure 4.6).  Both of the calibration curves have a slope that is less than 1, indicating that the 
actual DHS concentration ([DHS]actual) is less than the DHS concentration calculated from the 
spectrum ([DHS]calc) using equation 4.1.  This overestimation of calculated DHS 
concentration is due to the shorter spin-lattice relaxation time of the DHS proton relative to 
the reference proton, giving a more intense DHS signal relative to the reference signal at 
equal concentrations.  The actual concentration of DHS in the assay samples can therefore be 
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calculated from the 1H NMR spectra according to equation 4.2 where the calibration constant 
C is equal to the slope of the calibration curve. 
 
 [DHS]actual = 
DHS integral
Reference integral  
x  C[Reference] (4.2) 
 
The DMF calibration curves illustrate that using a value of d1 equal to 10 s gives a better 
approximation of the DHS concentration than does a value of d1 equal to 5 s (Figure 4.5 and 
Figure 4.6).  In spite of this, d1 = 10 s was deemed to increase the acquisition time to too 
great a degree, and a value of d1 = 5 s was adopted. 
 
 
 
4.3 OPTIMISATION OF THE EXPERIMENT 
 
With the establishment of a serviceable method for determining the concentration of DHS 1.5 
in the assay solution by 1H NMR, it became necessary to optimise the experiment in order to 
obtain the most reliable rate data possible by this method.  Various factors were taken into 
consideration in optimising the experiment, including the choice of reference as discussed in 
section 4.2.2, the reaction conditions of the assay, the way the 1H NMR experiment was set 
up and the way the data was processed. 
 
4.3.1 Optimisation of the Assay Conditions 
 
In optimising the reaction conditions of the assay, the best substrate and enzyme 
concentrations had to be chosen.  In order to construct a Dixon plot (Section 3.1.2) to 
determine Ki for the inhibitor, 3 or 4 different substrate concentrations are required.  The 
substrate and enzyme concentrations chosen would determine the rate of the reaction to be 
monitored.  The tailoring of the assay conditions to give an appropriate rate was a crucial 
factor in establishing a working assay.  The time available for collection of initial rate data 
and the concentration of the product present in the solution would be determined by the rate 
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of the reaction, these factors therefore had to be taken into account when selecting the 
substrate and enzyme concentrations for the assay. 
 
4.3.1.1 Detection Limit for Product Concentration 
 
The use of 1H NMR as a detection method imposes a limiting concentration of DHS 1.5, 
below which the signal to noise ratio is extremely poor, or the signal cannot be observed at 
all.  It was found that 50 µM was the practical minimum DHS concentration which could be 
readily observed by 1H NMR.  The substrate and enzyme concentrations therefore, must be 
sufficient to give rise to a DHS concentration of at least 50 µM within 2-3 minutes of 
initiating the reaction (the time required to set up the NMR experiment) in order to give a 
measurable signal for the duration of the data collection.  The greater the rate of the reaction, 
the earlier the limiting concentration of DHS would be reached.  However, the greater the 
rate of substrate turnover, the briefer the interval over which the progress curve remains 
linear.  The change in absorbance at 234 nm due to formation of DHS was monitored for 
different concentrations of DHQ 1.4 and S. coelicolor DHQase in order to determine which 
combinations would produce 50 µM concentrations of DHS within 2 minutes of initiation of 
the reaction. 
 
4.3.1.2 Linearity of Initial Rate 
 
Substrate and enzyme concentrations had to be chosen such that there was sufficient substrate 
for the reaction progress curve to remain linear (to a reasonable approximation) over the time 
required to acquire the data.  The minimum time required to set up the NMR experiment and 
collect the data was 12 minutes (2 minutes to set up the experiment and 10 minutes to collect 
the data).  The reaction progress for different combinations of enzyme and substrate 
concentrations was followed spectrophotometrically in order to find a combination which 
gave a reaction progress curve which remained linear for at least 12 minutes but also 
produced a product concentration of 50 µM within the first 2 minutes ( as discussed in the 
preceding section).  The lower the concentration of enzyme relative to substrate, the longer 
the period over which the progress curve remained linear.  However if the rate of reaction 
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was too low, sufficient quantities of DHS 1.5 would not be produced within the necessary 
time frame of the experiment. 
 
4.3.1.3 Dependence of Rate on Substrate Concentration 
 
Another issue to take into consideration was the degree of dependence of the rate of the 
reaction on the substrate concentration.  Obviously, attaining high concentrations of product 
in the initial stages of the reaction and maintaining a linear progress curve for an extended 
time interval would be favoured by a high substrate concentration relative to the enzyme 
concentration.  However, at very high substrate concentrations the rate becomes virtually 
independent of substrate concentration, as described by the Michaelis-Menten equation 
(equation 3.1) and illustrated in Figure 3.3.  To construct a Dixon plot, a series of substrate 
concentrations is required, each giving rise to a different initial rate.  Thus the chosen 
substrate concentrations must be low enough that there is a measurable difference between 
the resulting initial rates. 
 
4.3.1.4 Test Run 
 
Substrate concentrations in the region of 500-1250 µM and an enzyme concentration of 0.04 
µgmL-1 were initially chosen to satisfy the above criteria.  The1H NMR assay method was 
tested by determining the initial rates of reaction for duplicate samples from the chosen series 
of substrate concentrations in the absence of inhibitor.  It was found that although the rates of 
reaction at such high substrate concentrations could easily be distinguished 
spectrophotometrically, the differences between the rates were too small and the 1H NMR 
method not sufficiently sensitive to measure such small differences.  The result being that the 
measured initial rates for the different substrate concentrations were found to be 
approximately equal, within the range of error, by 1H NMR.  Figure 4.7 shows the rate data 
obtained by 1H NMR at substrate concentrations of 500, 750, 1000 and 1250 µM along with 
corresponding data obtained by UV/vis spectroscopy.  Choosing a series of lower substrate 
concentrations to obtain a larger difference between rates gave product concentrations which 
were too low to obtain useful data. 
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There seemed to be no practical solution offering a series of substantially different rates all at 
high substrate concentrations.  It was decided instead to obtain rate data for one high 
substrate concentration only, which would then be used to construct a dose-response plot, 
from which could be determined the IC50 for an inhibitor. 
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Figure 4.7  Comparison of rate data by 1H NMR with data obtained by UV/vis spectroscopy. 
 
4.3.2 Optimisation the NMR Experiment 
 
Several parameters were investigated in an attempt to optimise the NMR data obtained.  In 
general, two main sets of parameters were considered.  The parameters used when setting up 
the NMR experiment, and the parameters used when processing the spectra in order to extract 
the best quality data from the spectra obtained. 
 
4.3.2.1 Experimental Parameters 
 
The two main factors which need to be considered when selecting the parameters for setting 
up the 1H NMR experiment are signal-to-noise ratio and time-scale.  There is always a 
compromise between choosing parameters that give the best signal-to-noise ratio, and 
keeping the time-scale of the experiment within the period for which the progress curve is 
known to remain linear. 
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4.3.2.1.1 Signal-to-Noise Ratio 
A poor signal to noise ratio is one of the greatest contributing factors to error in the 
experimental data.  Irregularities in the baseline that overlap with the signals to be measured 
cause significant variations in the integrals and hence the concentrations calculated.  As the 
assay is conducted at very low concentrations relative to a normal NMR spectrum obtained 
for the purposes of product characterisation, the signals to be measured are weak and the 
baseline noise substantial.  A number of parameters can be adjusted in order to improve the 
signal to noise ratio. 
 
4.3.2.1.1.1 Number of Transients 
The number of transients acquired has a great affect on the quality of the spectra obtained.  
The greater the number of transients acquired, the better the signal to noise ratio.  In order to 
optimise the data obtained, a large number of transients ought to be collected.  However, the 
more transients acquired, the more time required to collect the spectra.  With a non-zero 
delay between acquisitions of transients, the time required to collect each spectrum becomes 
substantial.   
 
It was found that increasing the number of transients per spectrum from 8 to 16 resulted in an 
observable improvement in the smoothness of the baseline and consistency of the 
concentration vs. time data obtained.  However, without decreasing d1 below the allotted 5 s, 
a minimum of 20 minutes was required to collect 10 data points.  This was too long, as the 
progress curve only remained linear for a little longer than 12 minutes.  Increasing the 
number of transients acquired by 1 or 2 made no appreciable difference to the data.  As a 
compromise between quality of spectra and time required to collect the data, 8 transients 
were collected for each spectrum.  A value of d1 equal to 5 s allowed a series of 10 spectra to 
be collected over a period of 10 minutes. 
 
4.3.2.1.1.2 Relaxation Delay (d1) 
As discussed previously in section 4.2.2.3, the value of d1 chosen has an effect on the 
intensity of the resulting signal.  Increasing the relaxation delay increases the intensity of the 
signal by increasing the proportion of protons allowed to relax back to the ground state before 
subsequent re-excitation.  As relaxation is described by a decay curve (the half-life being 
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equal to the spin-lattice relaxation time T1), incremental increases in d1 correspond to 
consecutively smaller corresponding increases in the extent of relaxation and thus intensity of 
the signal.  Beyond a certain point, increasing d1 by 1 s makes minimal difference to the 
signal intensity.  In the interests of completing the data collection within an acceptable time 
interval, in this case, the 12 minutes for which the reaction progress curve was known to be 
approximately linear, a value of d1 equal to 5 s was chosen.  Some experiments were also 
carried out with d1 = 10 s, however, in order to reduce the time required to acquire the data, 
fewer data points were able to be obtained.  Although d1 = 10 seemed to give marginally 
more consistent data (i.e. the concentration vs. time data showed less scatter), it was deemed 
to be in the interests of experimental accuracy to obtain as many data points as possible in 
order to minimise the contribution of outlying points.  Therefore the majority of experiments 
were carried out with d1 = 5 s. 
 
4.3.2.1.1.3 Signal Suppression 
The assay experiments were carried out with water as the solvent and it was therefore 
necessary to suppress the water signal in order to observe the required resonances.  However, 
the signal due to the Tris.HCl buffer at a concentration of 50 mM was very large relative to 
the micromolar concentrations of DHS and reference, and overwhelmed much of the central 
region of the spectrum.  It was thought that a simultaneous suppression of both water and 
buffer signals might decrease the experimental error associated with the method, resulting in 
more consistent concentration vs. time data.  
 
Figure 4.8 shows the 1H NMR spectrum of a sample acquired with simultaneous suppression 
of water and buffer signals (spectrum A) and without suppression of the buffer signal i.e. 
with suppression of the water signal alone (spectrum B).  Note the absence of the very intense 
buffer peak at 3.6 ppm from spectrum A and the presence of the buffer satellite peaks, which 
were not apparent in spectrum B due to the distortion of the baseline resulting from the 
baseline correction.  No significant improvement was observed in the integrity of the rate 
data however, and so the double suppression approach was abandoned as the result did not 
justify the additional time required to set up the experiment.  The assay was therefore carried 
out with suppression of the water signal only. 
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Figure 4.8  1H NMR spectra of an assay sample A. with suppression of the buffer signal and B. without 
suppression of the buffer signal. 
 
4.3.2.1.1.4 Decoupling of the Doublet Product Signal 
Another approach employed in an attempt to increase the signal to noise ratio by increasing 
the intensity of the DHS 1.5 signal was to decouple the signal by irradiating H-6ax (δH(D2O) = 
2.6 ppm), the proton to which it is coupled (J = 2.9 Hz).  However, the increase in intensity 
of the signal when collapsed to a singlet was minor relative to the initial signal intensity.  It 
was concluded that this minimal gain in signal intensity did not justify the additional time and 
inconvenience required to set up the experiment with decoupling of the DHS 1.5 proton. 
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4.3.2.1.2 Time-Scale 
The 1H NMR assay depends on measuring the initial rate of reaction, that is, the linear part of 
the reaction progress curve.  The time required to collect the data therefore needs to be as 
short as is practically possible.  Every action taken to improve the quality of the data obtained 
increases the time required to collect the data.  In addition to the number of transients 
collected and the relaxation delay (d1) discussed above, factors that affect the time required 
to collect the data include the number of spectra acquired (i.e. the number of data points on 
the final concentration vs. time curve) and the time between acquisition of each spectrum. 
 
4.3.2.1.2.1 Number of Spectra Collected 
Each spectrum collected for an assay sample gives one point on the [DHS] vs. time curve.  
There is a substantial amount of scatter amongst these points and so, ideally, a large number 
of points would be collected to minimise the contribution of outliers.  However, the more 
points obtained, the more spectra that must be acquired and the longer the time required to 
collect the data.  The maximum number of spectra that could be acquired in one experiment 
was 12.  It was decided that 10 points would be taken for each curve, thus 10 spectra.  With a 
relaxation delay d1 of 5 s, 10 spectra could be collected in 12 minutes, including the 2 
minutes required to set up the experiment subsequent to initiation of the reaction. 
 
4.3.2.1.2.2 Pre-acquisition Delay 
The pre-acquisition delay is the time interval between the completion of acquisition of one 
spectrum and the start of acquisition of another.  In order to minimise the time taken to 
complete the experiment, a small delay was needed.  It was also felt that it would be best to 
choose a pre-acquisition delay at least equal to the relaxation delay d1 and so a pre-
acquisition delay of 5 seconds was chosen.  Collecting 8 transients per spectrum, with a 5 s 
relaxation delay between transients, and a 5 s pre-acquisition delay between spectra, for a 
total of 10 spectra, required a total data acquisition time of 10 minutes. 
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4.3.2.2 Data Processing Parameters 
 
Once the spectra have been acquired they must be processed in order to extract the 
concentration data.  There are several parameters that can be optimised in order to obtain the 
best possible data.  The two factors that can be influenced subsequent to acquiring the spectra 
are peak shape and integrals. 
 
4.3.2.2.1 Peak Shape 
The shapes of the peaks to be measured have a large impact on the quality of the 
concentration data.  If the shape of the peak varies significantly from one spectrum to another 
in a series, a significant error is introduced and the concentration vs. time data can manifest a 
great deal of scatter.  Thus the optimal peak shape must be obtained before selecting the 
integral regions. 
 
4.3.2.2.1.1 Fourier Number (fn) 
This parameter determines the number of points included in the Fourier transform of the free-
induction decay (FID).  Increasing the Fourier number can be used to increase the resolution 
of the resulting spectrum by zero-filling.  The better the resolution, the closer the signals 
appear to their true shape, and the more accurately the relative peak areas reflect the relative 
concentrations. 
 
4.3.2.2.1.2 Phasing 
If the signals to be measured are not phased properly and consistently, the area under the 
peak is not a good measure of the substance concentration.  The DHS 1.5 and reference 
signals must be phased manually and the optimum phasing for each signal judged by eye.  
The manual phasing carried out on one spectrum of the series also phases every other 
spectrum in that series to the same degree.  However, there is still a certain amount of 
unavoidable inconsistency in the shapes of the peaks from one spectrum to the next, arising 
mainly from irregularities in the baseline, and contributing significantly to the scatter 
observed in the concentration vs. time data. 
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4.3.2.2.1.3 Line broadening (lb) 
Another way of smoothing out the shapes of the peaks is to use line broadening.  Although 
the broadening of the signal makes it appear less intense, it also decreases significantly the 
baseline noise which can interfere with the measured signals.  Varying degrees of line 
broadening (lb) were trialled, from the standard 0 up to 3.  A value of lb = 2 was found to 
give the greatest improvement in the data.  Figure 4.9 shows the appearance of a typical assay 
spectrum after processing with A) lb = 0 and B) lb = 2.  It is plain to see that the line 
broadening makes the spectrum clearer so that the integral regions may be selected 
incorporating the minimum contribution from nearby baseline features. 
 
DMF CHO 
DHS H-2A
B
 
Figure 4.9  Partial 1H NMR spectrum of an assay sample showing the effect of line broadening (lb) on the 
appearance of the spectrum.  A. lb = 0; B. lb = 2. 
 
4.3.2.2.2 Integrals 
The shape and position of the integral regions has a significant effect on the resulting data.  
Thus great care must be taken in determining exactly which areas of the spectrum will be 
taken into account in the calculation of relative peak area. 
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4.3.2.2.2.1 Selection of Integral Regions 
When selecting the integral regions, the spectrum is expanded as much as possible about the 
two peaks to be measured.  Ideally, the integral region must include the entire signal to be 
measured, without including any nearby irregularities in the baseline.  This can sometimes be 
problematic as the signals often overlap with significant baseline irregularities and judgement 
must be exercised in determining the best positioning of the integral region to best reflect the 
true peak area. 
 
4.3.2.2.2.2 Baseline Correction 
Once the integral regions have been selected, the baseline correction straightens and evens 
out the baseline around the selected integral regions, bringing the two signals into line with 
one another.  This is necessary because both the phasing of the signals and the large vertical 
expansion of the spectrum required to view the signals of the dilute DHS 1.5 and reference 
components can severely distort the baseline. 
 
4.3.2.2.2.3 Level Tilt 
The level tilt can be used to ensure that any parts of the integral that extend beyond the edge 
of the signal and over the baseline are as near as possible to horizontal.  Any non-horizontal 
peripheral parts of integrals will add to (or subtract from) the measured relative peak area. 
 
 
 
4.4  GENERAL METHOD 
 
Based on the above considerations, a general method was developed for the 1H NMR assay.  
The assay samples consisted of 550 µL of solution, containing substrate, inhibitor, DMF, 
Tris.HCl buffer (50 mM), and water and were prepared in 2 mL vials.  The reaction was 
initiated by addition S. coelicolor DHQase solution in 50 mM buffer.  The sample was then 
transferred to a 5 mm NMR tube with a D2O-filled insert and inserted into the spectrometer, 
at a temperature of 25 ºC. 
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After locking and shimming the sample one transient was acquired in order to set up the 
solvent peak suppression.  The experiment was then set up to collect 10 spectra, with a 5 s 
pre-acquisition delay before the start of acquisition of each spectrum.  Each spectrum 
consisted of 8 transients, with a relaxation delay (d1) of 5 s between each transient.  The set-
up took approximately 2 minutes and acquisition of each spectrum took 55 s plus an extra 5 s 
delay before acquisition of the succeeding spectrum, leading to a total of 10 minutes for 
complete data acquisition. 
 
The spectra obtained were processed with fourier number (fn) = 128k and line-broadening 
(lb) = 2.  The spectrum was expanded vertically and horizontally so the DHS and DMF peaks 
could be seen clearly.  The two signals at 6.3 and 7.8 ppm were then phased manually.  The 
integral regions were selected, then the baseline corrected.  The level-tilt was adjusted if 
necessary.  The integral regions were displayed and their values recorded.  The baseline 
correction and recording of the integrals was repeated for each spectrum in the series. 
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Figure 4.10  An example of a partial product concentration vs. time curve for the conversion of DHQ 1.4 to 
DHS 1.5 by DHQase obtained by 1H NMR. 
 
The product concentrations were calculated for each spectrum using equation 4.2 and plotted 
against the time of completion of acquisition of each spectrum.  The rate was determined by 
fitting a straight line to the data and taking the slope.  An example of a [DHS] vs. time curve 
obtained by 1H NMR for the initial stage of the enzymatic reaction is shown in Figure 4.10. 
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4.5 ASSAY RESULTS AND DISCUSSION 
 
4.5.1 Dose-Response Curves for Inhibitors 
 
The activity of the inhibitors with sp2 character at C-3, 2.15, 2.27, 2.38, 2.44, 2.46 and 3.1, 
against S. coelicolor DHQase was assessed by 1H NMR assay.  Dose-response curves were 
obtained in preference to Dixon plots, as the NMR method lacked the sensitivity of the 
spectrophotometric method and so was unable to distinguish such small differences in rates.  
The IC50 for the inhibitor could then be determined from the dose-response plot by non-linear 
least-squares fitting of the data to Equation 4.3.1  The inhibition constant Ki can be calculated 
from the IC50 using the Cheng and Prusoff relationship for competitive inhibition (Equation 
4.4).1,2 
 
 
vi
v0
  =  
1
1 + 
[I]
IC50
  (4.3) 
 
 Ki  =  
IC50
1 + 
[S]
KM
 (4.4) 
 
 
4.5.1.1 Dose-Response Curve for Dicarboxylate Inhibitor 2.27 
 
Inhibitor 2.27 was assayed against S. coelicolor DHQase using the 1H NMR method.  A 
dose-response curve was compiled and is shown in Figure 4.11, where vi is the rate in the 
presence of inhibitor, v0 is the rate in the absence of inhibitor and vi/v0 is the fractional rate.  
As can be seen in the figure, the curve is incomplete, in that it does not extend as far as vi/v0 = 
0.  This is because it was not possible to obtain data for sufficiently high inhibitor 
concentrations to observe the full curve because the signals due to the inhibitor overwhelm 
those due to DHS 1.5 and the reference DMF at such high concentrations.  The other obvious 
contributing factor to the incomplete state of the curve is the lack of potency of the inhibitor 
2.27.  The fact that the fractional rate vi/v0 does not reach zero within an inhibitor 
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concentration of 30 mM indicates that 2.27 is not a very good inhibitor of S. coelicolor 
DHQase.  Also, the substrate concentration at which the experiment was carried out was high 
(800 µM) in order to generate a sufficient product concentration during the initial stage of the 
reaction.  Given the dependence of the IC50 on substrate concentration, using a lower 
concentration of substrate would give a lower IC50 and thus a more complete dose-response 
plot could be obtained using the same inhibitor concentrations.  Least squares fitting of the 
data to equation 4.3 gives a value of IC50 = 61 ± 9 mM.  Using equation 3.2 and KM = 200 µM 
to calculate Ki for [S] = 800 µM gives an inhibition constant of 12 ± 2 mM.  This result 
confirms that 2.27 is a very poor inhibitor of S. coelicolor DHQase. 
 
 
Figure 4.11  Dose-response plot for inhibitor 2.27.  Reference = DMF, d1 = 10. 
 
4.5.1.2 Dose-Response Curve for Oxime Inhibitor 1.36 
 
It was necessary to validate the method by using it to determine an inhibition constant for a 
known inhibitor and also to attempt to obtain a more complete dose-response plot using a 
more potent inhibitor.  Therefore the known inhibitor 1.36 was assayed against type II 
DHQase from S. coelicolor at a substrate concentration of 800 µM.  As in the case of 
inhibitor 2.27, the dose-response curve does not extend to a fractional rate of zero, although 
the curve for oxime 1.36 is more complete than that for 2.27.  Least squares fitting of the data 
gave an IC50 of 2600 ± 800 µM.  A Ki of 520 ± 150 µM was obtained using Equation 3.2.  
This is in agreement with the both the Ki of 530 ± 80 µM obtained using the 
spectrophotometric assay and the reported value of 500 ± 200 µM.3  This attainment of a Ki 
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for a known inhibitor, in agreement the values previously obtained using a 
spectrophotometric assay, proves that this is a valid method for assaying inhibitors of S. 
coelicolor DHQase. 
 
 
Figure 4.12  Dose-response plot for known oxime inhibitor 1.36 against S. coelicolor DHQase. 
 
4.5.1.3 Single-Point Inhibition Studies 
 
The incomplete nature of the dose-response curves obtained indicated that full curves would 
only be obtained for more potent inhibitors.  It was therefore decided not to obtain dose-
response plots for other inhibitors unless prior experiments indicated that the inhibitors would 
be sufficiently potent to obtain reasonably complete curves.  For inhibitors 2.15, 2.38, 2.44, 
2.46 and 3.1 therefore, the degree of inhibition was determined at fixed inhibitor and 
substrate concentrations.  The initial rates of reaction were measured both in the presence and 
absence of inhibitor, at the same substrate concentration and the activity remaining 
determined as a percentage of the initial activity in the absence of inhibitor.  The inhibition at 
the given inhibitor concentration was then defined as being equal to 100% minus the activity 
remaining.  The experiments were carried out at a substrate concentration of 800 µM.  The 
inhibitor concentrations employed were subject to availability of material and are shown, 
along with the inhibition results, in Table 4.1.  The inhibitor concentrations listed are for the 
major isomer only in the cases of 2.38 and 2.44, and the combined concentration of both 
isomers for 2.46.  The % inhibition by 2.27 that would be expected at an inhibitor 
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concentration of 5000 µM was calculated from the data obtained for the dose-response curve 
and is included in the table for the sake of comparison. 
 
Table 4.1  Inhibition results for inhibitors 2.15, 2.38, 2.44, 2.46 and 3.1 against S. coelicolor DHQase as 
determined by 1H NMR spectroscopy. 
         
Inhibitor [DHQ] (µM) [I] (µM) 
Enzyme Activity 
Remaining (%) 
Inhibition (%) 
         
     
2.15 800 5000 62 ± 17 38 ± 17 
2.27
a
 800 5000 92 8 
2.38
b
 800 5000 89 ± 16 11 ± 16 
2.44
c
 800 4500 11 ± 6 89 ± 6 
2.46
d
 800 1100 89 ± 7 11 ± 7 
3.1 800 5000 10 ± 5 90 ± 5 
         
a Calculated from data obtained for the dose-response plot.  b 20:1 (E:Z).  c 9:1 (E:Z).  d 3:2 (E:Z).   
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Two of the inhibitors whose activity was evaluated in this way were found to display 
substantial activity against S. coelicolor DHQase.  Allylic alcohol inhibitor 3.1 and 
thiosemicarbazone inhibitor 2.44 showed 90% and 89% inhibition respectively of S. 
coelicolor DHQase.  Dose-response plots for these inhibitors against S. coelicolor DHQase 
were therefore obtained by 1H NMR spectroscopy.  The remaining inhibitors 2.15, 2.38 and 
2.46 were deemed to be insufficiently active to justify obtaining dose-response plots. 
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4.5.1.4 Dose-Response Curve for Thiosemicarbazone Inhibitor 2.44 
 
Thiosemicarbazone inhibitor 2.44 was assayed as a 9:1 mixture of E and Z isomers and the 
calculated IC50 is based on the concentration of the major isomer.  The dose-response plot 
obtained for inhibitor 2.44 is shown in Figure 4.13.  The x-axis shows the log10 of the 
concentration (in µM) of the major isomer.  The experimental data is shown as points and the 
curve obtained by least squares fitting of the data to equation 4.3 is shown as a solid line.  An 
IC50 of 1100 ± 200 µM was obtained, which corresponds to an inhibition constant (at 800 µM 
substrate concentration) of 220 ± 40 µM, according to the Cheng and Prusoff relationship 
(equation 3.2). 
 
 
Figure 4.13  Dose-response curve for thiosemicarbazone inhibitor 2.44, in a 9:1 ratio of isomers (E:Z), with the 
x-axis displaying the log of the concentration (µM) of the major isomer. 
 
 
4.5.1.5 Dose-Response Curve for Alcohol 3.1 
 
The dose-response plot obtained for inhibitor 3.1 is shown in Figure 4.14.  The plot shows 
two curves obtained by least-squares fitting of the data to Equation 4.3.  The upper curve 
shows the fit including the outlying point at log[I] = 3.75, and the lower curve shows the fit 
calculated without including this point.  The upper fit gives an IC50 of 500 µM and the lower 
fit an IC50 of 280 µM.  The Cheng and Prusoff relationship (Equation 3.2) gives 
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corresponding inhibition constants Ki of 98 µM and 56 µM respectively.  Averaging the two 
results gives a Ki of 77 ± 21 µM. 
 
 
Figure 4.14  Dose-response plot for inhibitor 3.1 against S. coelicolor DHQase. 
 
4.5.2 Discussion of 
1
H NMR Assay Results 
 
The three inhibitors with C at C-3 and with sp2 character at C-3 (2.15, 2.27 and 3.1), showed 
dramatically different activities against S. coelicolor DHQase.  Nitrile 2.15 was found to be a 
fairly poor inhibitor of S. coelicolor DHQase.  This was unsurprising given the moderate 
activity observed for the reduced analogues 2.16 and 2.17 by spectrophotometric assay 
(Chapter 3).  The dicarboxylate inhibitor 2.27 was an even poorer inhibitor of S. coelicolor 
DHQase.  This is consistent with the lower activity of the saturated, equatorial carboxylate 
inhibitor 2.28 relative to the corresponding nitrile 2.16.  What is slightly surprising is the 
substantially greater activity displayed by allylic alcohol 3.1 against S. coelicolor DHQase 
relative to the other sp2 inhibitors 2.15 and 2.27.   
 
The x-ray crystal structure of S. coelicolor DHQase with the inhibitor 2,3-anhydroquinic acid 
1.37 bound in the active site indicates that this enzyme is able to bind a glycerol molecule in 
the active site, as well as the inhibitor.4  This is the basis of the design of the series of 
inhibitors 1.43-1.50 prepared by Abell and co-workers (Chapter 1).5  Inhibitor 3.1 is more 
active against S. coelicolor DHQase than the most potent of these inhibitors, compound 1.45.  
It is however less potent than the parent inhibitor 1.37.  It is possible that the side-chain 
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hydroxyl of 3.1 is able to enhance binding by binding in the glycerol binding pocket.  
However, if this is the case, the carboxylate side-chain of 2.27, expected to be of similar 
length to that of 3.1, ought also to extend into the glycerol binding pocket, leading to 
enhanced binding. This is clearly not the case, supporting the assumption that the carboxylate 
group participates in a particularly disadvantageous interaction when the side chain is 
equatorial (see discussion of spectrophotometric assay results for S. coelicolor DHQase in 
Section 3.3.3) or joined to the carbocyclic ring via a double bond. 
 
 
Table 4.2  Some inhibition constants for S. coelicolor DHQase. 
  
Inhibitor Ki (µM) 
 S. coelicolor DHQase 
  
  
1.37
a
 30 ± 10 
1.45
b
 180 ± 20 
2.16 800 ± 100 
2.27 12000 ± 2000 
2.28 3000 ± 1000 
2.44 220 ± 40 
3.1 77 ± 21 
  
a Ref. 3.  b Ref. 5.  c 2:1 2.17:2.16. 
 
 
The inhibitors with N at C-3 (2.38, 2.44 and 2.46) also showed interesting activity against S. 
coelicolor DHQase.  In general, they appear to be no more active than the carbon based 
inhibitors, in contrast to the results obtained for the M. tuberculosis enzyme.  This is 
consistent with the moderate activity of reported oxime inhibitor 1.36 against S. coelicolor 
DHQase.  In complete contrast to the results obtained for type II DHQase from M. 
tuberculosis (Section 3.4.2.2), the thiosemicarbazone inhibitor 2.44 was substantially more 
active against S. coelicolor DHQase than the semicarbazone 2.38 or the formylhydrazone 
2.46 (Table 4.1).  This is consistent however, with the observation that more hydrophilic 
side-chains at C-3 appear to be disfavoured by S. coelicolor DHQase, as indicated by the 
poorer activity of the carboxylate inhibitors 2.27 and 2.28 relative to the corresponding 
nitriles 2.15 and 2.16 and alcohol 3.1. 
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4.6 CONCLUSION 
 
1H NMR spectroscopy was investigated as an alternative detection method for conducting 
biological studies with S. coelicolor type II DHQase.  A new method using 1H NMR 
spectroscopy as the means of determining reaction rate was developed to obtain biological 
data in cases where the traditional spectrophotometric assay was inappropriate.  The 1H NMR 
method was used successfully to obtain inhibition constants for three new inhibitors and one 
previously reported inhibitor, and was shown to give a result in good agreement with that 
reported in the literature.  The method is more practical for determining the % inhibition at a 
fixed inhibitor concentration, than for determining inhibition constants, except in cases where 
the inhibitors are reasonably active (Ki < 500 µM). 
 
Although the method proved useful in enabling the acquisition of kinetic data that could not 
have been obtained using the spectrophotometric assay it is by no means an ideal assay for 
DHQase.  The particular attributes of the DHQase reaction which make it not well suited to 
this method are the absence of a good substrate signal, so that the formation of product must 
be monitored instead, and that the signal to be monitored is not a very intense one.  The 
sensitivity of the detection method is poor relative to UV/visible spectroscopy requiring high 
substrate concentrations and high reaction rates in order to generate sufficient product 
concentrations.  Such high substrate concentrations lessen the observable effect of inhibitors 
on the rate of reaction so that unless the inhibitor is particularly potent, only partial data can 
be obtained for the dose-response curves required to determine the inhibition constants.  The 
necessity for a high rate of reaction also means that the method would not be very appropriate 
for evaluating the activity of inhibitors against enzymes with a low kcat such as M. 
tuberculosis DHQase. 
 
An alternative methodology which would perhaps be more appropriate to the DHQase system 
is a coupled assay.  A coupled assay for DHQase would incorporate the subsequent enzyme 
on the shikimate pathway, shikimate dehydrogenase, which utilises the UV active co-factor 
NADPH.  NADPH has a λmax of 340 nm,
6 which does not overlap with the signals from the 
product dehydroshikimate or any of the inhibitors.  If sufficient shikimate dehydrogenase and 
NADPH were added, such that the DHQase reaction became the rate limiting step, the rate of 
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the DHQase reaction could be determined by monitoring the decrease in absorbance due to 
NADPH.   
 
The 1H NMR assay method would be more appropriate for a biological system in which the 
decrease in substrate concentration could be monitored in place of the increase in product 
concentration.  This would mean that lower substrate concentrations could be used without 
the necessity of allowing the product concentration to build up to detectable levels.  Systems 
possessing a very intense signal in the 1H NMR spectrum of the substrate, such as a methyl 
group, which could more easily be monitored by NMR spectroscopy with improved signal to 
noise ratio, allowing lower substrate concentrations to be employed would be particularly 
amenable to this method. 
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5 Summary and Future Work 
 
 
 
5.1 SUMMARY 
 
A series of potential DHQase inhibitors were prepared, based on the structure of known 
inhibitor oxime 1.36.  Two main classes of inhibitors were prepared.  Those of general 
structure 2.3 with N attached at C-3 (2.38, 2.42, 2.44 and 2.46) and those of general structures 
2.1 and 2.2 with C attached at C-3 via a single or double bond respectively (2.15-2.18 and 
2.27-2.29).  Epoxide based inhibitor 2.4 was also prepared. 
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The preparation of potential inhibitors 2.59, 2.76 and 2.77 was also investigated, and was 
ultimately unsuccessful due to problems with the protecting group chemistry. 
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The potential inhibitors were assayed against M. tuberculosis and S. coelicolor DHQase 
spectrophotometrically, by monitoring the increase in absorbance at 234 nm due to the enone-
carboxylate chromophore of the product dehydroshikimate.  This assay proved to be 
unsuitable for assaying UV active inhibitors against S. coelicolor DHQase as the high 
inhibitor concentrations required gave rise to too great a degree of background absorbance.  
An alternative 1H NMR based assay methodology was therefore developed.  This involved 
monitoring the appearance of the C-2 proton resonance of dehydroshikimate at 6.3 ppm.  The 
concentration of DHS was determined by integrating the H-2 signal relative to the CHO 
signal of a known concentration of the reference DMF. 
 
Table 5.1  Assay results for inhibitors against M. tuberculosis and S. coelicolor type II DHQases 
        
Inhibitor Ki (µM) % inhibition 
  M. tuberculosis DHQase S. coelicolor DHQase S. coelicolor DHQase 
    
    
KM 15 ± 1 200 ± 20 
 
2.4 ~ 925 e  
2.15 >3000  38 ± 17 
2.16 1150 ± 150 800 ± 100  
2.17 1000 ± 200 1600 ± 200a  
2.18 2000 ± 400 6000 ± 500  
2.27 2000 ± 600 12000 ± 2000  
2.28 850 ± 150 3000 ± 1000  
2.29 900 ± 150 1500 ± 500  
2.38
b
 45 ± 5  11 ± 16 
2.42 50 ± 5  e 
2.44
c
 425 ± 75 220 ± 40 89 ± 6 
2.46
d
 90 ± 10  11 ± 7 
3.1 1100 ± 100 77 ± 21 90 ± 5 
3.2 1600 ± 400  e 
        
a 2:1 2.17:2.16.  b 20:1 E:Z.  c 9:1 E:Z.  d 3:2 E:Z.  e Not determined due to lack of material. 
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Inhibitors with N attached at C-3 (2.38, 2.42, 2.44 and 2.46) were found to be more potent 
against M. tuberculosis DHQase than those with C at the corresponding position by roughly 
one order of magnitude, displaying activities ranging from 45-90 µM, with the exception of 
2.44 which had a Ki of 425 µM (Table 5.1).  The most potent of these inhibitors, 2.38, 
displayed a Ki of 45 µM, similar to that of oxime 1.36 which had a reported Ki of 20 µM.
1  
Inhibitors with C at C-3 on the other hand, displayed inhibition constants ranging from 850 
µM to >3000 µM.   
 
Inhibition constants for inhibitors with sp3 character and C at C-3 (2.26-2.18, 2.28 and 2.29) 
against S. coelicolor DHQase, determined by spectrophotometric assay, ranged from 800 to 
6000 µM, a similar range to that observed for the M. tuberculosis enzyme.  Inhibitors with sp2 
character and C at C-3 (2.15, 2.27 and 3.1) were evaluated by 1H NMR assay.  Inhibitors 2.15 
and 2.27 were found to be poor inhibitors of S. coelicolor DHQase.  Allylic alcohol inhibitor 
3.1 proved to be the exception, with a Ki of 77 ± 21 µM.  The activity of inhibitors with N at 
C-3 against S. coelicolor DHQase was also evaluated by 1H NMR assay.  Inhibitors 2.38 and 
2.46 showed only 11% inhibition at concentrations of 5 mM and 1.1 mM respectively.  The 
sulphur analogue of 2.44 on the other hand, displayed 89% inhibition at 5 mM, with a Ki of 
220 ± 40 µM, in direct contrast to the trend observed for the N containing inhibitors against 
M. tuberculosis DHQase.   
 
Inhibitor 2.4 was found to be a weak competitive inhibitor of Type I DHQase from S. typhi 
(Ki ≈ 1100 µM), and also displayed irreversible inhibition of the enzyme. 
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A selection of the inhibitors, 2.27, 2.38 and 2.44, along with the esters 2.31, 2.34 2.35 and 
2.43 and the oximes 1.36 and 2.47, were submitted for biological evaluation against M. 
tuberculosis strain H37Rv.  None of the compounds, including the two oximes, were found to 
be active against the bacterium at a concentration of 6.25 µgmL-1. 
 
 
 
5.2 FUTURE WORK 
 
Possible future directions for this work include pursuing the work that was begun with the 
synthesis of allylic bromide 2.74.  Alternative deprotection conditions and/or carboxy 
protecting groups ought to be explored for this compound as the deprotected form 2.76 could 
be a potential inhibitor of both type I and type II DHQase (S. coelicolor type II DHQase more 
than M. tuberculosis).  The preparation of analogues of potent S. coelicolor DHQase inhibitor 
1.37
1 by nucleophilic displacement of bromide from 2.74 might also be explored.  Azide 5.1 
for example, could be prepared from 2.74, and from that, the allylic amine 5.2.  This could be 
deprotected to give potential inhibitor 5.3.  Various nucleophiles (such as sugar derivatives), 
might also be employed in the derivitisation of 2.74, to produce compounds of general 
structure 5.4, which could be deprotected to give 5.5, with the nucleophile potentially binding 
in the glycerol binding site of S. coelicolor described by Roszak et al.2 
 
It is thought that lactam 5.6a (Scheme 5.2) would, through its resonance contributors, be 
particularly able to fulfil the structural requirements for binding by M. tuberculosis DHQase 
as discussed in Section 3.4.3.  That is, it displays both sp2 character and an electronegative 
atom at C-3.  It is also a good mimic for the structural features of the type II DHQase enolate 
intermediate 1.21 and would therefore be expected to be a good inhibitor of Type II DHQases 
in general, not just that from M. tuberculosis. 
 
In contrast to the dehydroquinate analogues described in this work, the lactam 5.6a, which 
contains an N atom at the 2-position of the carbocyclic ring, could not be prepared from the 
usual starting material, quinic acid 2.5.  It might however, be prepared via ring-closing 
metathesis, followed by epoxidation of the double bond and ring-opening to form the trans-
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diol, as illustrated in Scheme 5.2.  The C-1 hydroxyl would pose a problem however, as the α-
hydroxyamino acid 5.7a is not expected to be stable.  Alternative α-allylamino acids 5.7b and 
5.7c might be more practical options, eventually leading to lactams 5.6b and 5.6c.  The 
replacement of the C-1 hydroxyl however, might be expected to reduce the binding affinity, 
particularly for S. coelicolor DHQase, for which binding of the C-1 hydroxyl and carboxyl is 
important for substrate recognition.  It might be less of a problem for M. tuberculosis 
DHQase, for which C-3 carbonyl recognition is thought to be more important.  The affect of 
replacing the C-1 hydroxyl might be explored by preparing the substrate analogues 5.8b and 
5.8c and some of their C-3 derivatives. 
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Scheme 5.1  Proposed synthesis of derivatives of allylic bromide 2.74. 
 
It would also be useful to investigate improving the drug-like properties of dehydroquinate 
derivatives.  The choice of protecting group for the C-1 carboxyl in particular ought to be 
investigated.  The carboxyl group could be masked with a lipophilic ester, which could 
facilitate the uptake of the inhibitor into a cell, and be subsequently hydrolysed in vivo to 
produce the inhibitor in its active form. 
 5   Summary and Future Work 141 
 
 
HN
O
OH
R
OH
CO2H
N
O
R CO2H
N
O
R CO2H
H2N
O
R CO2H
OH
5.6
a R = OH
b R = H
c R = CH2OH
HN
O
OH
RO
OH
CO2H
5.7
O
OH
R
OH
CO2H
5.8
O
OH
HO
OH
CO2H
1.21
HO
OH
HO
OH
CO2H
2.5
 
Scheme 5.2  Retrosynthetic analysis of lactam 5.6. 
 
 
 
 5   Summary and Future Work 142 
 
5.3 REFERENCES FOR CHAPTER 5 
 
 (1) Frederickson, M.; Parker, E. J.; Hawkins, A. R.; Coggins, J. R.; Abell, C. J. 
Org. Chem. 1999, 64, 2612. 
 (2) Roszak, A. W. R., D. A.; Krell, T.; Hunter, I. S.; Frederickson, M.; Abell, C.; 
Coggins, J. R.; Lapthorn, A. J. Structure 2002, 10, 493-503. 
 
 6   Experimental Details 143 
 
6 Experimental Details 
 
 
 
6.1 GENERAL 
 
Melting points were obtained on an Electrothermal apparatus and are uncorrected. 
 
1H NMR spectra were recorded on a Varian Unity 300 or Varian Inova 500 spectrometer 
operating at 500 MHz.  13C NMR spectra were recorded on a Varian Unity 300 spectrometer 
operating at 75 Mz with a relaxation delay (d1) of 1 s.  19F NMR spectra were recorded on a 
Varian Unity 300 NMR spectrometer.  Spectra were obtained at 23 ºC unless otherwise stated.  
Chemical shifts are reported in parts per million (ppm). 
 
Electron impact (EI) mass spectra were recorded on a Kratos MS80 RFA mass spectrometer 
operating at a 4000 V accelerating potential and 70 eV ionization energy.  The source 
temperature was 200-250 ºC.  Electrospray (ES) mass spectra were detected on a micromass 
LCT TOF mass spectrometer, with a probe voltage of 3200 V and temperature of 150 ºC and 
a source temperature of 80 ºC.  Direct ionization used 10 µL of an 8 or 10 µgmL-1 solution, 
with 50% MeCN/H2O as the carrier solvent at a flow rate of 20 µLmin
-1.  Ionisation was 
assisted by the addition of 0.5% formic acid. 
 
UV/vis spectra were recorded on a GBC 920 UV VIS spectrophotometer with a slit width of 
0.2 nm and an integration time of 1 s in 3 mL 1 cm path-length quartz cuvettes. 
 
Optical rotations were recorded on a Perkin Elmer 341 polarimeter with a 10 cm path length.  
Optical rotations are given in units of 10-1deg cm2 g-1.  Concentrations are quoted in g/100 
mL. 
 
Starting material and reagents were obtained commercially and used without further 
purification unless otherwise stated.  Solvents for organic synthesis and chromatography were 
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dried and distilled prior to use.  THF was dried by distillation from Na/benzophenone.  Pet. 
ether, EtOAc, CH2Cl2, MeCN, toluene, Et3N and pyridine were dried by distillation from 
CaH2.  Methanol was dried by distillation from Mg/I2.  DMF was dried over 4 Å activated 
molecular sieves, replacing the sieves two times over 48 h.  Pet. ether refers to the fraction 
boiling between 50 and 70 ºC. 
 
Flash chromatography was carried out using 230-400 mesh Merck Silica Gel 60 under 
positive pressure.  Deactivated silica refers to silica that has been neutralised by the addition 
of Et3N (1%) to the solvent used to pack the column.  The column was then rinsed with eluent 
prior to loading the material to be separated.  Analytical thin-layer chromatography was 
carried out on Merck Keiselgel KG60F254 silica plates and visualised using KMnO4. 
 
Assay solutions were prepared using water from a Milli-Q MilliPore (≥ 18 MΩ cm-1) water 
purification system in which distilled water was sequentially passed through a Super-C carbon 
cartridge, Ion-ex anion and cation exchange cartridges, an Organex-Q cartridge and finally a 
Millipak 0.22 µm pore size filter. 
 
Evaporation of solvents from reaction products was carried out using a rotary evaporator, 
connected to a diaphragm pump.  Drying of samples was carried out under high-vacuum, 
using a rotary oil pump.  Lyophilisation was carried out using either a Chriss Alpha I-5 freeze 
dryer or a rotary oil high vacuum pump with a cold-finger. 
 
For the purpose of naming compounds, the mono- and bi-cyclic ring systems were named and 
numbered as follows: 
 
1
2
3
4
5
6
O
O
CO2
1
2
3
4
5
6
7
8
9
10
cyclohexane-1-carboxylate 2,5-dioxabicyclo[4.4.0]decane
O
1
2
345
6
7
8 9
9-oxabicyclo[4.3.0]nonane  
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6.2 SYNTHETIC DETAILS 
 
Methyl (1R,3S,4S,6R,7R,9S)-7,9-dihydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.11 
 
O
HO
O
CO2Me
HO
OMe
OMe
 
 
Quinic acid 2.5 (6.28 g, 32.7 mmol), 2,3-butanedione (5.5 mL, 63 mmol), trimethyl 
orthoformate (17.0 mL, 155 mmol) and D-camphorsulphonic acid (332 mg, 1.03 mmol) were 
heated at reflux under an inert atmosphere for 20 h.  The reaction mixture was allowed to cool 
to rt, quenched with solid NaHCO3 and the solvent evaporated.  The residue was re-dissolved 
in EtOAc and heated at reflux over activated charcoal for 2.5 h.  The reaction mixture was 
cooled to rt, then filtered through silica, eluting with 10% MeOH/EtOAc.  The solvent was 
evaporated in vacuo to give a yellow oil which crystallised on standing (12.38 g).  The 
product was purified by repetitive recrystallisations from EtOAc to give 2.11 as a white solid 
(7.63g, 73% yield). 
 
1
H NMR (CDCl3):  δ  4.31 (1H, ddd, J = 4.4, 10.3, 12.2 Hz), 4.20 (1H, ddd, J = 2.9, 2.9, 2.9 
Hz), 3.79 (3H, s), 3.60 (1H, dd, J = 2.9, 10.3 Hz), 3.26 (3H, s), 3.26 (3H, s), 2.19 (1H, ddd, J 
= 2.9, 2.9, 14.7 Hz), 2.11 (1H, ddd, J = 2.9, 4.4, 12.7 Hz), 2.04 (1H, dd, J = 2.9, 14.7 Hz), 
1.92 (1H, dd, J = 12.2, 12.7 Hz), 1.34 (3H, s), 1.30 (3H, s). 
 
13
C NMR (CDCl3):  δ  174.3, 100.3, 99.7, 75.8, 72.7, 69.1, 62.4, 52.9, 47.9, 47.9, 38.6, 37.3, 
17.8, 17.6. 
 
mp:  136-139 ºC (lit.: 138-140 ºC)1 
 
Anal.:  Calculated for C14H24O8: C 52.49; H 7.55.  Found C 52.51; H 7.49. 
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Optical rotation:  [α]
20
D
 +139.7 (c. 1.05, CH2Cl2); lit.: +121.9 (c. 1.08, CH2Cl2).
2  
 
TOF MS ES+:  453.0531; C14H24O8Cs [MCs]
+ requires 453.0526. 
 
 
Methyl (1R,3S,4S,6S,9R)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-7-oxo-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.12 
 
O
HO
O
CO2Me
O
OMe
OMe
 
 
A suspension of protected quinic acid 2.11 (7.58 g, 23.7 mol) and pyridinium chlorochromate 
(26.03 g, 120.8 mmol) in CH2Cl2 were stirred over 4 Å molecular sieves at rt until reaction 
was complete by TLC (20 h).  The reaction mixture was filtered through silica, washing with 
15% MeOH/EtOAc (300 mL) and the solvent evaporated.  The residue was heated at reflux in 
EtOAc over activated charcoal for 3.5 h then cooled and filtered through silica as above.  The 
solvent was evaporated leaving a white solid which was recrystallised from EtOAc to give 
2.12 as white crystals (5.89 g, 78%). 
 
1
H NMR (CDCl3):  δ  4.40 (1H, d, J = 10.3 Hz), 4.25 (1H, ddd, J = 4.4, 10.3, 12.0Hz), 3.83 
(3H, s), 3.25 (3H, s), 3.21 (3H, s), 2.88 (1H, d, J = 14.2 Hz), 2.49 (1H, dd, J = 2.9, 14.2 Hz), 
2.35 (1H, dd, J = 12.0, 13.0 Hz), 2.10 (1H, ddd, J = 2.9, 4.4, 13.0 Hz), 1.38 (3H, s), 1.28 (3H, 
s). 
 
13
C NMR (CDCl3):  δ  199.5, 174.1 100.5, 99.6, 77.2, 74.0, 67.0, 53.6, 49.0, 48.3, 48.0, 37.8, 
17.6, 17.5. 
 
mp:  211-214 ºC (lit.: 212-214 ºC)1 
 
Anal.:  Calculated for C14H22O8: C 52.83; H 6.97.  Found: C 52.95; H 6.96. 
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Optical rotation:  [α]
20
D
 +114.2 (c. 1.04, CHCl3); lit.: +105.1 (c. 1.05, CHCl3).
2  
 
 
Methyl (1R,4S,5R)-1,4,5-trihydroxy-3-oxocyclohexane-1-carboxylate (Methyl 3-
dehydroquinate) 2.13 
 
OH
HO
OH
CO2Me
O
 
 
Protected dehydroquinate 2.12 (542 mg, 1.70 mmol) was stirred in 95% TFA(aq) (5 mL) over 
ice for 1 h and the solvent evaporated.  The residue was subjected to flash chromatography on 
deactivated silica to give methyl dehydroquinate 2.13 as a colourless oil (312 mg, 90%). 
 
1
H NMR (D2O):  δ  4.18 (1H, dd, J = 1.0, 9.3 Hz), 3.79 (1H, ddd, J = 5.9, 9.3, 9.3 Hz), 3.65 
(3H, s), 3.03 (1H, dd, J = 1.0, 14.2 Hz), 2.46 (1H, dd, J = 2.4, 14.2 Hz), 2.18-2.21 (2H, m). 
 
13
C NMR (D2O):  δ  207.8, 174.7, 80.6, 74.1, 71.1, 53.4, 47.4, 39.4. 
  
Anal.:  Calculated for C8H12O6·0.25 H2O:  C 46.04; H 6.04.  Found:  C 46.06; H 5.98.   
 
Optical rotation:  [α]
20
D
 -35.07 (c. 1.50, CH3OH); lit.: -34.8 (c. 1.50, CH3OH).
2  
 
 
Methyl (4S,5R)-4,5-dihydroxy-3-oxocyclohex-1-ene-1-carboxylate (Methyl 3-
dehydroshikimate) 2.14 
 
OH
OHO
CO2Me
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Protected dehydroquinate 2.12 (2.54 g, 7.97 mmol) was stirred in 50% TFA(aq) for 45 min at 
60 ºC.  The solvent was removed to give a colourless oil (1.52 g).  A portion of the crude 
product (571 mg) was subjected to flash chromatography on silica gel, eluting with 1-3% 
MeOH/EtOAc to furnish methyl dehydroquinate 2.13 (350 mg, 58%) as a colourless oil and 
methyl dehydroshikimate 2.14 (74 mg 13%) as a white solid whose NMR data were 
consistent with the literature.3 
 
1
H NMR (CD3OD):  δ  6.70 (1H, d, J = 3.4 Hz), 4.06 (1H, d, J = 10.7 Hz), 3.86 (1H, ddd, J = 
5.4, 9.8, 10.7 Hz), 3.83 (3H, s), 3.08 (1H, dd, J = 5.4, 18.6 Hz), 2.54 (1H, ddd, J = 3.4, 9.8, 
18.6 Hz). 
 
13
C NMR (CD3OD):  δ  201.2, 167.7, 147.7, 132.5, 80.4, 72.6, 53.6, 34.5. 
 
mp:  127-130 ºC.  
 
 
Potassium 3-dehydroquinate (Potassium (1R,4S,5R)-1,4,5-trihydroxy-3-oxocyclohexane-
1-carboxylate) 1.4 
 
OH
HO
OH
CO2K
O
 
 
KOH(aq) (0.48 M, 0.80 mL, 0.38 mmol) and H2O (0.5 mL) were added, over ice, to methyl 
dehydroquinate 2.13 (76 mg, 0.37 mmol).  The solution was stirred over ice for 5 min then 
freeze-dried.  The dehydroquinate potassium salt 1.4 was obtained as a hygroscopic pale 
yellow glass (84 mg, quant) whose 1H NMR data were in agreement with the literature.2 
 
1
H NMR (D2O):  δ  4.24 (1H, d, J = 9.8 Hz), 3.82 (1H, ddd, J = 5.4, 9.8, 11.2 Hz), 3.01 (1H, d, 
J = 14.2 Hz), 2.40 (1H, dd, J = 2.9, 14.2 Hz), 2.20 (1H, dd, J = 11.2, 13.7 Hz), 2.13 (1H, ddd, 
J = 2.9, 5.4, 13.7 Hz). 
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Methyl (1R,3S,4S,6R,7E,9S)-7-(cyanomethylene)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-
2,5-oxabicyclo[4.4.0]decane-9-carboxylate 2.19 
 
O
HO
O
CO2Me
OMe
OMe
NC
 
 
A solution of protected dehydroquinate 2.19 (4.07 g, 12.8 mmol) and 
(cyanomethylene)triphenylphosphorane (7.01 g, 23.3 mmol) in MeCN (100 mL) was heated 
at reflux over 4 Å molecular sieves until the reaction was judged complete by TLC (1.25 h).  
The reaction mixture was filtered, evaporated and subjected to flash chromatography on 
deactivated silica, eluting with 20% pet. ether/EtOAc.  A pale yellow oil was obtained which 
crystallized on cooling (3.58 g, 82%).  Recrystallisation from 50% pet. ether/EtOAc furnished 
2.19 as a white crystalline solid (2.64 g, 60%). 
 
1
H NMR (CDCl3):  δ  5.70 (1H, dd, J = 2.0, 2.0 Hz), 4.22 (1H, dd, J = 2.0, 9.6 Hz), 3.96 (1H, 
ddd, J = 4.9, 9.6, 12.2 Hz), 3.84 (3H, s), 3.24 (3H, s), 3.23 (3H, s), 2.99 (1H, dd, J = 2.4, 14.2 
Hz), 2.65 (1H, dd, J = 2.0, 14.6 Hz), 2.12 (1H, dd, J = 12.2, 12.7 Hz), 1.98 (1H, ddd, J = 2.4, 
4.9, 12.7 Hz), 1.36 (3H, s), 1.30 (3H, s). 
 
13
C NMR (CDCl3):  δ  174.5, 156.7, 116.4, 100.4, 99.7, 94.9, 73.3, 72.6, 67.8, 53.5, 48.1, 48.0, 
40.8, 37.6, 17.6, 17.6. 
 
mp:  142.5-144 ºC  
 
Anal.:  Calculated for C16H23NO7:  C 56.29; H 6.79; N 4.10.  Found C 56.54; H 6.85; N 4.17. 
 
Optical rotation:  [α]
20
D
 +59.8 (c. 1.06, CH2Cl2).  
 
TOF MS ES+:  364.1374;  C16H23NO7Na [MNa]
+ requires 364.1372. 
 
Preparation of the reagent (cyanomethylene)triphenylphosphorane 
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50% NaOH(aq) (5 mL) was added drop-wise with stirring to solution of 
(Cyanomethyl)triphenylphosphonium chloride (10.03 g, 29.69 mmol) in H2O (200 mL) and 
stirred for a further 10 min.  The precipitate was filtered, washed with H2O and dried under 
vacuum to give a white solid (7.95 g, 89%).  The product was used without further 
purification. 
 
 
Methyl (1S,3E,4R,5R)-3-(cyanomethylene)-1,4,5-trihydroxycyclohexane-1-carboxylate 
2.20 
 
OH
HO
OH
CO2Me
NC
 
 
Protected derivative 2.19 (142 mg, 0.42 mmol) was stirred in 95% TFA(aq) over ice for 2 h.  
The solvent was removed in vacuo.  The residue was re-dissolved in MeOH and evaporated 
again to give a colourless oil which crystallised on standing.  Recrystallisation from EtOAc 
furnished 2.20 as a white solid (69 mg, 72%). 
 
1
H NMR (D2O, 300 MHz):  δ  5.69 (1H, dd, J = 2.0, 2.0 Hz), 4.09 (1H, dd, J = 2.0, 9.1 Hz), 
3.71 (3H, s), 3.62 (1H, ddd, J = 5.2, 9.1, 11.2 Hz), 2.96 (1H, dd, J = 2.9, 14.9 Hz), 2.76 (1H, 
dd, J = 2.0, 14.9 Hz), 2.13 (1H, ddd, J = 2.9, 5.2, 13.7 Hz), 1.98 (1H, dd, J = 11.2, 13.7 Hz). 
 
13
C NMR (D2O):  δ  175.2, 162.8, 117.5, 95.1, 76.1, 74.7, 70.9, 53.4, 39.7, 39.6. 
 
Anal.:  Calculated for C10H13NO5:  C 52.86; H 5.77; N 6.17.  Found:  C 52.99; H 5.67; N 
6.16. 
 
Optical rotation:  [α]
20
D
 -68.2 (c. 1.06, MeOH).  
 
+EI MS:   227.0794;  C10H13NO5 M
+ requires 227.0794. 
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Potassium (1S,3E,4R,5R)-3-(cyanomethylene)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.15 
 
OH
HO
OH
CO2K
NC
 
 
To a solution of 2.20 (14 mg, 0.06 mmol) in H2O over ice was added 0.30 M KOH(aq) (200 
µL, 0.06 mmol) and the solution stirred for 10 min.  The solvent was evaporated and the 
residue dried under vacuum to give the potassium salt 2.15 as a colourless glass (15 mg, 
quant) 
 
1
H NMR (D2O):  δ  5.59 (1H, dd, J = 1.5, 1.7 Hz), 4.04 (1H, dd, J = 1.7, 9.3 Hz), 3.54 (1H, 
ddd, J = 5.4, 9.3, 11.2 Hz), 2.78 (1H, dd, J = 2.7, 14.2 Hz), 2.63 (1H, d, J = 1.5, 14.2 Hz), 
1.94 (1H, ddd, J = 2.7, 5.4, 13.5 Hz), 1.90 (1H, dd, J = 11.2, 13.5 Hz). 
 
13
C NMR (D2O):  δ  180.2, 164.6, 117.9, 93.9, 76.4, 76.0, 71.9, 40.7, 40.6. 
 
TOF MS ES+:  196.0609;  C9H10NO4 [MH2– K– H2O]
+  requires 196.0610. 
 
 
Methyl (1R,3S,4S,6R,7S,9S)-7-(cyanomethyl)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-
2,5-dioxabicyclo[4.4.0]decane-9 carboxylate 2.21 and Methyl (1R,3S,4S,6R,7R,9S)-7-
(cyanomethyl)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-dioxabicyclo[4.4.0]decane-9 
carboxylate 2.22 
 
O
HO
O
CO2Me
OMe
OMe
NC
O
HO
O
CO2Me
OMe
OMe
NC
2.21 2.22  
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Olefin 2.19 (512 mg, 1.50 mmol) was stirred at rt over 5% Pd/C (1.20 g) in CH2Cl2 (5 mL) 
under 1 atm H2(g) for 44 h.  The suspension was filtered through celite and rinsed with 
CH2Cl2.  Evaporation of the solvent gave a yellow foam (478 mg) containing 2.21, 2.22 and 
2.23 in a ratio of 1.2:3:1.  The foam was subjected to flash chromatography on silica, eluting 
with 20% pet. ether/EtOAc, giving partial separation of the isomers.  Fractions containing 
mixtures of isomers were combined and evaporated and the chromoatographic separation 
repeated.  Fractions containing mostly one diastereomer (less than 20% of the alternate 
isomer) were combined and evaporated.  Recrystallisation of the sample enriched in the major 
(3R-) epimer from 25% EtOAc/pet. ether gave 2.22 as a white solid (98 mg, 19%).  
Recrystallisation of the sample enriched in the minor (3S-) epimer from 33% EtOAc/pet. ether 
gave 2.21 as a white solid (23 mg, 5%).  
 
(7S)-Epimer 2.21 
 
1
H NMR (CDCl3):  δ  3.94 (1H, ddd, J = 4.9, 9.8, 12.2 Hz), 3.78 (3H, s), 3.50 (1H, dd, J = 9.8, 
10.9 Hz), 3.29 (3H, s), 3.23 (3H, s), 3.22 (1H, br s), 2.69 (1H, dd, J = 6.1, 16.6 Hz), 2.45 (1H, 
dd, J = 3.9, 16.6 Hz), 2.30 (1H, ddddd, J = 3.9, 3.9, 6.1, 10.9, 12.7 Hz), 1.95 (1H, dd, J = 
12.2, 12.7 Hz), 1.88 (1H, dd, J = 12.7, 13.2 Hz), 1.85 (1H, ddd, J = 2.4, 4.9, 12.7 Hz), 1.78 
(1H, ddd, J = 2.4, 3.9, 13.2 Hz), 1.30 (3H, s), 1.27 (3H, s). 
 
13
C NMR (CDCl3):  δ  175.7, 117.7, 99.9, 99.6, 73.4, 72.3, 66.6, 53.3, 48.2, 48.0, 38.6, 37.9, 
32.0, 18.4, 17.7, 17.5. 
 
(7R)-Epimer 2.22 
 
1
H NMR (CDCl3):  δ  3.94 (1H, ddd, J = 4.9, 10.3, 11.5 Hz), 3.81 (3H, s), 3.76 (1H, dd, J = 
5.4, 10.3 Hz), 3.25 (3H, s), 3.23 (3H, s), 2.99 (1H, dd, J = 12.2, 16.6 Hz), 2.80 (1H, dd, J = 
3.9, 16.6 Hz), 2.41 (1H, m), 2.08 (2H, m), 1.94 (1H, dd, J = 11.5, 12.7 Hz), 1.88 (1H, ddd, J = 
2.0, 4.9, 12.7 Hz), 1.28 (3H, s), 1.27 (3H, s). 
 
13
C NMR (CDCl3):  δ  175.7, 120.2, 99.9, 99.5, 74.9, 70.7, 62.4, 53.4, 47.9, 38.5, 35.0, 34.4, 
17.7, 17.6, 16.8. 
 
mp:  95-97 ºC  
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Anal.:  Calculated for C16H25NO7:  C 55.96; H 7.34; N 4.08.  Found C 56.13; H 7.54; N 4.00. 
 
Optical rotation:  [α]
20
D
 +117.19 (c. 1.02, CH2Cl2).  
 
TOF MS ES+:  476.0684;  C16H25NO7Cs [MCs]
+ requires 476.0685. 
 
 
Methyl (1R,3S,4S,6R,7R,9S)-7-(2-aminoethyl)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-
2,5-dioxabicyclo[4.4.0]decane-9 carboxylate 2.23 
 
O
HO
O
CO2Me
OMe
OMe
H2N
 
 
Nitrile 2.19 (1.53 g, 4.49 mmol) was added to a suspension of 10% Pd/C (325 mg) in MeOH 
under H2(g) (1 atm).  The system was evacuated then stirred under H2(g) at rt.  TLC showed 
starting material remaining after 48 h so a further 100 mg of catalyst was added.  The starting 
material was no longer evident after 68 h and the reaction was filtered through celite, washing 
with MeOH.  The solvent was evaporated to give a pale yellow foam (1.58 g) containing 2.22 
and 2.23 in a ratio of 1:3 (plus trace 2.21).  Flash chromatography on deactivated silica, 
eluting with a gradient of 20% pet. ether/EtOAc to 20% MeOH/EtOAc gave nitrile 2.22 as a 
colourless oil (309 mg, 20%), amine 2.23 as a yellow oil (601 mg, 39%) and a 2:1 mixture of 
the epimers 2.21 and 2.22 (43 mg, 3%).  A portion of the amine 2.23 (320 mg) was columned 
again, eluting with 15% MeOH/CH2Cl2 to give 2.23 (153 mg, 10%) as a white glass. 
 
1
H NMR ((CD3)2CO):  δ  4.18 (1H, ddd, J = 4.5, 10.2, 11.9 Hz), 3.81 (3H, s), 3.73 (1H, dd, J 
= 5.3, 10.2 Hz), 3.33 (3H, s), 3.32 (3H, s), 2.79 (1H, m), 2.43 (1H, m), 2.01-2.15 (5H, m), 
1.97 (1H, dd, J = 5.4, 14.6 Hz), 1.87 (1H, dd, J = 11.9, 12.2 Hz), 1.37 (3H, s), 1.33 (3H, s). 
 
13
C NMR ((CD3)2CO):  δ  176.4, 100.2, 99.9, 75.9, 73.6, 64.0, 53.0, 52.5, 47.8, 39.0, 36.3, 
35.5, 24.2, 18.2, 18.2. 
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Methyl (1S,3S,4R,5R)-3-(cyanomethyl)-1,4,5-trihydroxycyclohexane-1-carboxylate 2.24 
 
OH
HO
OH
CO2Me
NC
 
 
Nitrile 2.21 (21 mg, 0.06 mmol) was stirred in 95% TFA(aq) (0.5 mL) over ice for 35 min.  
The solvent was evaporated and the residue re-dissolved in MeOH and evaporated again.  The 
residue was dried under vacuum for 18 h to give the free diol 2.24 as a colourless oil (16 mg, 
quant). 
 
1
H NMR (D2O):  δ  3.60-3.65 (1H, m), 3.62 (3H, s), 3.12 (1H, dd, J = 9.0, 10.5 Hz), 2.59 (1H, 
dd, J = 4.5, 17.1 Hz), 2.53 (1H, dd, J = 6.5, 17.1 Hz), 1.96-2.02 (2H, m), 1.81 (1H, ddd, J = 
3.4, 3.9, 14.1 Hz), 1.69-1.75 (2H, m).   
 
13
C NMR (D2O):  δ  176.3, 119.8, 76.3, 74.0, 53.1, 39.5, 37.1, 34.4, 19.2. 
 
 
Methyl (1S,3R,4R,5R)-3-(cyanomethyl)-1,4,5-trihydroxycyclohexane-1-carboxylate 2.25 
 
OH
HO
OH
NC
CO2Me
 
 
Nitrile 2.22 (84 mg, 0.25 mmol) was stirred in 95% TFA(aq) (0.5 mL) over ice for 2.5 h.  The 
solvent was evaporated and the residue re-dissolved in MeOH and evaporated again.  The 
residue was dried under vacuum for 3 h to give the free diol 2.25 as a colourless oil (59 mg, 
quant). 
 
1
H NMR (D2O):  δ  3.86 (1H, m), 3.67 (1H, m), 3.64 (3H, s), 2.60 (1H, dd, J = 7.8, 17.1 Hz), 
2.55 (1H, dd, J = 7.8, 17.1 Hz), 2.39 (1H, m), 2.03-2.10 (2H, m), 1.89 (1H, dd, J = 3.9, 13.7 
Hz), 1.62 (1H, dd, J = 8.3, 13.7 Hz).   
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13
C NMR (D2O):  (from a 2:1 mixture of 2.25 and 2.24) δ  175.8, 121.0, 73.6, 70.6, 67.8, 52.8, 
37.6, 33.7, 33.1, 18.3. 
 
 
Potassium (1S,3S,4R,5R)-3-(cyanomethyl)-1,4,5-trihydroxycyclohexane-1-carboxylate 
2.16 
 
OH
HO
OH
CO2K
NC
 
 
To a solution of ester 2.24 (16 mg, 0.07 mmol) in H2O (100 µL) was added KOH(aq) (0.30 M, 
260 µL, 0.08 mmol) and the reaction was stirred over ice for 15 min.  The solvent was 
evaporated and the residue dried under vacuum to give the potassium salt 2.16 as a colourless 
glass (17 mg, quant). 
 
1
H NMR (D2O):  δ  3.65 (1H, ddd, J = 4.9, 9.3, 11.7 Hz), 3.18 (1H, dd, J = 9.3, 10.7 Hz), 2.64 
(1H, dd, J = 4.9, 17.1 Hz), 2.59 (1H, dd, J = 6.5, 17.1 Hz), 2.00 (1H, m), 1.91 (1H, dd, J = 4.9 
13.2 Hz), 1.71-1.77 (3H, m). 
 
13
C NMR (D2O):  δ  182.3, 120.8, 77.5, 75.9, 71.5, 41.4, 38.8, 35.8, 20.1. 
 
TOF MS ES
-:  214.0933;  C9H12NO5 [M-K]
- requires 214.0716. 
 
 
Potassium (1S,3R,4R,5R)-3-(cyanomethyl)-1,4,5-trihydroxycyclohexane-1-carboxylate 
2.17 
 
OH
HO
OH
NC
CO2K
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To a solution of ester 2.25 (7 mg, 0.03 mmol) in H2O (100 µL) was added KOH(aq) (0.30 M, 
103 µL, 0.03 mmol) and the reaction was stirred over ice for 5 min.  The solvent was 
evaporated and the residue dried under vacuum to give the potassium salt 2.17 as a colourless 
glass (7 mg, quant). 
 
1
H NMR (D2O):  δ  3.79 (1H, m), 3.69 (1H, dd, J = 3.9, 5.9 Hz), 2.59 (2H, d, J = 7.8 Hz), 2.36 
(1H, m), 1.80-1.88 (3H, m), 1.67 (1H, dd, J = 8.3, 13.7 Hz). 
 
13
C NMR (D2O):  (from a 2:1 mixture of 2.17 and 2.16) δ  182.6, 121.87, 76.2, 72.6, 68.7, 
38.2, 36.1, 34.1, 19.0. 
 
TOF MS ES
-:  214.0943;  C9H12NO5 [M-K]
- requires 214.0716. 
 
 
Potassium (1S,4R,5R)-3-(2-aminoethyl)-1,4,5-trihydroxycyclohexane-1-carboxylate 2.18 
 
OH
HO
OH
CO2K
H2N
 
 
A solution of nitrile 2.20 (71 mg, 0.31 mmol) in MeOH was stirred over 5% Pd/C (220 mg) 
under 1 atm H2(g) at rt for 67 h.  The suspension was filtered through celite and the residue 
washed with MeOH.  The combined filtrates were evaporated to give a colourless oil (50 mg). 
 
A portion of the oil (7 mg) was dissolved in H2O (400 µL) and 1.0 M KOH(aq) (32 µL, 0.03 
mmol) added over ice.  The solution was stirred over ice for 10 min and the solvent removed 
by lyophilisation.  1H NMR showed a small amount of the ester remaining and so a further 
0.01 mmol of 1.0 M KOH(aq) was added under the same conditions.  The solvent was again 
removed by lyophilisation to give the potassium salt 2.18 as a yellow glass which was not 
purified further (9 mg, 71% over 2 steps). 
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1
H NMR (D2O):  δ  3.78 (1H, m), 3.57 (1H, m), 2.82-2.92 (2H, m), 1.84-1.91 (3H, m), 1.60-
1.74 (3H, m), 1.52 (1H, dd, J = 10.3, 13.2 Hz). 
 
13
C NMR (D2O):  δ  182.4, 75.5, 72.0, 68.7, 46.0, 36.8, 35.7, 33.0, 27.1. 
 
TOF MS ES+:  220.1178;  C9H18NO5 [MH2-K]
+ requires 220.1186. 
 
 
Methyl (1R,3S,4S,6R,7E,9S)-7-(carbethoxymethylene)-9-hydroxy-3,4-dimethoxy-3,4-
dimethyl-2,5-dioxabicyclo[4.4.0]decane-9-carboxylate 2.30 
 
O
HO
O
CO2Me
OMe
OMe
EtO
O
 
 
Protected dehydroquinic acid 2.12 (1.03 g, 3.24 mmol) was heated at reflux with 
(carbethoxymethylene)triphenylphosphorane (1.90 g, 5.46 mmol) in dry MeCN (25 mL) over 
4 Å molecular sieves until the reaction was judged complete by TLC (1.75 h).  The reaction 
mixture was cooled, filtered and the filtrate evaporated to give a yellow oil.  The oil was 
subjected to flash chromatography on silica, eluting with 25% pet. ether/EtOAc.  Fractions 
containing the product were combined and the solvent evaporated to give the diester 2.30 as 
an off-white foam (1.12 g, 89%), whose NMR data was consistent with the literature.4 
 
1
H NMR (CDCl3):  δ  6.22 (1H, dd, J = 1.5, 2.0 Hz), 4.13 (3H, m), 4.01 (1H, dd, J = 2.7, 14.5 
Hz), 3.93 (1H, ddd, J = 4.9, 9.8, 12.0 Hz), 3.77 (3H, s), 3.21 (3H, s), 3.19 (3H, s), 2.31 (1H, 
dd, J = 1.5, 14.5 Hz), 2.09 (1H, dd, J = 12.0, 13.0 Hz), 1.97 (1H, ddd, J = 2.7, 4.9, 13.0 Hz), 
1.33 (3H, s), 1.27 (3H, s), 1.25 (3H, t, J = 7.3 Hz). 
 
13
C NMR (CDCl3):  δ  174.8, 166.8, 150.6, 115.2, 100.1, 99.4, 74.9, 72.9, 68.5, 60.0, 53.0, 
48.0, 47.9, 37.4, 36.9, 17.7, 14.2. 
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Anal.:  Calculated for C18H28O9:  C 55.66; H 7.27.  Found C 56.06; H 7.21. 
 
 
Methyl (1S,3E,4R,5R)-3-(carbethoxymethylene)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.31 
 
OH
HO
OH
CO2Me
EtO
O
 
 
Diester 2.30 (75 mg, 0.19 mmol) was stirred in 95% TFA(aq) over ice for 1 h.  The solvent was 
evaporated and the residue re-dissolved in MeOH and evaporated again.  The residue was 
dried under vacuum for 18 h to give 2.31 as a colourless oil (60 mg, quant). 
 
1
H NMR (D2O):  δ  6.09 (1H, dd, J = 2.0, 2.0 Hz), 4.08 (2H, q, J = 7.3 Hz), 4.00 (1H, dd, J = 
2.0, 9.3 Hz), 3.76 (1H, dd, J = 2.9, 14.5 Hz), 3.70 (3H, s), 3.59 (1H, ddd, J = 4.9, 9.3, 11.2 
Hz), 2.43 (1H, d, J = 14.5 Hz), 2.10 (1H, ddd, J = 2.9, 4.9, 13.7 Hz), 1.96 (1H, dd, J = 11.2, 
13.7 Hz), 1.17 (3H, t, J = 7.3 Hz). 
 
13
C NMR (D2O):  δ  175.8, 168.5, 155.1, 115.4, 76.3, 74.2, 71.2, 61.4, 53.2, 39.8, 35.6, 13.3. 
 
 
Dipotassium (1S,3E,4R,5R)-3-(carboxylatomethylene)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.27 
 
OH
HO
OH
CO2K
KO
O
 
 
 6   Experimental Details 159 
 
To a solution of diester 2.31 (34 mg, 0.12 mmol) in H2O (100 µL) was added 0.30 M KOH(aq) 
(846 µL, 0.25 mmol) and the reaction was stirred over ice for 5 min.  The solvent was 
removed by lyophilisation to give dicarboxylate 2.27 as a yellow glass (40 mg, quant). 
 
1
H NMR (D2O):  δ  5.98 (1H, s), 3.91 (1H, d, J = 9.8 Hz), 3.56 (1H, ddd, J = 5.4, 9.8, 10.7 
Hz), 3.14 (1H, dd, J = 2.4, 14.5 Hz), 2.31 (1H, d, J = 14.5 Hz), 1.94 (1H, ddd, J = 2.4, 5.4, 
13.7 Hz), 1.89 (1H, dd, J = 10.7, 13.7 Hz). 
 
13
C NMR (D2O):  δ  181.5, 176.5 144.3, 120.9, 76.4, 76.0, 72.0, 40.7, 37.4. 
 
TOF MS ES-:  231.0512.  C9H11O7 (MH-2K)
- requires 231.0505. 
 
 
Methyl (1R,3S,4S,6R,7R,9S)-7-(carbethoxymethyl)-9-hydroxy-3,4-dimethoxy-3,4-
dimethyl-2,5-dioxabicyclo[4.4.0]decane-9-carboxylate 2.32 and Methyl 
(1R,3S,4S,6R,7S,9S)-7-(carbethoxymethyl)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.33 
 
O
HO
O
CO2Me
OMe
OMe
O
HO
O
CO2Me
OMe
OMe
2.32 2.33
O
EtO EtO
O
 
 
A solution of olefin 2.30 (179 mg, 0.46 mmol) in EtOAc (3 mL) was stirred over 10% Pd/C 
(274 mg) under 1 atm H2(g) for 26 h.  The suspension was filtered through celite, washing with 
EtOAc and the filtrate evaporated to give a colourless oil (175 mg) containing both (R)- and 
(S)- epimers in a 1.25:1 ratio by 1H NMR.  The oil was subjected to flash chromatogtaphy on 
silica, eluting with 20% EtOAc/pet. ether.  Fractions containing each epimer were combined 
and evaporated to give 67 mg of the (R)-epimer 2.32 (37%) and 67 mg of the (S)-epimer 2.33 
(37%), both as colourless oils. 
 
(7R)-Epimer 2.32 
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1
H NMR (CDCl3):  δ  4.08 (1H, dq, J = 1.5, 7.3 Hz), 3.97 (1H, ddd, J = 4.4, 9.8, 12.2 Hz), 
3.75 (3H, s), 3.32 (1H, dd, J = 9.8, 10.7 Hz), 3.23 (3H, s), 3.22 (3H, s), 3.10 (1H, br s), 2.77 
(1H, dd, J = 4.4, 15.1 Hz), 2.44 (1H, m), 2.09 (1H, dd, J = 8.8, 15.1 Hz), 1.93 (1H, dd, J = 
12.2, 12.2 Hz), 1.80-1.87 (2H, m), 1.62 (1H, dd, J = 13.2, 13.2 Hz), 1.27 (3H, s), 1.26 (3H, s), 
1.22 (3H, t, J = 7.3 Hz). 
 
13
C NMR (CDCl3):  δ  176.0, 172.2, 99.7, 99.4, 73.7, 73.6, 66.8, 60.3, 53.0, 47.9, 39.3, 37.8, 
35.6, 32.3, 17.7, 17.7, 14.2. 
 
TOF MS ES+:  391.1982.  C18H31O9 (MH)
+ requires 391.1968. 
 
(7S)-Epimer 2.33 
 
1
H NMR (CDCl3):  δ  4.07 (2H, m), 3.95 (1H, ddd, J = 4.8, 10.5, 11.1 Hz), 3.72 (3H, s), 3.65 
(1H, dd, J = 5.2, 10.5 Hz), 3.33 (1H, br s), 3.19 (3H, s), 3.18 (3H, s), 2.84 (1H, dd, J = 11.1, 
16.3 Hz), 2.76 (1H, dd, J = 4.4, 16.3 Hz), 2.53 (1H, m), 1.94 (1H, dd, J = 5.2, 15.1 Hz), 1.81-
1.90 (3H, m), 1.22 (3H, s), 1.21 (3H, s), 1.20 (3H, t, J= 7.5 Hz). 
 
13
C NMR (CDCl3):  δ  176.3, 174.0, 99.7, 99.3, 75.2, 71.5, 63.0, 60.2, 53.1, 47.8, 47.8, 38.5, 
35.6, 33.3, 32.3, 17.8, 17.6, 14.2. 
 
TOF MS ES+:  391.1986.  C18H31O9 (MH)
+ requires 391.1968. 
 
Methyl (1S,3R,4R,5R)-3-(carbethoxymethyl)-1,4,5-trihydroxycyclohexane-1-carboxylate 
2.34 
 
OH
HO
OH
CO2Me
O
EtO
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Diester 2.32 (28 mg, 0.07 mmol) was stirred in 95% TFA(aq) (0.5 mL) over ice for 40 min.  
The solvent was evaporated and the residue re-dissolved in MeOH and the solvent evaporated 
again.  The residue was dried under vacuum for 20 h to give 2.34 as a yellow oil (21 mg, 
quant). 
 
1
H NMR (D2O):  δ  4.07 (2H, dq, J = 2.0, 7.3), 3.67 (4H, m), 3.13 (1H, dd, J = 9.8, 9.8 Hz), 
2.62 (1H, dd, J = 5.0, 15.0 Hz), 2.22 (1H, dd, J = 8.0, 15.0 Hz), 2.14 (1H, m), 2.02 (1H, ddd, J 
= 2.9, 4.4, 13.7 Hz), 1.73-1.78 (2H, m), 1.65 (1H, dd, J = 12.7, 13.7 Hz), 1.16 (3H, t, J= 7.3 
Hz). 
 
13
C NMR (D2O):  δ  176.6, 175.5, 77.3, 74.2, 70.1, 61.7, 53.0, 39.6, 37.6, 36.96, 35.0, 13.3. 
 
 
Dipotassium (1S,3R,4R,5R)-3-(carboxylatomethyl)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.28 
 
OH
HO
OH
CO2K
O
KO
 
 
To an ice-cooled solution of diester 2.34 (13 mg, 0.05 mmol) in H2O (160 µL) was added 
0.30 M KOH(aq) (340 µL, 0.10 mmol) and the reaction was stirred over ice for 10 min.  The 
solvent was removed by lyophilisation to give 2.28 as a pale brown glass (16 mg, quant). 
 
1
H NMR (D2O):  δ  3.63 (1H, ddd, J = 4.9, 9.3, 11.7 Hz), 3.04 (1H, dd, J = 9.3, 10.3 Hz), 2.60 
(1H, dd, J = 4.4, 14.2 Hz), 1.97 (1H, m), 1.83-1.88 (2H, m), 1.72 (1H, dd, J = 11.7, 13.2 Hz), 
1.59 (1H, ddd, J = 3.9, 3.9, 14.2 Hz), 1.51 (1H, dd, J = 12.2, 14.2 Hz). 
 
13
C NMR (D2O):  δ  182.2, 78.2, 75.5, 71.2, 40.8, 40.7, 38.8, 36.2. 
 
TOF MS ES-:  233.0666;  C9H13O7 [MH-2K]
- requires 233.0661. 
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Methyl (1R,2R,4S,6S)-2,4-dihydroxy-8-oxo-9-oxabicyclo[4.3.0]nonane-4-carboxylate 2.35 
 
HO
OH
CO2Me
O
O  
 
Diester 2.33 (46 mg, 0.12 mmol) was stirred in 95% TFA(aq) (0.5 mL) over ice for 30 min and 
the solvent removed by lyophilisation to give a brown oil (36 mg).  The oil was subjected to 
flash chromatography on silica, eluting with 20% pet. ether/EtOAc, to give the lactone 2.35 as 
a colourless oil (16 mg, 58%). 
 
1
H NMR (CD3OD):  δ  4.36 (1H, dd, J = 7.3, 7.8 Hz), 4.04 (1H, ddd, J = 4.4, 7.8, 11.2 Hz), 
3.73 (3H, s), 2.96 (1H, m), 2.87 (1H, dd, J = 10.7, 17.1 Hz), 2.52 (1H, dd, J = 8.3, 17.1 Hz), 
2.08 (1H, dd, J = 6.4, 14.7 Hz), 1.98 (1H, ddd, J = 2.4, 4.4, 13.7 Hz), 1.88 (1H, dd, J = 11.2, 
13.7 Hz), 1.83 (1H, ddd, J= 2.4, 3.4, 14.7 Hz). 
 
13
C NMR (D2O):  δ  180.8, 176.3, 84.7, 74.7, 66.7, 53.0, 37.8, 33.9, 33.3, 31.9. 
 
TOF MS ES+:  231.1276.  C10H15O6 [MH]
+ requires 231.0869. 
 
 
Dipotassium (1S,3S,4R,5R)-3-(carboxylatomethyl)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.29 
 
OH
HO
OH
CO2K
O
KO
 
 
To a solution of lactone 2.35 (11 mg, 0.05 mmol) in H2O (160 µL) over ice was added 0.30 M 
KOH(aq) (340 µL, 0.10 mmol) and the reaction was stirred over ice for 10 min.  The solvent 
 6   Experimental Details 163 
 
was removed by lyophilisation to give dicarboxylate inhibitor 2.29 as a pale yellow glass (16 
mg, quant). 
 
1
H NMR (D2O):  δ  3.76 (1H, m), 3.57 (1H, m), 2.26 (2H, m), 2.16 (1H, dd, J = 10.7, 15.6 
Hz), 1.85 (2H, m), 1.68 (1H, dd, J = 3.4, 13.7 Hz), 1.51 (1H, dd, J = 9.3, 13.7 Hz). 
 
13
C NMR (D2O):  δ  182.5, 182.2, 75.5, 72.6, 68.8, 39.4, 36.5, 36.0, 33.0. 
 
TOF MS ES+:  233.0702;  C9H13O7 [MH-2K]
- requires 233.0661. 
 
 
Methyl (1R,3S,4S,6R,7E/Z,9S)-7-[(aminocarbonyl)hydrazono]-9-hydroxy-3,4-dimethoxy-
3,4-dimethyl-2,5-dioxabicyclo[4.4.0]decane-9-carboxylate 2.39 
 
O
HO
O
CO2Me
N
OMe
OMe
H
NH2N
O
 
 
Protected dehydroquinate 2.12 (51 mg, 0.16 mmol) was added to a solution of semicarbazide 
hydrochloride (97 mg, 0.87 mmol) and sodium acetate trihydrate (152 mg, 1.11 mmol) in H2O 
(1 mL).  MeOH (1 mL) was added and the solution heated at 50 ºC for 1.5 h.  The reaction 
mixture was cooled to rt and extracted with CH2Cl2 (3×).  The combined organic extracts 
were dried (MgSO4), filtered and the solvent evaporated to give two isomers (2:1 ratio) of the 
protected semicarbazone 2.39 as a pale yellow glass (32 mg, 53%). 
 
1
H NMR (CDCl3, 300 MHz):  δ  (major isomer from 2:1 mixture) 9.79 (1H, s), 5.46 (2H, br s), 
4.22 (1H, d, J = 9.3 Hz), 3.98 (1H, m), 3.70 (3H, s), 3.22 (3H, s), 3.15 (3H, s), 2.24 (1H, d, J 
= 14.7 Hz), 1.98-2.10 (3H, m), 1.30 (3H, s), 1.23 (3H, s) (minor isomer from 2:1 mixture) 
10.21 (1H, s), 4.52 (1H, d, J = 10.3 Hz), 4.13-4.24 (1H, m), 3.73 (3H, s), 3.26 (3H, s), 3.17 
(3H, s), 2.58 (1H, d, J = 14.2 Hz), 2.38 (1H, d, J = 14.2 Hz), 1.98-2.10 (2H, m), 1.37 (3H, s), 
1.20 (3H, s). 
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13
C NMR (CDCl3):  δ  (both isomers in 2:1 mixture) 174.7, 174.4, 159.9, 157.4, 145.8, 139.6, 
100.5, 100.0, 99.3, 77.0, 74.2, 73.7, 72.8, 68.4, 66.3, 53.1, 52.8, 48.6, 48.1, 47.9, 47.8, 43.7, 
37.6, 37.0, 35.3, 17.7, 17.6, 17.5. 
 
 
Methyl (1S,3E/Z,4R,5R)-3-[(aminocarbonyl)hydrazono]-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.40 
 
OH
HO
OH
CO2Me
N
H
NH2N
O  
 
To a solution of methyl dehydroquinate 2.13 (104 mg, 0.51 mmol) in MeOH (0.5 mL) and 
H2O (1 mL) was added semicarbazide hydrochloride (60 mg, 0.54 mmol).  Sodium acetate 
trihydrate was added (212 mg, 1.56 mmol) until the solution reached pH 7, as judged by 
universal indicator paper.  The solution was heated to 40 ºC and stirred for 4 h.  The solvent 
was evaporated.  The resulting yellow oil showed a 10:1 ratio of isomers by 1H NMR.  The 
residue was purified by flash chromatography on deactivated silica, eluting with 30% 
MeOH/EtOAc to give the isomers 2.40 (20:1 ratio, major isomer presumed to be E) as a pale 
yellow glass (111 mg, 82%). 
 
1
H NMR (D2O, 300 MHz):  δ  (major isomer from 20:1 mixture) 4.08 (1H, d, J = 9.3 Hz), 
3.68-3.76 (1H, m), 3.70 (3H, s), 2.98 (1H, dd, J = 2.7, 14.8 Hz), 2.48 (1H, d, J = 14.8 Hz), 
2.14 (1H, ddd, J = 2.7, 4.9, 13.7 Hz), 2.02 (1H, dd, J = 11.2, 13.7 Hz). 
 
13
C NMR (D2O):  δ  (major isomer from 20:1 mixture) 175.1, 160.0, 149.2, 75.8, 74.2, 71.3, 
53.4, 39.4, 33.8. 
 
Anal.  Calculated for C9H15N3O6·2H2O: C 36.36; H 6.44; N 14.14.  Found C 36.86; H 5.42; N 
13.80. 
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Optical rotation:  [α]
20
D
  -18.24 (c. 1.03, CH3OH). 
 
TOF MS ES+:  262.1032;  C9H16N3O6 [MH]
+ requires 262.1039. 
 
Potassium (1S,3E/Z,4R,5R)-3-[(aminocarbonyl)hydrazono]-1,4,5-trihydroxycyclohexane-
1-carboxylate 2.38 
 
OH
HO
OH
CO2K
N
H
NH2N
O  
 
To a solution of ester 2.40 (20:1 mixture of E/Z isomers) (27 mg, 0.10 mmol) in H2O (0.5 
mL) over ice was added 0.30 M KOH(aq) (320 µL, 0.10 mmol) and the reaction was stirred 
over ice for 5 min.  The solvent was evaporated and the residue dried under vacuum to give 
the isomers 2.38 (20:1) as a yellow glass (34 mg, quant). 
 
1
H NMR (D2O, 300 MHz):  δ  (major isomer from 20:1 mixture) 3.95 (1H, d, J = 9.6 Hz), 
3.59 (1H, ddd, J = 6.3, 9.6, 10.3 Hz), 3.02 (1H, dd, J = 2.0, 14.7 Hz), 2.20 (1H, d, J = 14.7 
Hz), 1.88-1.92 (2H, m). 
 
13
C NMR (D2O):  δ  (major isomer from 20:1 mixture) 180.9, 165.0, 150.3, 76.5, 75.7, 72.7, 
40.3, 34.8. 
 
Optical rotation:  [α]
20
D
  -18.05 (c. 1.03, CH3OH). 
 
TOF MS ES+:  286.0427;  C8H13N3O6K [MH]
+ requires 286.0441. 
 
 
Methyl (1S,3E/Z,4R,5R)-3-hydrazono-1,4,5-trihydroxycyclohexane-1-carboxylate 2.41 
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OH
HO
OH
CO2Me
N
H2N
 
 
To a solution of hydrazine hydrochloride (55 mg, 0.53 mmol) in H2O (2 mL) was added 
NaOAc·3H2O until the solution reached pH 7 (720 mg, 5.29 mmol).  Methyl dehydroquinate 
2.13 (107 mg, 0.52 mmol) was added and the solution stirred at rt for 22 h.  The solvent was 
removed by lyophilisation to give a dark brown solid containing E and Z isomers of the 
product in a 2:1 ratio (with the major isomer presumed to be E).  The solid was subjected to 
flash chromatography on deactivated silica eluting with 20% MeOH/EtOAc to give a red oil 
(71 mg).  The oil was again subjected to flash chromatography, this time without deactivating 
the silica, again eluting with 20% MeOH/EtOAc to give only the major (E) isomer of 2.41 as 
a beige solid (12 mg, 10%). 
 
Alternative Method 
To a solution of methyl dehydroquinate 2.13 (36 mg, 0.18 mmol) in H2O (0.5 mL) over ice 
was added hydrazine hydrate (8.65 µL, 0.18 mmol).  The solution was stirred at rt f or 47 h, 
30 ºC for 5 h and rt for 18 h.  The reaction did not appear to be progressing any further by 
TLC and so the solution was freeze-dried to give a yellow glass (36 mg) containing two 
isomers of the product, starting material and an unidentified side-product in a 5:4:2:1 ratio 
respectively.  The yellow glass was subjected to flash chromatography on silica, eluting with 
20% MeOH/EtOAc, to give a 3:1 ratio of the isomers 2.41 as a pale yellow solid (17 mg, 
44%). 
 
1
H NMR (D2O):  δ  (major isomer only) 4.16 (1H, d, J = 9.3 Hz), 3.85 (1H, ddd, J = 4.9, 9.3, 
11.5 Hz), 3.69 (3H, s), 2.99 (1H, dd, J = 2.9, 14.9 Hz), 2.34 (1H, d, J = 14.9 Hz), 2.17 (1H, 
ddd, J = 2.9, 4.9, 13.7 Hz), 2.03 (1H, dd, J = 11.5, 13.7 Hz). 
 
13
C NMR (D2O):  δ  (major isomer only) 175.1, 160.2, 75.9, 74.4, 71.0, 53.3, 39.0, 34.6. 
 
TOF MS ES+:  219.1665;  C8H15N2O5 [MH]
+ requires 219.0981. 
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Potassium (1S,3E,4R,5R)-3-hydrazono-1,4,5-trihydroxycyclohexane-1-carboxylate 2.42 
 
OH
HO
OH
CO2K
N
H2N
 
To a solution of the major (E) isomer of 2.41 (4 mg, 0.02 mmol) in H2O (200 µL) over ice 
was added 0.30 M KOH(aq) (70 µL, 0.02 mmol).  The solution was stirred over ice for 10 min 
and the solvent removed by lyophilisation to give the E-isomer 2.42 as a brown glass (6 mg, 
quant). 
 
1
H NMR (D2O, 300 MHz):  δ  4.17 (1H, d, J = 9.3 Hz), 3.86 (1H, ddd, J = 5.4, 9.3, 11.2 Hz), 
2.94 (1H, dd, J = 2.4, 14.9 Hz), 2.33 (1H, d, J = 14.9 Hz), 2.08 (1H, ddd, J = 2.4, 5.4, 13.7 
Hz), 1.99 (1H, dd, J = 11.2, 13.7 Hz). 
 
13
C NMR (D2O):  δ  180.5, 162.2, 76.3, 75.8, 71.9, 40.2, 35.6. 
 
TOF MS ES-:  203.0663;  C7H11N2O5 [M-K]
- requires 203.0668. 
 
 
Methyl (1S,3E/Z,4R,5R)-3-[(aminocarbonothioyl)hydrazono]-1,4,5-
trihydroxycyclohexane-1-carboxylate 2.43 
 
OH
HO
OH
CO2Me
N
H
NH2N
S  
 
Methyl dehydroquinate 2.13 (1.02 g, 4.99 mmol) and thiosemicarbazide (510 mg, 5.59 mmol) 
were heated at 40 ºC in a mixture of MeOH (3 mL) and acetate buffer (pH 7, 1.8 M, 2 mL) for 
7 h then the solvent evaporated.  The residue (a brown oil) was subjected to flash 
chromatography on deactivated silica, eluting with 5% MeOH/EtOAc to give the isomers 2.43 
in a 9:1 ratio (major isomer presumed to be E) as a beige solid (704 mg, 51%). 
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1
H NMR (D2O, 300 MHz):  δ  (major isomer from a 9:1 mixture) 4.11 (1H, d, J = 8.8 Hz), 
3.71 (1H, ddd, J = 4.7, 8.8, 11.0 Hz), 3.68 (3H, s), 3.05 (1H, dd, J = 2.4, 14.9 Hz), 2.52 (1H, 
d, J = 14.9 Hz), 2.13 (1H, ddd, J = 2.4, 4.7, 13.7 Hz), 2.00 (1H, dd, J = 11.0, 13.7 Hz). 
 
13
C NMR (D2O):  δ  (major isomer from a 9:1 mixture) 177.6, 174.9, 152.6, 75.9, 74.2, 71.4, 
53.4, 39.2, 34.4. 
 
Anal.  Calculated for C9H15N3O5S·H2O: C 36.60; H 5.80; N 14.23; S 10.86.  Found C 36.64; 
H 5.82; N 15.13; S 11.42. 
 
Optical rotation:  [α]
20
D
  -31.46 (c. 1.03, CH3OH). 
 
TOF MS ES+:  278.0818;  C9H16N3O5S [MH]
+ requires 278.0811. 
 
 
Potassium (1S,3E/Z,4R,5R)-3-[(aminocarbonothioyl)hydrazono]-1,4,5-
trihydroxycyclohexane-1-carboxylate 2.44 
 
OH
HO
OH
CO2K
N
H
NH2N
S  
 
To a solution of thiosemicarbazone 2.43 (114 mg, 0.41 mmol) (9:1 E:Z) in H2O (1 mL) over 
ice was added 0.30 M KOH(aq) (1.38 mL, 0.41 mmol).  The solution was stirred 5 min over ice 
then freeze-dried.  1H NMR showed a small amount of the ester remaining so a second aliquot 
of KOH(aq) (0.17 mL, 0.05 mmol) was added with 1 mL H2O.  After stirring over ice for 
another 5 min the reaction was freeze-dried to give 2.44 (9:1 E:Z) as a brown glass (123 mg, 
quant). 
 
1
H NMR (D2O, 300 MHz):  δ  (major isomer from 9:1 mixture) 4.08 (1H, d, J = 9.3 Hz), 3.64 
(1H, ddd, J = 5.4, 9.3, 11.2 Hz), 2.94 (1H, dd, J = 2.4, 14.7 Hz), 2.37 (1H, d, J = 14.7 Hz), 
1.97 (1H, ddd, J = 2.4, 5.4, 13.7 Hz), 1.92 (1H, dd, J = 11.2, 13.7 Hz). 
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13
C NMR (D2O):  δ  (major isomer from 9:1 mixture) 180.0, 177.3, 154.4, 76.3, 75.5, 72.5, 
40.2, 35.6. 
 
Anal.  Calculated for C8H12N3O5KS·2.5H2O: C 27.74; H 4.95; N 12.13; S 9.26.  Found C 
27.69; H 4.50; N 12.62; S 9.60. 
 
Optical rotation:  [α]
20
D
  -24.51 (c. 1.02, H2O). 
 
TOF MS ES+:  264.0655;  C8H14N3O5S [MH2-K]
+ requires 264.0654. 
 
 
Methyl (1S,3E/Z,4R,5R)-3-(formylhydrazono)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.45 
 
OH
HO
OH
CO2Me
N
H
NH
O  
 
Methyl dehydroquinate 2.13 (78 mg, 0.38 mmol) and formic hydrazide (21 mg, 0.35 mmol) 
were stirred in H2O (1.5 mL) at rt for 55 h.  The solution was freeze dried to give a yellow 
glass containing the product, an unidentified side-product and methyl dehydroquinate 
(8:1:0.75).  The product was present as a pair of isomers (3:4).  The mixture was subjected to 
flash chromatography on silica, eluting with 15% MeOH/EtOAc.  Fractions containing the 
product 2.45 were evaporated separately and analysed by 1H NMR.  The fraction containing 
the least side product (25:1 product:side-product) was set aside for deprotection and assay (22 
mg, 24%).  This fraction contained a 3:2 ratio of isomers, with the major isomer presumed to 
be the E-isomer.  The remaining fractions were combined to give a 6:1 mixture of product and 
side-product (39 mg, 4:3 E:Z, 39%). 
 
1
H NMR (CD3OD):  δ  (major isomer from 3:2 mixture) 8.07 (1H, s), 4.05 (1H, d, J = 8.8 Hz), 
3.79 (1H, ddd, J = 4.9, 8.8, 10.7 Hz), 3.76 (3H, s), 3.04 (1H, dd, J = 2.4, 14.7 Hz), 2.54 (1H, 
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d, J = 14.7 Hz), 2.15 (1H, m), 2.01 (1H, m) (minor isomer from 3:2 mixture) 8.68 (1H, s), 
4.01 (1H, d, J = 8.6 Hz), 3.79 (1H, ddd, J = 4.9, 8.6, 10.7 Hz), 3.76 (3H, s), 3.04 (1H, dd, J = 
2.4, 14.7 Hz), 2.50 (1H, d, J = 14.7 Hz), 2.15 (1H, m), 2.01 (1H, m). 
 
13
C NMR (D2O):  δ  (both isomers from 3:2 mixture) 175.0, 174.9, 168.0, 160.6, 158.5, 153.5, 
75.8, 75.6, 74.3, 74.2, 71.3, 71.1, 53.4, 48.9, 39.1, 39.0, 34.5, 34.2. 
 
TOF MS ES+:  247.0963.  C9H15N2O6 (MH)
+ requires 247.0930. 
 
 
Potassium (1S,3E/Z,4R,5R)-3-(formylhydrazono)-1,4,5-trihydroxycyclohexane-1-
carboxylate 2.46 
 
OH
HO
OH
CO2K
N
H
NH
O  
 
To ester 2.45 (23 mg, 0.09 mmol) in H2O (200 µL) was added 0.30 M KOH(aq) (350 µL, 0.10 
mmol) and the reaction stirred over ice for 5 min.  The solvent was removed by lyophilisation 
to give a brown glass 2.46 as a 2:3 mixture of isomers (24 mg, quant) 
 
1
H NMR (D2O):  δ  (major isomer from a 3:2 mixture) 7.96 (1H, s), 4.15 (1H, d, J = 9.3 Hz), 
3.71 (1H, m), 2.90 (1H, dd, J = 2.4, 14.9 Hz), 2.43 (1H, d, J = 14.9 Hz), 1.93-2.03 (2H, m), 
(minor isomer from a 3:2 mixture) 8.57 (1H, s), 4.08 (1H, d, J = 9.3 Hz), 3.69 (1H, m), 2.95 
(1H, dd, J = 2.4, 14.9 Hz), 2.36 (1H, d, J = 14.9 Hz), 1.93-2.03 (2H, m). 
 
13
C NMR (D2O):  δ  (both isomers from a 3:2 mixture) 180.1, 179.9, 169.1, 160.8, 159.7, 
155.3, 76.5, 76.1, 75.5, 72.6, 72.3, 40.2, 35.8, 35.5. 
 
TOF MS ES-:  231.0652.  C8H11N2O6 (M-K)
- requires 231.0617. 
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Methyl (1S,3E,4R,5R)-3-(hydroxyimino)-1,4,5-trihydroxycyclohexane-1-carboxylate 2.47 
 
OH
HO
OH
CO2Me
N
HO
 
 
To a solution of hydroxylamine hydrochloride (21 mg, 0.30 mmol) in H2O (1 mL) was added 
NaOAc·3H2O until the solution reached pH 7 (212 mg, 1.56 mmol).  Methyl dehydroquinate 
2.13 (41 mg, 0.20 mmol) was added and the reaction stirred at rt for 18 h.  The solvent was 
removed by lyophilisation and the residue subjected to flash chromatography on silica, eluting 
with EtOAc.  Fractions containing the product were evaporated, then re-dissolved in H2O and 
freeze-dried to remove traces of EtOAc and CH3COOH.  A single isomer of the product 2.47 
was obtained as colourless glass (23.8 mg, 55%), whose 1H NMR data were in agreement 
with the literature.5 
 
1
H NMR (D2O):  δ  4.06 (1H, d, J = 9.3 Hz), 3.74 (1H, ddd, J = 4.4, 9.3, 11.2 Hz), 3.68 (3H, 
s), 3.31 (1H, dd, J = 2.9, 14.9 Hz), 2.33 (1H, d, J = 14.9 Hz), 2.11 (1H, ddd, J = 2.9, 4.4, 13.7 
Hz), 1.97 (1H, dd, J = 11.2, 13.7 Hz). 
 
 
Potassium (1S,3E,4R,5R)-3-(hydroxyimino)-1,4,5-trihydroxycyclohexane-1-carboxylate 
1.32 
 
OH
HO
OH
CO2K
N
HO
 
 
To a solution of oxime methyl ester 2.47 (11.8 mg, 0.06 mmol) in H2O (300 µL) over ice was 
added 0.30 M KOH(aq) (200 µL, 0.06 mmol).  The reaction was stirred over ice for 10 min 
then freeze-dried to give the potassium salt of 1.32 as a pale yellow glass (15 mg, quant), 
whose 1H NMR data were in agreement with the literature.5 
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1
H NMR (D2O):  δ  4.03 (1H, d, J = 9.3 Hz), 3.69 (1H, ddd, J = 4.9, 9.3, 10.7 Hz), 3.18 (1H, 
dd, J = 2.4, 14.7 Hz), 2.18 (1H, d, J = 14.7 Hz), 1.97 (1H, ddd, J = 2.4, 4.9, 13.2 Hz), 1.90 
(1H, dd, J = 10.7, 13.2 Hz). 
 
 
Methyl (1R,3S,4S,6S,9R)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-7,9-
bis(trimethylsiloxy)-2,5-dioxabicyclo[4.4.0]dec-7-ene-9-carboxylate 2.55 
 
O
TMSO
O
CO2Me
TMSO
OMe
OMe
 
 
To a solution of protected dehydroquinate 2.12 (101 mg, 0.32 mmol) in dry toluene (4 mL) 
under Ar was added dry Et3N (0.45 mL, 3.2 mmol), then trimethylsilyl 
trifluoromethanesufonate (0.35 mL, 1.9 mmol) and the reaction was heated at reflux for 2.5 h.  
The reaction was allowed to cool, diluted with pentane and the organic fraction washed with 
sat. NaHCO3 (3×) and H2O (1×), dried (MgSO4), filtered and evaporated to furnish 
silylenolether intermediate 2.54 (138 mg) as a yellow oil which was used without further 
purification.  
 
1
H NMR (CDCl3):  δ  4.92 (1H, dd, J = 1.5, 2.0 Hz), 4.05 (1H, ddd, J = 3.4, 9.1, 12.2 Hz), 
4.00 (1H, dd, J = 2.0, 9.1 Hz), 3.69 (3H, s), 3.23 (3H, s), 3.21 (3H, s), 2.06 (1H, dd, J = 12.2, 
12.7 Hz), 1.97 (1H, ddd, J = 1.5, 3.4, 12.7 Hz), 1.30 (3H, s), 1.26 (3H, s), 0.20 (9H, s), 0.10 
(9H, s). 
 
13
C NMR (CDCl3):  δ  174.1, 152.0, 107.9, 100.3, 99.6, 75.2, 69.4, 65.3, 52.3, 47.6, 38.0, 17.7, 
17.62, 1.9, 0.4. 
 
 
Methyl (1R,3S,4S,6S)-3,4-dimethoxy-3,4-dimethyl-7-oxo-2,5-dioxabicyclo[4.4.0]dec-8-
ene-9-carboxylate 2.56 
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O
OO
OMe
OMe
CO2Me
 
 
To a solution of protected dehydroquinate 2.12 (113 mg, 0.35 mmol) in dry toluene under Ar 
was added dry Et3N (0.25 mL, 1.8 mmol), then trimethylsilyl trifluoromethanesufonate (0.39 
mL, 2.12 mmol) and the reaction was heated at reflux for 2 h.  The reaction was allowed to 
cool, diluted with pentane and the organic fraction washed with sat. NaHCO3 (4×) and H2O 
(1×), dried (MgSO4), filtered and evaporated to give 2.56 as a yellow oil which crystallised on 
standing (100 mg, 94%). 
 
1
H NMR (CDCl3):  δ  6.77 (1H, d, J = 3.2 Hz), 4.29 (1H, d, J = 11.7 Hz), 4.07 (1H, ddd, J = 
5.4, 10.7, 11.7 Hz), 3.82 (3H, s), 3.28 (3H, s), 3.23 (3H, s), 3.05 (1H, dd, J = 5.4, 18.6 Hz), 
2.62 (1H, ddd, J = 3.2, 10.7, 18.6 Hz), 1.39 (3H, s), 1.31 (3H, s). 
 
13
C NMR (CDCl3):  δ  194.4, 165.8, 144.6, 132.6, 100.3, 99.3, 75.0, 67.0, 52.9, 48.4, 48.0, 
30.4, 17.6, 17.5. 
 
mp:  115-118 ºC  (lit: 98-99 ºC)1 
 
 
Methyl (1R,3S,4S,6S,8S,9R)-8-fluoro-3,4-dimethoxy-3,4-dimethyl-7-oxo-9-
(trimethylsiloxy)-2,5-dioxabicyclo[4.4.0]decane-9-carboxylate 2.57 
 
O
TMSO
O
CO2Me
O
OMe
OMe
F
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A mixture of silylenolether intermediate 2.54 and ketone 2.55 (5:2) (160 mg) was taken up in 
dry MeCN and Selectfluor® fluorinating reagent (131 mg, 0.37 mmol) added over 4 Å 
molecular sieves.  The reaction was stirred at rt under Ar for 2.5 h.  The reaction mixture was 
diluted with diethyl ether, washed with H2O (3×), dried (MgSO4), filtered and evaporated to 
give a 1:1 mixture of (2S)-2-fluoroketone 2.57 and unfluorinated ketone 2.55 as a yellow oil 
(210 mg).  Flash chromatography on silica, eluting with 15% EtOAc/pet. ether furnished (2S)-
2-fluoroketone 2.57 as a colourless oil (42 mg, 32% over 2 steps from 2.12) and ketone 2.55 
(58 mg, 31%). 
 
1
H NMR (CDCl3):  δ  4.77 (1H, dd, J = 7.5, 10.0 Hz), 4.67 (1H, dd, J = 1.6, 48.8 Hz), 4.01 
(1H, dddd, J = 1.0, 3.8, 10.0, 12.0 Hz), 3.78 (3H, s), 3.23 (3H, s), 3.21 (3H, s), 2.47 (1H, ddd, 
J = 4.7, 12.0, 14.3 Hz), 2.29 (1H, dddd, J = 1.6, 3.0, 3.8, 14.3 Hz), 1.37 (3H, s), 1.29 (3H, s), 
0.08 (9H, s). 
 
13
C NMR (CDCl3):  δ  196.2 (d, JC-F = 19.2 Hz), 169.7, 100.4, 99.6, 92.6 (d, JC-F = 186.3 Hz), 
76.9 (d, JC-F = 26.5 Hz), 74.5 (d, JC-F = 2.1 Hz), 66.2, 52.8, 48.3, 48.0, 33.1, 18.0, 17.5, 1.0. 
 
19
F NMR (CDCl3, 282 MHz):  δ  -185.24 (1F, m, J = 48.8 Hz).   
 
 
Methyl (1R,3S,4S,6S,8R,9R)-8-fluoro-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-7-oxo-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.60 
 
O
HO
O
CO2Me
O
OMe
OMe
F
 
 
Unpurified silylenolether intermediate 2.54 (138 mg) was taken up in dry MeCN and 
Selectfluor® fluorinating reagent (118 mg, 0.33 mmol) added over 4 Å molecular sieves.  The 
reaction was stirred at rt under Ar for 2.5 h.  The reaction mixture was diluted with diethyl 
ether, washed with H2O (3×), dried (MgSO4), filtered and evaporated to give a 6:1 mixture of 
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(2S)-2-fluoroketone 2.57 and unfluorinated ketone 2.55 as a brown oil (90 mg).  Flash 
chromatography on deactivated silica, eluting with 20-30% EtOAc/pet. ether, furnished (2R)-
2-fluoroketone 2.60 (52 mg, 51% over 2 steps from 2.12). 
 
1
H NMR (CDCl3):  δ  5.23 (1H, dd, J = 1.5, 46.7 Hz), 4.43 (1H, dd, J = 1.5, 10.3 Hz), 4.22 
(1H, ddd, J = 4.8, 10.3, 12.2 Hz), 3.88 (3H, s), 3.25 (3H, s), 3.21 (3H, s), 2.31 (1H, dd, J = 
12.2, 13.5 Hz), 2.21 (1H, ddd, J = 4.8, 7.1, 13.5 Hz), 1.39 (3H, s), 1.29 (3H, s). 
 
13
C NMR (CDCl3):  δ  193.97 (d, JC-F = 16.6 HZ), 171.22, 100.32, 99.75, 92.74 (d, JC-F = 199.2 
Hz), 76.57 (d, JC-F = 18.2 Hz), 75.15 (d, JC-F = 2.6 Hz), 66.70, 53.97, 48.49, 48.09, 34.30 (d,  
JC-F = 4.2 Hz), 17.58, 17.36. 
 
19
F NMR (CDCl3, 282 MHz):  -31.31 (1F, dd, J = 7.1, 46.7 Hz). 
 
 
(1R,3S,4S,6R,7R,9S)-7,9-Dihydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylic acid 2.61 
 
O
HO
O
CO2H
HO
OMe
OMe
 
 
1.00 M KOH(aq) (1.5 mL, 1.5 mmol) was added to protected quinic acid 2.11 (201 mg, 0.63 
mmol) and the reaction stirred over ice for 10 min.  Amberlite IR 120 (H) ion exchange resin 
was added and the suspension stirred a further 5 min.  The resin was removed by filtration and 
the filtrate freeze-dried to give the free acid intermediate 2.61 as a white solid (183 mg, 95%) 
which was used without further purification. 
 
1
H NMR (D2O):  δ  4.21 (1H, ddd, J = 4.4, 10.7, 12.0Hz), 4.13 (1H, ddd, J = 2.9, 2.9, 2.9 
Hz),3.59 (1H, dd, J = 2.9, 10.7 Hz), 3.21 (3H, s), 3.19 (3H, s), 1.99-2.07 (3H, m), 1.88 (1H, 
dd, J = 12.0, 12.7 Hz), 1.27 (3H, s), 1.23 (3H, s). 
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13
C NMR (D2O):  δ  178.2, 101.2, 101.0, 76.2, 73.3, 68.7, 63.7, 48.5, 48.4, 38.1, 17.7, 17.6. 
 
 
Allyl (1R,3S,4S,6R,7R,9S)-7,9-dihydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.62 
 
O
HO
O
CO2
HO
OMe
OMe
 
 
To a solution of acid intermediate 2.61 (438 mg, 1.43 mmol) in DMF (4 mL) was added 
KHCO3 (329 mg, 3.28 mmol) and allyl bromide (2.0 mL, 23 mmol) and the suspension stirred 
at rt for 23 h.  The reaction was diluted with diethyl ether and the organic phase washed with 
1 M KHSO4 (1×), sat. NaCl (1×) and H2O (1×), dried (MgSO4), filtered and evaporated.  The 
residue was subjected to flash chromatography on silica gel, eluting with 50% pet. 
ether/EtOAc to give the desired allyl ester 2.62 as a colourless oil which crystallised on 
standing (322 mg, 65%). 
 
1
H NMR (CDCl3):  δ  5.87 (1H, dddd, J = 5.7, 5.7, 10.5, 17.2 Hz), 5.30 (1H, dddd, J = 1.3, 
1.3, 2.7, 17.2 Hz), 5.23 (1H, dddd, J = 1.3, 1.3, 2.7 10.5 Hz), 4.66 (1H, dddd, J = 1.3, 1.3, 5.7, 
13.1 Hz), 4.61 (1H, dddd, J = 1.3, 1.3, 5.7, 13.1 Hz), 4.29 (1H, ddd, J = 4.6, 10.3, 11.9 Hz), 
4.21 (1H, s), 4.16 (1H, m), 3.57 (1H, dd, J = 2.8, 10.3 Hz), 3.23 (3H, s), 3.23 (3H, s), 2.15 
(1H, ddd, J = 3.0, 3.2, 14.9 Hz), 2.08 (1H, ddd, J = 3.0, 4.6, 12.7 Hz), 2.02 (1H, dd, J = 2.8, 
14.9 Hz), 1.92 (1H, dd, J = 11.9, 12.7 Hz), 1.31 (3H, s), 1.27 (3H, s). 
 
13
C NMR (CDCl3):  δ  173.6, 131.2, 119.1, 100.3, 99.7, 75.7, 72.8, 69.1, 66.4, 47.9, 38.6, 37.4, 
17.8, 17.7. 
 
mp:  82-84 ºC 
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Allyl (1R,3S,4S,6S,9R)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-7-oxo-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.63 
 
O
HO
O
CO2
O
OMe
OMe
 
 
Alcohol 2.62 (838 mg, 2.42 mmol) in CH2Cl2 (10 mL) was added to a suspension of PCC (5.0 
g, 23 mmol) in CH2Cl2 (15 mL) over 4 Å molecular sieves and the reaction stirred at rt for 20 
h.  The brown suspension was filtered through silica, rinsing with 10% MeOH/EtOAc (150 
mL).  The filtrate was concentrated, re-dissolved in EtOAc and heated at reflux with activated 
charcoal for 3 h.  The suspension was filtered through silica, rinsing with 10% MeOH/EtOAc 
(150 mL).  The filtrate was evaporated and the residue subjected to flash chromatography on 
silica, eluting with 40% EtOAc/pet. ether to give 2.63 as a colourless oil which slowly 
crystallised on cooling (589 mg, 71%). 
 
1
H NMR (CDCl3):  δ  5.87 (1H, dddd, J = 5.8, 5.8, 10.5, 17.1 Hz), 5.32 (1H, ddd, J = 1.2, 1.4, 
17.1 Hz), 5.27 (1H, ddd, J = 1.2, 1.4, 10.5 Hz), 4.71 (1H, dddd, J = 1.2, 1.4, 5.8, 13.1 Hz), 
4.63 (1H, dddd, J = 1.2, 1.4, 5.8, 13.1 Hz), 4.40 (1H, dd, J = 1.1, 10.3 Hz), 4.23, (1H, ddd, J = 
4.5, 10.3, 12.3 Hz), 3.31 (1H, s), 3.23 (3H, s), 3.20 (3H, s), 2.89 (1H, dd, J = 1.1, 14.3 Hz), 
2.49 (1H, dd, J = 3.0, 14.3 Hz), 2.36 (1H, dd, J = 12.3, 12.9 Hz), 2.10 (1H, ddd, J = 3.0, 4.5, 
12.9 Hz), 1.36 (3H, s), 1.27 (3H, s). 
 
13
C NMR (CDCl3):  δ  199.4, 173.3, 130.7, 119.7, 100.5, 99.6, 77.2, 74.0, 67.1, 67.0, 49.0, 
48.3, 48.0, 37.8, 17.6, 17.5. 
 
mp:  143-145 ºC 
 
TOF MS ES+:  345.1536;  C16H25O8 [MH]
+ requires 345.1549. 
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Allyl (1R,4S,5R)-1,4,5-trihydroxy-3-oxocyclohexane-1-carboxylate (Allyl 3-
dehydroquinate) 2.64 
 
OH
HO
OH
CO2
O
 
 
To ketone 2.63 (80 mg, 0.23 mmol) over ice was added H2O (25 µL) and TFA (475 µL) and 
the reaction stirred over ice for 3 h.  The solvent was removed by lyophilisation and the 
residue re-dissolved in MeOH and evaporated to give the free diol 2.64 as a colourless oil (52 
mg, 96%). 
 
1
H NMR (CD3OD):  δ  5.96 (1H, m), 5.35 (1H, d, J = 17.2 Hz), 5.23 (1H, d, J = 10.5 Hz), 4.67 
(2H, d, J = 5.5 Hz), 4.40 (1H, d, J = 9.3 Hz), 3.90 (1H, ddd, J = 5.0, 9.6, 11.2 Hz), 3.05, (1H, 
d, J = 14.0 Hz), 2.54 (1H, dd, J = 3.0, 14.0 Hz), 2.28 (1H, ddd, J = 3.0, 5.0, 13.4 Hz), 2.22 
(1H, dd, J = 11.2, 13.4 Hz). 
 
13
C NMR (D2O):  δ  208.5, 174.5, 132.0, 119.5, 81.3, 74.8, 71.8, 67.7, 48.1, 40.1. 
 
TOF MS ES+:  195.1147;  C10H11O4 [MH-2H2O]
+ requires 195.0657. 
 
 
Allyl (1R,3S,4S,6S,9R)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-7,9-bis(trimethylsiloxy)-
2,5-dioxabicyclo[4.4.0]dec-7-ene-9-carboxylate 2.65 
 
O
TMSO
O
CO2
TMSO
OMe
OMe
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Ketone 2.63 (103 mg, 0.30 mmol), dry Et3N (1.8 mL, 13 mmol), and TMSOTf (1.0 mL, 5.5 
mmol) were heated at reflux in dry toluene (5 mL) for 2.5 h under Ar.  The reaction was 
allowed to cool, then diluted with pentane and the organic fraction washed with sat. NaHCO3 
(5×), dried (MgSO4) and filtered.  The filtrate was evaporated to give silylenolether 
intermediate 2.65 as a yellow oil (137 mg) which was used without further purification. 
 
1
H NMR (CDCl3):  δ  5.88 (1H, dddd, J = 5.7, 5.7, 10.4, 17.3 Hz), 5.30 (1H, dddd, J = 1.3, 
1.3, 1.4, 17.3, Hz), 5.22 (1H, dddd, J = 1.3, 1.3, 1.4, 10.4 Hz), 4.95 (1H, dd, J = 1.6, 1.7 Hz), 
4.61 (1H, dddd, J = 1.3, 1.3, 5.7, 13.3 Hz), 4.56 (1H, dddd, J = 1.3, 1.3, 5.7, 13.3 Hz), 4.07 
(1H, ddd, J = 3.2, 9.2, 12.5 Hz), 4.03 (1H, dd, J = 1.7, 9.2 Hz), 3.25 (3H, s), 3.23 (3H, s), 2.11 
(1H, dd, J = 12.5, 12.6 Hz), 2.00 (1H, ddd, J = 1.6, 3.2, 12.6 Hz), 1.32 (3H, s), 1.28 (3H, s), 
0.21 (9H, s), 0.12 (9H, s). 
 
 
Methyl (1R,3S,4S,6S,8S,9R)-8-fluoro-3,4-dimethoxy-3,4-dimethyl-7-oxo-9-
(trimethylsiloxy)-2,5-dioxabicyclo[4.4.0]decane-9-carboxylate 2.66 
 
O
TMSO
O
CO2
O
OMe
OMe
F
 
 
To a solution of silylenolether intermediate 2.65 (137 mg) in dry MeCN over 4 Å molecular 
sieves was added Selectfluor® fluorinating reagent (107 mg, 0.30 mmol) and the reaction 
stirred at rt for 20 h.  The reaction mixture was diluted with diethyl ether and extracted with 
H2O (3×).  The organic phase was dried (MgSO4), filtered and evaporated to give a brown oil 
containing a 3:1 mixture of 2.66 and 2.67.  The oil was subjected to flash chromatography on 
silica gel, eluting with 25% EtOAc/pet. ether to give the α-fluoroketone 2.66 as a colourless 
oil (46 mg, 37% over 2 steps from 2.63). 
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1
H NMR (CDCl3):  δ  5.91 (1H, dddd, J = 5.7, 5.7, 10.5, 17.1 Hz), 5.36 (1H, dd, J = 1.3, 17.1, 
Hz), 5.29 (1H, dd, J = 1.3, 10.5 Hz), 4.80 (1H, dd, J = 7.4, 10.5 Hz), 4.70 (1H, dd, J = 1.3, 
48.7 Hz), 4.67 (2H, m), 4.03 (1H, ddd, J = 4.3, 10.5, 12.0 Hz), 3.25 (3H, s), 3.22 (3H, s), 2.53 
(1H, ddd, J = 4.7, 12.0, 16.8 Hz), 2.31 (1H, m), 1.39 (3H, s), 1.31 (3H, s), 0.11 (9H, s). 
 
13
C NMR (CDCl3):  δ  196.2 (d, JC-F = 19.2 Hz), 169.1, 130.8, 119.4, 100.5, 99.7, 92.7 (d, JC-F 
= 186.8 Hz), 77.1 (d, JC-F = 26.5 Hz), 74.6 (d, JC-F = 2.6 Hz), 66.6, 66.4, 48.4, 48.1, 33.2, 17.7, 
17.5, 1.2. 
 
19
F NMR (CDCl3, 282 MHz):  -185.07 (1F, m, J = 48.7 Hz).   
 
 
4-Methoxybenzyl (1R,3S,4S,6R,7R,9S)-7,9-dihydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.68 
 
O
HO
O
CO2
HO
OMe
OMe
OMe
 
 
To protected quinic acid 2.11 (549 mg, 1.72 mmol) was added 1.00 M KOH(aq) (5.0 mL, 5.0 
mmol) and the reaction stirred for 10 min over ice.  Amberlite IR120 (H) ion exchange resin 
was added and the suspension stirred a further 5 min.  The reaction was filtered and the 
filtrate freeze-dried. To the residue was added KHCO3 (345 mg, 3.4 mmol), p-methoxybenzyl 
chloride (0.35 mL, 2.6 mmol) and dry DMF and the suspension stirred at rt under Ar for 45 h.  
The reaction was diluted with diethyl ether and washed with H2O (2×) and sat. NaCl (2×), 
dried (MgSO4), filtered and evaporated to give a yellow oil.  The oil was subjected to flash 
chromatography on silica gel, eluting with 40% pet. ether/EtOAc to give the p-methoxybenzyl 
ester 2.68 as a colourless oil (304 mg, 41%). 
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1
H NMR (CDCl3):  δ  7.26 (2H, d, J = 8.7 Hz), 6.87 (2H, d, J = 8.7 Hz), 5.12 (1H, d, J = 11.7 
Hz), 5.09 (1H, d, J = 11.7 Hz), 4.29 (1H, ddd, J = 4.8, 10.3, 12.5 Hz), 4.15 (2H, m), 3.80 (3H, 
s), 3.55 (1H, dd, J = 3.2, 10.3 Hz), 3.24 (3H, s), 3.23 (3H, s), 2.14 (1H, ddd, J = 2.8, 2.8, 15.1 
Hz), 2.05 (1H, ddd, J = 2.8, 4.8, 12.7 Hz), 2.01 (1H, dd, J = 2.8, 15.1 Hz), 1.90 (1H, dd, J = 
12.5, 12.7 Hz), 1.32 (3H, s), 1.28 (3H, s). 
 
13
C NMR (CDCl3):  δ  173.8, 159.8, 130.1, 127.2, 114.0, 100.3, 99.7, 75.6, 72.8, 69.0, 67.5, 
62.5, 55.3, 47.9, 38.5, 37.4, 17.8, 17.7. 
 
TOF MS ES+:  395.1695;  C20H27O8 [MH2-H2O-CH3]
+ requires 395.1706. 
 
 
Methyl (1R, 3S, 4S, 6S, 9R)-3,4-dimethoxy-3,4-dimethyl-7-oxo-9-(trimethylsiloxy)-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.55 
 
O
TMSO
O
CO2Me
O
OMe
OMe
 
 
Protected dehydroquinate 2.12 (807 mg, 2.53 mmol), hexamethyldisilazane (2.0 mL, 9.5 
mmol) and TMSCl (1.5 mL, 12 mmol) were stirred in pyridine at rt under Ar for 16 h.  The 
reaction mixture was concentrated in vacuo and the residue partitioned between ether and 
water.  The organic layer was washed with H2O (1×), CuSO4 (2×), H2O (1×) and sat. NaHCO3 
(1×).  The organic fraction was dried over MgSO4, filtered and evaporated to give 2.55 as a 
cream coloured solid (948 mg, 96%) whose NMR data agreed with the literature6 and which 
was used without further purification. 
 
1
H NMR (CDCl3):  δ  4.34 (1H, dd, J = 1.5, 10.3 Hz), 4.11 (1H, ddd, J = 4.9, 10.3, 11.2 Hz), 
3.75 (3H, s), 3.23 (3H, s), 3.21 (3H, s), 2.80 (1H, dd, J = 1.5, 14.7 Hz), 2.61 (1H, dd, J = 2.5, 
14.7 Hz), 2.25 (1H, dd, J = 11.2, 13.2 Hz), 2.20 (1H, ddd, J = 2.5, 4.9, 13.2 Hz), 1.37 (3H, s), 
1.27 (3H, s), 0.09 (9H, s). 
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13
C NMR (CDCl3):  δ  199.9, 172.8, 100.4, 77.1, 77.0, 67.1, 52.6, 49.9, 48.3, 47.9, 39.0, 17.7, 
17.5, 1.6. 
 
 
Methyl (1R, 3S, 4S, 6R, 9S)-3,4-dimethoxy-3,4-dimethyl-7-methylidene-9-
(trimethylsiloxy)-2,5-dioxabicyclo[4.4.0]decane-9-carboxylate 2.70 
 
O
TMSO
O
CO2Me
OMe
OMe
 
 
To a suspension of activated Zn dust (439 mg, 6.7 mmol) in anhydrous THF (2.5 mL) under 
Ar was added diiodomethane (220 µL, 2.73 mmol) and the suspension stirred at rt. for 45 min.  
The reaction vessel was cooled to 0 ºC and a 0.8 M solution of titanium (IV) chloride in 
CH2Cl2 was added slowly.  The mixture was stirred at rt for a further 35 min, than a solution 
of ketone 2.55 (201 mg, 0.51 mmol) in THF (3.5 mL) was added over ice.  The reaction was 
allowed to warm to room temperature and stirred for 3.5 h.  The reaction mixture was diluted 
with diethyl ether and poured into ice cold 1 N HCl and the aqueous fraction extracted with 
diethyl ether (3×).  The combined organic fractions were washed with sat. NaHCO3, dried 
(MgSO4) and evaporated.  The residue was subjected to flash chromatography on silica gel, 
eluting with a gradient of 10 – 40% EtOAc/pet. ether to furnish the protected olefin 2.70 as a 
colorless oil (126 mg, 64%) (whose NMR data were consistent with the literature),6 as well as 
the free alcohol 2.72 (16 mg, 10%). 
 
1
H NMR (CDCl3):  δ  5.23 (1H, s), 4.85 (1H, s), 4.01 (1H, d, J = 9.8 Hz), 3.79 (1H, ddd, J = 
5.9, 9.8, 10.3 Hz), 3.72 (3H, s), 3.23 (3H, s), 3.23 (3H, s), 2.47 (2H, s), 2.00-2.03 (2H, m), 
1.35 (3H, s), 1.29 (3H, s), 0.09 (9H, s). 
 
13
C NMR (CDCl3):  δ  174.4, 139.4, 109.5, 99.8, 99.4, 77.3, 72.7, 68.2, 52.2, 47.9, 43.8, 39.1, 
17.9, 17.9, 1.7. 
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Methyl (1R, 3S, 4S, 6R, 9S)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-7-methylidene-2,5-
dioxabicyclo[4.4.0]decane-9-carboxylate 2.72 and Methyl (1S,4R,5R)-1,4,5-trihydroxy-3-
methylidenecyclohexane-1-carboxylate 2.73 
O
HO
O
CO2Me
OMe
OMe
OH
HO
OH
CO2Me
2.72 2.73  
 
To a suspension of activated Zn dust (1.94 g, 29.6 mmol) in anhydrous THF (15 mL) was 
added CH2I2 (1.15 mL, 14.3 mmol).  The suspension was stirred at rt under Ar for 1 h, then a 
0.8 M solution of titanium (IV) chloride in CH2Cl2 (1.15 mL) added in portions over ice.  
After stirring a further 45 min at rt a solution of ketone 2.55 (1.13 g, 2.89 mmol) in THF (10 
mL) was added over ice.  The reaction was stirred at rt for 3.5 h under Ar, then diluted with 
diethyl ether and poured with stirring into ice-cold 1 N HCL.  The aqueous layer was 
extracted with diethyl ether (3×) and the combined organic extracts washed with sat. NaHCO3 
(2×), dried (MgSO4) and evaporated.  The residue was subjected to flash chromatography on 
silica gel, eluting with pet. ether/EtOAc (3:1) to EtOAc/MeOH (19:1) to furnish protected 
olefin 2.72 as a pale yellow oil (459 mg, 50%) and the triol 2.73 as a colourless oil (147 mg, 
25%). 
 
Protected olefin 2.72 
 
1
H NMR (CDCl3):  δ  5.28 (1H, m), 4.92 (1H, m), 4.06 (1H, d, J = 9.7 Hz), 3.87 (1H, ddd, J = 
4.6, 9.7, 12.3 Hz), 3.78 (3H, s), 3.24 (3H, s), 3.21 (3H, s), 2.61 (1H, dd, J = 0.9, 13.9 Hz), 
2.33 (1H, dd, J = 2.8, 13.9 Hz), 2.07 (1H, dd, J = 12.3, 12.7 Hz), 1.92 (1H, ddd, J = 2.8, 4.6, 
12.7 Hz), 1.34 (3H, s), 1.29 (3H, s). 
 
13
C NMR (CDCl3):  δ  175.4, 139.1, 109.9, 99.9, 99.5, 74.1, 72.4, 68.1, 53.0, 47.8, 47.8, 42.95, 
37.9, 17.7, 17.7. 
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TOF MS ES+:  285.1350;  C14H21O6 [MH2-H2O-CH3]
+ requires 285.1338. 
 
Olefin Triol 2.73 
 
1
H NMR (CDCl3):  δ  5.23 (1H, s), 4.94 (1H, s), 3.93 (1H, d, J = 9.1 Hz), 3.77 (3H, s), 3.73 
(1H, ddd, J = 4.4, 9.1, 11.7 Hz), 2.59 (1H, d, J = 14.2 Hz), 2.38 (1H, dd, J = 3.4, 14.2 Hz), 
2.11 (1H, ddd, J = 3.4, 4.4, 13.2 Hz), 1.95 (1H, dd, J = 11.7, 13.2 Hz). 
 
13
C NMR (CDCl3):  δ  175.4, 142.5, 110.9, 76.9, 74.2, 71.8, 53.0, 42.6, 40.7. 
 
TOF MS ES+:  203.0856;  C9H15O5 [MH]
+ requires 203.0919. 
 
 
Methyl (1R, 3S, 4S, 6R, 9R)-7-(bromomethyl)-9-hydroxy-3,4-dimethoxy-3,4-dimethyl-
2,5-dioxabicyclo[4.4.0]dec-7-ene-9-carboxylate 2.74 
 
O
HO
O
CO2Me
OMe
OMe
Br
 
 
Na2CO3 (20 mg, 0.19 mmol) was added to a solution of phenylselenyl bromide (34 mg, 0.14 
mmol) in dry CH2Cl2 (0.5 mL) under Ar.  The mixture was cooled to -78 ºC and a solution of 
olefin 2.72 (39 mg, 0.12 mmol) in CH2Cl2 (0.75 mL) added.  The reaction was stirred at -78 
ºC for 23 h, then pyridine (23 µL, 0.29 mmol) was added, followed by a solution of m-CPBA 
(27 mg, 0.16 mmol) in CH2Cl2 (0.5 mL).  The reaction was stirred a further 15 min at -78 ºC 
then at rt for 4.5 h.  The reaction was partitioned between diethyl ether and H2O and the 
organic phase washed with Na2S2O3 (2×), CuSO4 (2×), sat. NaHCO3 (2×) and H2O (2×), dried 
(MgSO4) and evaporated.  The resulting orange oil was subjected to flash chromatography on 
silica gel, eluting with 25% EtOAc/pet. ether to furnish allylic bromide 2.74 as a colourless 
oil (21 mg, 42%), whose NMR data was consistent with the literature.6 
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1
H NMR (CDCl3):  δ  5.60 (1H, s), 4.44 (1H, dd, J = 2.4, 9.3 Hz), 4.40 (1H, d, J = 9.8 Hz), 
4.05 (1H, ddd, J = 3.9, 9.3, 13.2 Hz), 3.80 (4H, m), 3.41 (3H, s), 3.26 (3H, s), 2.19 (1H, dd, J 
= 13.2, 13.2 Hz), 1.94 (1H, ddd, J = 1.5, 3.9, 13.2 Hz), 1.34 (3H, s), 1.30 (3H, s). 
 
13
C NMR (CDCl3):  δ  175.2, 139.2, 126.8, 100.5, 99.9, 73.1, 67.7, 65.4, 53.6, 48.7, 48.0, 37.0, 
30.0, 17.8. 
 
 
Methyl (1R,4R,5R)-3-(bromomethyl)-1,4,5-trihydroxycyclohex-2-ene-1-carboxylate 2.75 
 
OH
HO
OH
CO2Me
Br
 
 
TFA (475 µL) and H2O (25 µL) were added to protected allylic bromide 2.72 (5.9 mg, 0.01 
mmol) and the reaction stirred over ice for 35 min.  The solvent was removed by 
lyophilisation and the residue re-dissolved in MeOH and evaporated to furnish 2.75 as a 
colourless oil (4.9 mg, quant). 
 
1
H NMR (CD3OD):  δ  5.88 (1H, s), 4.38 (1H, d, J = 9.8 Hz), 4.22 (1H, dd, J = 1.5, 7.8 Hz), 
3.95 (1H, d, J = 9.8 Hz), 3.91 (1H, ddd, J = 5.4, 7.8, 10.3 Hz), 3.74 (3H, s), 2.00-2.02 (2H, 
m). 
 
13
C NMR (CD3OD):  δ  176.1, 142.7, 128.9, 74.5, 73.3, 71.0, 53.5, 40.9, 33.4. 
 
TOF MS ES+: 281.0056;  C9H14BrO5 [MH]
+ requires 281.0024. 
 
 
Methyl (3S,4S,5R)-3-(bromomethyl)-4,5-dihydroxycyclohex-1-ene-1-carboxylate 2.79 
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OH
OH
CO2Me
Br
 
 
To allylic bromide 2.78 (86 mg, 0.24 mmol) in H2O (25 µL) over ice was added TFA (475 
µL) and the reaction stirred over ice for 1.75 h.  The solvent was removed by lyophilisation 
and the residue re-dissolved in MeOH then evaporated.  The product was purified by flash 
chromatography on silica gel, eluting with 33% pet. ether/EtOAc to furnish the free diol 2.79 
as a colourless oil (55 mg, 91%). 
 
1
H NMR (CD3OD):  δ  6.81 (1H, dd, J = 2.9, 2.9 Hz), 4.64 (1H, m), 3.75 (3H, s), 3.71 (1H, 
dd, J = 7.8, 9.8 Hz), 3.60 (1H, ddd, J = 5.4, 9.8, 9.8 Hz), 2.80 (1H, ddd, J = 1.5, 5.4, 17.6 Hz), 
2.23 (1H, dddd, J = 2.9, 3.4, 9.8, 17.6 Hz). 
 
13
C NMR (CD3OD):  δ  167.8, 138.9, 130.5, 80.0, 71.0, 53.2, 53.0, 50.2, 33.4. 
 
 
 
Allyl (1S,4R,5R)-1,4,5-trihydroxy-3-methylidenecyclohexane-1-carboxylate 2.80 
 
OH
HO
OH
CO2
 
 
1.00 M KOH(aq) (0.75 mL, 0.75 mmol) was added to olefin 2.73 (59 mg, 0.29 mmol) and the 
reaction stirred over ice for 10 min.  Amberlite IR 120 (H) ion exchange resin was added and 
the suspension stirred a further 5 min.  The resin was removed by filtration and the filtrate 
freeze-dried.  The free acid intermediate was obtained as a yellow glass (57 mg) which was 
used without further purification. 
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1
H NMR (D2O):  δ  5.07 (1H, d, J = 1.5 Hz), 4.91 (1H, d, J = 1.5 Hz), 3.91 (1H, d, J = 9.4 Hz), 
3.54 (1H, ddd, J = 4.9, 9.4, 11.5 Hz), 2.60 (1H, dd, J = 0.9, 14.2 Hz), 2.41 (1H, dd, J = 3.2, 
14.2 Hz), 2.07 (1H, ddd, J = 3.2, 4.9, 13.6 Hz), 1.93 (1H, dd, J = 11.5, 13.6 Hz). 
 
To a solution of the free acid intermediate (54 mg, 0.29 mmol) in DMF (1 mL) was added 
KHCO3 (62 mg, 0.62 mmol) and allyl bromide (0.40 mL, 4.6 mmol) and the reaction was 
stirred at rt for 24 h.  The solvent was removed in vacuo and the residue taken up in EtOAc 
and washed with 1 M KHSO4 (1×), sat. NaHCO3 (1×), sat. NaCl (1×) and H2O (1×).  The 
organic phase was dried (MgSO4), filtered and evaporated to give the crude product as a 
colourless oil (21 mg).  The combined aqueous washings were extracted with CH2Cl2 (4×) 
and EtOAc (4×) and the organic fractions dried (MgSO4) and evaporated to give a further 24 
mg of the crude product.  The two samples of product were combined and subjected to flash 
chromatography on silica, eluting with 30% pet. ether/EtOAc, to furnish the allyl ester 2.80 as 
a colourless oil (29 mg, 45% over 2 steps from 2.73). 
 
1
H NMR (CDCl3):  δ  5.65 (1H, dddd, J = 5.7, 5.7, 10.4, 17.3 Hz), 5.33 (1H, dd, J = 1.3, 17.3 
Hz), 5.25 (1H, dd, J = 1.3, 10.4 Hz), 5.24 (1H, d, J = 1.4 Hz), 4.96 (1H, d, J = 1.4 Hz), 4.67 
(2H, d, J = 5.7 Hz), 3.95 (1H, d, J = 9.3 Hz), 3.75 (1H, ddd, J = 4.8, 9.3, 11.5 Hz), 3.63 (1H, 
br s), 3.44 (2H, br s), 2.63 (1H, d, J = 13.9 Hz), 2.39 (1H, dd, J = 3.0, 13.9 Hz), 2.12 (1H, 
ddd, J = 3.0, 4.8, 13.5 Hz), 1.99 (1H, dd, J = 11.5, 13.5 Hz). 
 
 
Allyl (4S,5R,7R)-4,5,7-trihydroxy-1-oxaspiro[2.5]octane-7-carboxylate 2.81 
 
OH
HO
OH
CO2
O
 
 
To a solution of alkene 2.80 (21 mg, 0.09 mmol) in CH2Cl2 (1.5 mL) was added 70% m-
CPBA (24 mg, 0.10 mmol) and the reaction stirred at rt for 1.5 h.  The solvent was evaporated 
to give the crude product as a 4:1 ratio of isomers.  Two repetitions of flash chromatography 
on silica, eluting with 10% pet. ether/EtOAc furnished the major isomer of epoxide 2.81 as a 
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colourless oil containing 11% residual m-CPBA (15 mg, 60% yield by 1H NMR).  The minor 
isomer was also obtained, contaminated with 15% m-CPBA (3 mg, 13% by 1H NMR). 
 
1
H NMR (CDCl3):  δ  (major isomer, containing 11% m-CPBA) 5.88 (1H, dddd, J = 5.7, 5.7, 
10.5, 17.1 Hz), 5.31 (1H, dd, J = 1.3, 17.1 Hz), 5.24 (1H, d, J = 10.5 Hz), 4.63 (2H, d, J = 5.7 
Hz), 4.06 (1H, ddd, J = 4.0, 9.3, 11.5 Hz), 3.96 (3H, br s), 3.70 (1H, d, J = 9.3 Hz), 3.01 (1H, 
d, J = 4.8 Hz), 2.52 (1H, d J = 14.7 Hz), 2.46 (1H, d, J = 4.8 Hz), 2.25 (1H, ddd, J = 3.4, 4.0, 
13.1 Hz), 1.92 (1H, dd, J = 11.5, 13.1 Hz), 1.58 (1H, dd, J = 3.4, 14.7 Hz). 
 
13
C NMR (CDCl3):  δ  (major isomer, containing 11% m-CPBA) 174.1, 131.3, 119.1, 74.5, 
72.6, 69.4, 66.4, 58.1, 46.3, 40.5, 39.7. 
 
TOF MS ES+: 245.0985;  C11H17O6 [MH]
+ requires 245.1025. 
 
 
(4S,5R,7R)-4,5,7-Trihydroxy-1-oxaspiro[2.5]octane-7-carboxylic acid 2.4 
 
OH
HO
OH
CO2H
O
 
 
To a solution of the major isomer of epoxide 2.81 (contaminated with 11% m-CPBA) (10 mg, 
0.036 mmol) in dry THF (0.75 mL) was added Pd(0)(PPh3)4 (5 mg, 4.1 µmol) and dimedone 
(61 mg, 0.44 mmol) and the reaction was stirred at rt under Ar for 1 h.  The solvent was 
evaporated and the residue partitioned between CH2Cl2 and H2O.  The aqueous phase was 
extracted with CH2Cl2 (3×) and EtOAc (5×), then freeze-dried to furnish the free acid 2.4 as a 
colourless glass (5 mg, 72%). 
 
1
H NMR (CD3OD):  δ  3.93 (1H, ddd, J = 3.9, 9.3, 11.5 Hz), 3.61 (1H, d, J = 9.3 Hz), 2.89 
(1H, d, J = 5.2 Hz), 2.51 (1H, d, J = 14.4 Hz), 2.42 (1H, d J = 5.2 Hz), 2.16 (1H, m), 1.93 
(1H, dd, J = 11.5, 12.2 Hz), 1.57 (1H, d, J = 14.4 Hz). 
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13
C NMR (CD3OD):  δ  174.1, 74.2, 70.6, 59.4, 47.2, 42.3, 41.0. 
 
TOF MS ES-:  203.0660;  C8H11O6 [M-H]
- requires 203.0556. 
 
 
6.3 ASSAY DETAILS 
 
Biological studies on type I DHQase were carried out in phosphate buffer.  Studies on type II 
DHQase were carried out in Tris·HCl buffer.  Buffer concentrations employed in individual 
experiments are detailed in Table 6.2. 
 
Stock solutions of enzymes were stored in 1:1 glycerol:0.05M buffer at -4 ºC.  Stock enzyme 
solution concentrations were 9.1 mgmL-1 (S. typhi DHQase), 5.1 mgmL-1 (S. coelicolor 
DHQase) and 1 mgmL-1 (M. tuberculosis DHQase).  Enzyme samples for assay were prepared 
by dilution of the stock solution into a buffer solution of the concentration to be employed in 
the assay (Table 6.2), and stored over ice while in use.  
 
The concentration of substrate solutions for assay was determined spectrophotometrically at 
234 nm.  A 20 µL aliquot of substrate solution in 50 mM buffer was reacted with 2 µL of 
enzyme stock solution until equilibrium.  The change in absorbance was measured and the 
initial substrate concentration in the sample calculated using Beer’s Law and an equilibrium 
constant for the conversion of DHQ to DHS of 15 (Equation 6.1). 
 
 [DHQ](µM) = 
∆Abs
εl
 × 
16
15 × 10
6 (6.1) 
 
The concentration of inhibitor samples was determined by 1H NMR.  A sample was prepared 
from a known volume of the inhibitor solution and a known volume of the DMF reference 
solution in H2O, or 50 mM tris·HCl buffer, and a proton NMR spectrum acquired with solvent 
suppression and with the relaxation delay (d1) set to 60 s to account for discrepancies in 
relaxation times between the various proton signals.  The integrals of the reference signal and 
an inhibitor signal were measured and the inhibitor concentration in the sample calculated 
according to Equation 6.2. 
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 [inhibitor] = 
inhib integral
ref integral  × 
Vref [ref]
Vinhib
  (6.2) 
 
 
6.3.1 Spectrophotometric Assays 
 
Assays of inhibitors were carried out at ambient temperature.  Data for Michaelis-Menten 
curves was obtained in a temperature controlled room at 25 ºC. 
 
Assay samples were prepared in 3 mL, 1 cm path-length quartz cuvettes.  Stock solutions of 
substrate, inhibitor, buffer and water were pipetted directly into the cuvette.  The 
concentrations of substrate, inhibitor, buffer and enzyme employed in the individual assays 
are detailed in Table 6.2.  The reaction was initiated by addition of enzyme solution (10 or 20 
µL) to make a final volume of 2000 µL.  Enzyme solutions were 5.1 µgmL-1 for S. coelicolor 
DHQase, 50 µgmL-1 for M. tuberculosis DHQase and 9.1 µgmL-1 for S. typhi DHQase.  The 
absorbance at 234 nm was recorded for 60-120 s.  A straight line was fitted to the data using 
MS Excel.  Beer’s Law was used to calculate the rate of the reaction from the slope of the Abs 
vs. t curve.  The rates of reaction were plotted against inverse inhibitor concentration in a 
Dixon plot to determine Ki as described in Chapter 3. 
Irreversible inhibition studies 
Samples of S. typhi DHQase were incubated with epoxide 2.4 at rt (Table 6.1). 
 
In order to study the progress of the inhibition by UV/vis spectroscopy, aliquots of enzyme 
incubation A (Table 6.1) were taken at intervals over a period of 3 h and diluted into a 
solution containing substrate (31 µM) and buffer (368 mM) with a total volume of 2000 µL.  
The reaction progress was monitored at 234 nm. 
 
Sample B (Table 6.1) was prepared in order to study the irreversible binding of 2.4 by LCMS.  
Prior to LCMS the extent of inactivation after 93 h was determined by UV/vis by carrying out 
a 10-fold dilution of a 2 µL aliquot of sample B, and then adding a 1 µL aliquot of the diluted 
sample into a 123 µM substrate solution in 100 mM buffer in a quartz cuvette (total volume 
2000 µL).  The reaction progress was monitored at 234 nm.  The steady state rate was 
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compared to that of a control sample prepared under identical conditions except for the 
absence of inhibitor. 
 
 
Table 6.1  Experimental details for time-dependent inhibition of S. typhi DHQase by 2.4. 
   
 Irreversible Inhibition Assay of 2.4 
 S. typhi DHQase 
 UV/vis study LCMS study 
 (Sample A) (Sample B) 
   
   
[Buffer] 368 mM (Phosphate) 100 mM (Phosphate) 
[Enzyme] 4.6 µgmL-1 1.37 mgmL-1 (50 µM) 
[Inhibitor] 400 µM 9413 µM 
Time 0-3 h 93 h 
   
 
 
6.3.2 
1
H NMR Assays 
 
1H NMR spectra were acquired at 500 MHz on a Varian Inova 500 spectrometer.  All 1H 
NMR data for the purpose of determining reaction rates was acquired at 25 ºC.  NMR spectra 
were measured using a 5 mm NMR tube with an insert containing D2O.  Spectra were 
acquired with suppression of the water signal. 
 
Solutions of the enzymatic product DHS were prepared enzymatically and their 
concentrations determined spectrophotometrically at 234 nm using Beer’s Law. 
 
Assay samples were prepared by pipetting milli-Q water, substrate, inhibitor and reference 
solutions into 2 mL vials.  The concentrations employed in the individual assays are detailed 
in Table 6.3.  The reaction was initiated by addition of S. coelicolor DHQase solution (8 µL 
of a 2.55 µgmL-1 solution, or 16 µL of a 1.28 µgmL-1 solution) to make a final volume of 550 
µL.  The solution was transferred to an NMR tube and the sample inserted into the 
spectrometer. 
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The experiment was set up for a 1H NMR in D2O, with lock power and lock gain set to 28 and 
38 respectively.  After locking and shimming, one transient was acquired with nt=1, pw=2, 
gain=2.  The spectrum was autophased and the cursor set on the solvent signal, the decoupler 
set by entering sd, and the suppression pulse sequence selected (suppr).  Data acquisition was 
initiated with gain=30, d1=5 and pad=0,5,5,5,5,5,5,5,5,5,5.  This meant that a series of 10 
spectra would be acquired with a 5 s delay between each, with 8 transients (the default value) 
per spectrum and a relaxation delay of 5 s between each transient.  The spectra were 
processed with fn=128k and lb=2.  The product concentration was calculated for each 
spectrum as described in Chapter 4, and the rate of reaction determined by fitting a straight 
line to the [DHS] vs. time data. 
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Table 6.2  Experimental details for reversible competitive inhibition spectrophotometric assays. 
    
Inhibitor Enzyme 
 S. typhi DHQase M. tuberculosis DHQase S. coelicolor DHQase 
    
    
1.36   [B] = 50 mM (Tris·HCl) 
   [E] =26 ngmL
-1
 
   [S] = 207, 311, 415 µM 
   [I] = 0-500 µM 
    
2.4 
[B] = 396 mM 
(Phosphate) 
[B] = 297 mM (Tris·HCl)  
 [E] = 91 ngmL
-1
 [E] = 0.99 µgmL
-1
  
 [S] = 12, 31 µM [S] = 12, 30 µM  
 [I] = 0-210 µM [I] = 0-208 µM  
  Vtot = 2020 µL  
    
2.5  [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
  [E] = 0.50 µgmL
-1
 [E] = 51 ngmL
-1
 
  [S] = 8, 15, 30, 63 µM [S] = 25, 63, 125, 250 µM 
  [I] = 0-330 µM [I] = 0-998 µM 
    
2.15  [B] = 50 mM (Tris·HCl)  
  [E] = 0.50 µgmL
-1
  
  [S] = 20, 40, 100 µM  
  [I] = 0-257 µM  
    
2.16  [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
  [E] = 0.50 µgmL
-1
 [E] = 51 ngmL
-1
 
  [S] = 10, 20, 35, 60 µM [S] = 25, 50, 100, 200 µM 
  [I] = 0-171 µM [I] = 0-662 µM 
    
2.17  [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
  [E] = 0.25 µgmL
-1
 [E] = 51 ngmL
-1
 
  [S] = 10, 20, 30 µM [S] = 25, 50, 100, 200 µM 
  [I] = 0-256 µM [I] = 0-1075 µM* 
   * 2:1 2.17:2.16 
    
2.18  [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
  [E] = 0.50 µgmL
-1
 [E] = 51 ngmL
-1
 
  [S] = 15, 25, 50 µM [S] = 25, 50, 100, 200 µM 
  [I] = 0-1128 µM [I] = 0-1128 µM 
    
2.27  [B] = 50 mM (Tris·HCl)  
  [E] = 0.50 µgmL
-1
  
  [S] = 20, 30, 50, 100 µM  
  [I] = 0-396 µM  
  Vtot = 2010 µL  
    
2.28  [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
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Inhibitor Enzyme 
 S. typhi DHQase M. tuberculosis DHQase S. coelicolor DHQase 
    
  [E] = 0.50 µgmL
-1
 [E] = 51 ngmL
-1
 
  [S] = 24, 33, 49, 82 µM [S] = 52, 78, 104 µM 
  [I] = 0-516 µM [I] = 0-1960 µM 
    
2.29  [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
  [E] = 0.50 µgmL
-1
 [E] = 26 ngmL
-1
 
  [S] = 10, 21, 31, 52 µM [S] = 78, 104, 130 µM 
  [I] = 0-502 µM [I] = 0-1675 µM 
    
2.38  [B] = 50 mM (Tris·HCl)  
20:1 E:Z  [E] = 0.50 µgmL
-1
  
  [S] = 12, 25, 37, 61 µM  
  [I] = 0-84 µM  
    
2.42  [B] = 50 mM (Tris·HCl)  
E only  [E] = 0.05 µgmL
-1
  
  [S] = 33, 49, 82 µM  
  [I] = 0-77 µM  
    
2.44  [B] = 50 mM (Tris·HCl)  
9:1 E:Z  [E] = 0.50 µgmL
-1
  
  [S] = 6, 12, 25, 61 µM  
  [I (E)] = 0-72 µM  
    
2.46  [B] = 50 mM (Tris·HCl)  
3:2 E:Z  [E] = 0.50 µgmL
-1
  
  [S] =12, 25, 62 µM  
  [I (E+Z)] = 0-130 µM*  
    
3.1  [B] = 50 mM (Tris·HCl)  
  [E] = 0.05 µgmL
-1
  
  [S] = 20, 40, 60 µM  
  [I] = 0-502 µM  
    
3.2  [B] = 50 mM (Tris·HCl)  
  [E] = 0.50 µgmL
-1
  
  [S] = 20, 40, 60, 100 µM  
  [I] = 0-185 µM  
    
Key:  B = buffer, E = enzyme, S = substrate, I = inhibitor, R = reference.  E/Z refers to the E/Z 
isomers of the inhibitor. 
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Table 6.3  Experimental details for 1H NMR assays against S. coelicolor DHQase. 
      
Inhibitor S. coelicolor DHQase 
  
 Dose-response curve % Inhibition study 
      
   
1.32 [B] = 50 mM (Tris·HCl)  
 [E] = 37 ngmL
-1
  
 [S] = 812 µM  
 [I] = 0.84-27000 µM  
 [R] = 364 µM  
   
2.15  [B] = 50 mM (Tris·HCl) 
  [E] = 37 ngmL
-1
 
  [S] = 823 µM 
  [I] = 5611 µM 
  [R] = 364 µM 
   
2.27 [B] = 50 mM (Tris·HCl)  
 [E] = 46 ngmL
-1
  
 [S] = 1000 µM  
 [I] = 9.7x10
-5
 - 3.2x10
4
 µM  
 [R] = 364 µM  
   
2.38  [B] = 50 mM (Tris·HCl) 
20:1 E:Z  [E] = 37 ngmL
-1
 
  [S] = 800 µM 
  [I (E)] = 5000 µM 
  [R] = 436 µM 
   
2.44 [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
9:1 E:Z [E] = 37  ngmL-1 [E] = 37  ngmL-1 
 [S] = 800 µM [S] = 800 µM 
 [I (E)] = 0.1-20800 µM [I (E)] = 4500 µM 
 [R] = 436 µM [R] = 430 µM 
  total concn = 558  µL 
   
2.46  [B] = 50 mM (Tris·HCl) 
3:2 E:Z  [E] = 37 ngmL
-1
 
  [S] = 800 µM 
  [I (E+Z)] = 1100 µM 
  [R] = 436 µM 
   
3.1 [B] = 50 mM (Tris·HCl) [B] = 50 mM (Tris·HCl) 
 [E] = 37 ngmL
-1
 [E] = 37 ngmL
-1
 
 [S] = 823 µM [S] = 823 µM 
 [I] = 0.7-5000 µM [I] = 5000 µM 
 [R] = 364 µM [R] = 364 µM 
      
Key:  B = buffer, E = enzyme, S = substrate, I = inhibitor, R = reference.  E/Z refers to the 
E/Z isomers of the inhibitor. 
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List of Abbreviations 
 
 
 
ADP adenosine diphosphate 
Arg arginine 
ATP adenosine triphosphate 
BBA butane-2,3-bisacetal 
CSA camphorsulphonic acid 
DAHP deoxy-D-arabino-heptulosonate 7-phosphate 
DAST diethylaminosulphur trifluoride 
DCM dichloromethane 
DHQ dehydroquinate, dehydroquinic acid 
DHQase dehydroquinase 
DHS dehydroshikimate, dehydroshikimic acid 
DMAP 4-(dimethylamino)pyridine 
DME 1,2-dimethoxyethane 
DMF N,N-dimethylformamide 
EPSP 5-enolpyruvylshikimate 3-phosphate 
His histidine 
HMDS 1,1,1,3,3,3-hexamethyldisilazane 
Lys lysine 
m-CPBA m-chloroperbenzoic acid 
MDR-TB multi-drug resistant Mycobacterium tuberculosis 
MOM methoxymethyl 
MRSA methicillin resistant Staphylococcus aureus 
NADP+ nicotinamide adenine dinucleotide phosphate 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NMR nuclear magnetic resonance spectroscopy 
PCC pyridinium chlorochromate 
PDC pyridinium dichromate 
PEP phosphoenol pyruvate 
PMB  p-methoxybenzyl 
TBDMSCl  tert-butyldimethylsilyl chloride 
TFA trifluoroacetic acid 
TMB 2,2,3,3-tetramethoxybutane 
TMS  trimethylsilyl 
TMSOTf trimethylsilyl trifluoromethanesuphonate 
Tyr tyrosine 
VRE vancomycin resistant enterococci 
 
